Validation Experiments¶

Overview¶

Single-source consolidated experiment library for the Open Enzyme project. The navigable queue/dashboard lives immediately below this overview; full protocols (purpose, protocol, cost, timeline, dependencies, success criteria) follow in the phase sections.

As of 2026-04-24 this is the authoritative experiments file — earlier ambiguity about a separate experiments.md has been resolved, and all content lives here. The sweep daemon and human editors update this page in place.

Scope note (2026-05-15): The experiments below are largely koji-track-anchored because the koji chassis is the most mature OE engineering track. Validation paths for chassis-pending interventions (kidney-tropic siRNA URAT1, engineered LBPs, PDB via engineered EcN, mRNA-IL-1RA pulse, intra-articular uricase + catalase, phage modulation) are tracked on each intervention's home page and indexed in chassis-pending-interventions.md. Each chassis-pending entry has its own "Cheapest first move" — usually a $0 lit scan or sub-$5K wet-lab gate — not duplicated here. As chassis-pending interventions select a chassis and mature into dedicated tracks, their validation experiments will fold into this file or a parallel track-specific file (per the maintenance pattern that already produced engineered-lbp-chassis.md and compounding-pharmacy-track.md).

Experiment Queue¶

Dashboard view of all 34 experiments in the library. Sorted by phase then ID. Detail lives in the phase sections below — click the ID to jump.

Status legend: - Proposed — no work done yet; in the design/queue stage. - In Progress — active work underway (wet-lab, self-experiment, or analysis). - Done — completed with results captured in the protocol section or a referenced wiki page. - Abandoned — deprioritized or replaced; reason noted inline.

As of 2026-04-24, all experiments are Proposed (Phase 0 — no wet-lab work has been executed yet; self-experiments have not started).

#1 priority gate (elevated 2026-04-27, re-scoped 2026-05-16 per chaperone-framework calibration verdict): the platform-architecture gating experiment is the chaperone-orthogonal stacking framework's α-coefficient calibration set — §1.9 Ward 1995 dual-cassette feasibility test paired with §1.25 DAF SCR1-4 single-cassette expression. Either is informative alone, but the framework calibration only works as a pair under harmonized conditions (matching host = NSlD-ΔP10, matching format = solid-state shio-koji, matching promoter, matching titer units). The α coefficients drive whether DAF SCR1-4 routes to a separate strain vs the endgame strain, whether triple-cassette designs are feasible, and whether the single-strain endgame thesis holds — see chaperone-orthogonal-stacking.md §3.5.4 + §8 item 6 for the framework's own calibration uncertainty. Until this calibration set returns empirical data, every framework-driven architecture decision rests on α coefficients derived from non-koji in vitro folding kinetics. Combined cost ~$5–7K / 8–12 weeks. §1.9 also independently gates the koji-endgame single-strain thesis (its original #1 role); §1.25 also independently gates the DAF SCR1-4 CP0 engineering candidate (per H05).

ID	Title	Category	Cost	Weeks	Status	Wiki refs
§1.1	Uricase gene performance comparison	In Vitro	$2,000–3,000	4–6	Proposed	engineered-yeast-uricase-proposal, uricase-variant-selection, uricase, codon-optimization-expression-cassette
§1.2	Secretion vs. intracellular expression	In Vitro	$500–1,000	2–3	Proposed	engineered-yeast-uricase-proposal, saccharomyces-cerevisiae, gi-survival-prediction
§1.3	Uricase survival in beer fermentation	In Vitro	$200–400	3–4	Proposed	engineered-yeast-uricase-proposal, saccharomyces-cerevisiae
§1.4	Uricase stability after drying	In Vitro	$300–800	1–2	Proposed	engineered-yeast-uricase-proposal, gi-survival-prediction
§1.5	Koji uricase expression and activity	In Vitro	$1,500–2,500	4–6	Proposed	engineered-koji-protocol, aspergillus-oryzae, koji-construct-design, uricase
§1.6	Koji enzyme stability at digestive pH/temperature	In Vitro	$300–600	1–2	Proposed	engineered-koji-protocol, gi-survival-prediction, digestive-enzymes
§1.7	NLRP3 pathway validation (THP-1 MSU macrophage)	In Vitro	$5,000–8,000	8–10	Proposed	nlrp3-exploit-map, nlrp3-inhibitor-screen, supplements-stack, egcg
§1.8	EGCG dose-escalation CP1a readout	In Vitro	$500–800	3–4	Proposed	egcg, tnfsf14-gout-target, nlrp3-exploit-map
§1.9	Ward 1995 dual-cassette feasibility (koji endgame gate) — #1 priority	In Vitro	$3,000–5,000	8–12	Proposed	koji-endgame-strain, lactoferrin, engineered-koji-protocol, aspergillus-oryzae
§1.10	Uricase + lactoferrin stability in shio-koji ferment (gates dual-use thesis for both payloads)	In Vitro	$600–1,100	3–4	Proposed	koji-home-fermentation, engineered-koji-protocol, lactoferrin, synthesis/
§1.11	Ergothioneine → ABCG2 Caco-2 (native koji synergy)	In Vitro	$1,000–1,500	3–4	Proposed	abcg2-modulators, aspergillus-oryzae, engineered-koji-protocol, gut-lumen-sink
§1.12	Local H₂O₂ epithelial stress from gut-lumen uricase	In Vitro	$800–1,200	2–3	Proposed	uricase, aspergillus-oryzae, gut-lumen-sink
§1.13	Limonene → ABCG2 Caco-2 (Tier-3 stack synergy)	In Vitro	$800–1,200	3–4	Proposed	supplements-stack, abcg2-modulators, cannabinoids-terpenes
§1.14	DHT + TNFα additive ABCG2 suppression + butyrate/lactoferrin rescue + supplement ABCG2 antagonism + Q141K arm	In Vitro	$2,100–3,200	4–6	Proposed	abcg2-modulators, androgen-urate-axis, gut-lumen-sink, lactoferrin, supplements-stack, koji-endgame-strain
§1.15	Rice-bran substrate × koji uricase GI survival	In Vitro	$800–1,200	3	Proposed	engineered-koji-protocol, aspergillus-oryzae, gi-survival-prediction
§1.16	OPT-1 disulfide uricase in koji vs. WT (GI survival)	In Vitro	$1,800–2,500	6–8	Proposed	engineered-koji-protocol, uricase-variant-selection, protein-engineering-strategy
§1.17	Quercetin × ursolic × carnosine 3-way synergy (THP-1 MSU)	In Vitro	$1,500–2,000	3–4	Proposed	nlrp3-inhibitor-screen, supplements-stack, carnosine
§1.18	Native koji enzyme SGF (free extract vs. whole biomass)	In Vitro	$300–500	2	Proposed	koji-home-fermentation, engineered-koji-protocol, gi-survival-prediction
§1.19	Methodology — rodent cellular IC50 translation caveat	Standing	$0	ongoing	Standing	chembl-cross-check, nlrp3-inhibitor-screen, supplements-stack
§1.20	Lactoferrin + EGCG CP1a super-additivity (THP-1 2×3 matrix) — gated on §1.9	In Vitro	$1,500	3–4	Proposed	lactoferrin, egcg, nlrp3-exploit-map, supplements-stack, koji-endgame-strain
§1.21	Natural-product C5aR1 antagonist screen (CP0 fermentable-coverage question)	Computational	$0	0.5	Closed (negative, 2026-04-27)	complement-c5a-gout, nlrp3-exploit-map, open-enzyme-vision
§1.22	Gut-selective food-grade HDAC inhibitor screen for Q141K-ABCG2 trafficking rescue	In Vitro	$5,000–8,000	8–10	Proposed	abcg2-modulators, supplements-stack, gut-lumen-sink
§1.23	Androgen × MSU × NLRP3 macrophage tiered protocol (T1 THP-1 / T2 PBMC / T3 mouse air-pouch) — fills literature gap	In Vitro	$5–10K (T1); $105–160K (full cascade)	6–8 (T1); ~12 mo (full)	Proposed	androgen-urate-axis, nlrp3-inflammasome, self-experiment-protocol
§1.24	Carnosine co-expression in A. oryzae (koji endgame optional third cassette)	In Vitro	$1,500–2,500	4–6	Proposed	koji-endgame-strain, engineered-koji-protocol, carnosine, androgen-urate-axis
§1.25	*DAF SCR1-4 single-cassette expression in A. oryzae* (CP0 candidate + chaperone-framework calibration)** — co-#1 priority gate with §1.9	In Vitro	$3,500–5,500 (two-arm)	6–8	Proposed	daf-cd55-scr14-truncated-computational, hypotheses/H05-daf-scr14-cp0-thesis, chaperone-orthogonal-stacking, complement-c5a-gout
§2.1	Gnotobiotic mouse colonization (S. boulardii)	Animal	$5,000–15,000	8–12	Proposed	engineered-yeast-uricase-proposal, gut-lumen-sink, team
§2.2	Hyperuricemic rat model (yeast efficacy)	Animal	$8,000–12,000	6–8	Proposed	engineered-yeast-uricase-proposal, gout-deep-dive, uricase
§2.3	Engineered koji EPI model	Animal	$6,000–10,000	8–10	Proposed	engineered-koji-protocol, digestive-enzymes, enzyme-deficit-deep-dive
§2.4	NLRP3 inhibition in MSU arthritis model	Animal	$10,000–15,000	10–12	Proposed	nlrp3-exploit-map, nlrp3-inflammasome, gout-deep-dive, supplements-stack
§2.5	PULSE probiotic validation (hyperuricemic mice)	Animal	$5,000–8,000	8	Proposed	gout-deep-dive, gout-clinical-pipeline, gut-lumen-sink
§3.1	Brian: engineered yeast uricase tracking	Human	$200–400	20	Proposed	engineered-yeast-uricase-proposal, self-experiment-protocol, open-enzyme-vision
§3.2	Brian: NLRP3 suppression stack biomarker panel	Human	$700–1,400	20	Proposed	nlrp3-exploit-map, supplements-stack, self-experiment-protocol, open-enzyme-vision
§3.3	Lynn: wild-type koji digestive enzyme trial	Human	$600–1,000	12	Proposed	engineered-koji-protocol, digestive-enzymes, sibo, open-enzyme-vision, koji-home-fermentation
§3.4	Joint trial: engineered koji (both users)	Human	$300–500	14	Proposed	engineered-koji-protocol, open-enzyme-vision, self-experiment-protocol
§3.5	Long-term flare prevention (Brian, 6-mo extension)	Human	$400–600	26	Proposed	open-enzyme-vision, self-experiment-protocol, gout-deep-dive
§3.6	Brian: urinary LTB4 (quercetin CP6a in vivo)	Human	$150–300	12	Proposed	self-experiment-protocol, nlrp3-exploit-map, nlrp3-inhibitor-screen, synthesis/
§3.7	Brian: serum C5a baseline + week 12 (CP0)	Human	$300–400	12	Proposed	complement-c5a-gout, nlrp3-exploit-map, self-experiment-protocol
§3.8	Brian: DHA vs. EPA omega-3 crossover	Human	$550–700	9	Proposed	spm-resolution-pathway, supplements-stack, tnfsf14-gout-target, self-experiment-protocol
§3.9	Brian: zileuton off-label CP6a trial	Human	~$500	16	Proposed	zileuton, gout-clinical-pipeline, nlrp3-exploit-map, self-experiment-protocol
§3.10	Brian: fructose challenge test (acute n=1 uricase readout)	Human	~$50	0.1 + 4 wk gap	Proposed	fructose-connection, self-experiment-protocol, synthesis/

Phase 1: In Vitro Validation¶

1.1 Uricase Gene Performance Comparison¶

Status: Proposed | Cost: $2,000–3,000 | Weeks: 4–6 | Phase: 1

Affected wiki: engineered-yeast-uricase-proposal, uricase-variant-selection, uricase, codon-optimization-expression-cassette

What it tests: Which uricase gene (Aspergillus flavus, Candida utilis, or Vibrio vulnificus) performs best in S. cerevisiae?

Proposed in: engineered-yeast-uricase-proposal.md (§3)

Protocol: - Order codon-optimized synthetic genes for all three candidates (A. flavus, C. utilis, V. vulnificus) - Each in the same expression cassette (pTEF1 promoter, CYC1 terminator) - Integrate at the same chromosomal locus in S. cerevisiae - Compare: (a) expression level by Western blot, (b) specific uricase activity in cell lysate, © enzyme stability at 37°C over 24h

Estimated cost: $2,000–3,000 (gene synthesis ~$0.10/bp × ~900 bp × 3 genes + reagents)

Estimated timeline: 4–6 weeks

Dependencies: None

Success criteria: Identify highest-performing gene with >50 μmol/h/OD activity

Pre-gate option (deferred 2026-05-13) — Ginkgo Cloud Lab cell-free expression ($39/protein, ~5–10 day turnaround): Before committing to the full $2,000–3,000 gene synthesis + transformation + screening pipeline, a single $39 cell-free run on the lead uricase variant from uricase-variant-selection.md can confirm the ORF translates without ribosomal stalling and the polypeptide folds into a soluble state in an E. coli-lysate-like environment. Negative result = redesign the construct before any fungal work. Positive result = construct is worth committing fungal-host effort to. Status: deferred per the 2026-05-13 priority-stack decision — the existing computational corpus (comp-019 flux model, comp-022 cassette ranking, comp-023 cordycepin burden, ViennaRNA mRNA folding + ESM2 pseudo-pLDDT proxies) already answers the questions this test would surface to high confidence; the rationale stands and the option remains queued for when wet-lab work becomes load-bearing. See ginkgo-cloud-lab-evaluation.md TL;DR for full deferred-decision context. (source: ginkgo-cloud-lab-evaluation.md; Mechanistic Extrapolation)

1.2 Secretion vs. Intracellular Expression¶

Status: Proposed | Cost: $500–1,000 | Weeks: 2–3 | Phase: 1

Affected wiki: engineered-yeast-uricase-proposal, saccharomyces-cerevisiae, gi-survival-prediction

What it tests: Should uricase be secreted into the medium or retained intracellularly?

Proposed in: engineered-yeast-uricase-proposal.md (§3)

Protocol: - Clone A. flavus uaZ into two constructs: (1) with α-factor signal peptide for secretion, (2) without for intracellular accumulation - Transform both into same yeast strain - At 48h growth in liquid culture, draw samples and run uricase activity assay: - Supernatant (for secreted enzyme) - Cell pellet lysate (for intracellular enzyme) - Compare total enzyme output, specific activity, and fraction secreted

Estimated cost: $500–1,000

Estimated timeline: 2–3 weeks

Dependencies: None (can be done in parallel with 1.1)

Success criteria: Identify format with highest bioavailable uricase in food product context

1.3 Uricase Survival in Beer Fermentation¶

Status: Proposed | Cost: $200–400 | Weeks: 3–4 | Phase: 1

Affected wiki: engineered-yeast-uricase-proposal, saccharomyces-cerevisiae

What it tests: Does uricase remain enzymatically active through beer fermentation?

Proposed in: engineered-yeast-uricase-proposal.md (§4)

Protocol: - Brew 1-gallon test batch with engineered yeast - At each stage—active fermentation (day 3), end of primary (day 7), after conditioning (day 14), after bottling (day 21)—draw samples - Run uricase activity assay (spectrophotometric at 293 nm, measuring uric acid consumption) - Control: purified uricase added to finished beer at same stages (distinguishes production from survival)

Estimated cost: $200–400 (homebrew supplies + uric acid assay reagents)

Estimated timeline: 3–4 weeks

Dependencies: Requires engineered yeast strain from Phase 1 optimization

Success criteria: Retain >30% activity through bottling (lower indicates degradation during fermentation)

1.4 Uricase Stability After Drying¶

Status: Proposed | Cost: $300–800 | Weeks: 1–2 | Phase: 1

Affected wiki: engineered-yeast-uricase-proposal, gi-survival-prediction

What it tests: Can uricase survive lyophilization or heat drying for a shelf-stable product?

Proposed in: engineered-yeast-uricase-proposal.md (§4)

Protocol: - Take concentrated pellet of engineered yeast, split into four aliquots: 1. Fresh lysate (positive control) 2. Freeze-dried/lyophilized pellet 3. Heat-killed at 55°C then dried 4. Spray-dried at 120°C inlet temperature - Rehydrate each, lyse, and assay uricase activity - Report as % activity retained vs. fresh lysate

Estimated cost: $300–800 (lyophilizer access via core facility)

Estimated timeline: 1–2 weeks

Dependencies: Requires engineered yeast strain from Phase 1 optimization

Success criteria: >40% activity retained via lyophilization for capsule formulation viability

1.5 Koji Uricase Expression and Activity¶

Status: Proposed | Cost: $1,500–2,500 | Weeks: 4–6 | Phase: 1

Affected wiki: engineered-koji-protocol, aspergillus-oryzae, koji-construct-design, uricase

What it tests: Can A. flavus uricase gene express functionally in A. oryzae?

Proposed in: engineered-koji-protocol.md (§3, §5)

Protocol: - Clone uaZ into engineered A. oryzae with PamyB promoter + SPamyB secretion signal + uaZ CDS + TtrpC terminator - Grow on steamed rice (traditional koji conditions: 30°C, 48–72h) - Harvest koji, prepare extract, assay uricase activity - Compare: (a) expression level by Western blot, (b) specific uricase activity, © total enzyme yield per gram rice

Estimated cost: $1,500–2,500 (gene synthesis, transformation, reagents)

Estimated timeline: 4–6 weeks

Dependencies: None

Success criteria: >20 μmol/h/OD activity; enzyme properly secreted into rice substrate

1.6 Koji Enzyme Stability at Digestive pH and Temperature¶

Status: Proposed | Cost: $300–600 | Weeks: 1–2 | Phase: 1

Affected wiki: engineered-koji-protocol, gi-survival-prediction, digestive-enzymes

What it tests: Does koji-produced uricase survive gastric and duodenal conditions?

Proposed in: engineered-koji-protocol.md (§6)

Protocol: - Prepare koji extract with active uricase - Expose to simulated gastric juice (pH 2.0, 37°C, pepsin) for 30 min - Then simulated intestinal juice (pH 8.0, 37°C, pancreatin) for 120 min - Assay uricase activity at each stage - Compare to control uricase (Aspergillus nidulans uricase or rasburicase)

Estimated cost: $300–600 (digestive enzyme prep, assay reagents)

Estimated timeline: 1–2 weeks

Dependencies: Requires koji strain from 1.5

Success criteria: Retain >20% activity after duodenal transit (similar to ALLN-346 engineering target)

1.7 NLRP3 Inflammasome Pathway Validation (THP-1 MSU Macrophage Assay)¶

Status: Proposed | Cost: $5,000–8,000 | Weeks: 8–10 | Phase: 1

Affected wiki: nlrp3-exploit-map, nlrp3-inhibitor-screen, supplements-stack, egcg

What it tests: Do proposed compounds in the [[supplements-stack]] actually inhibit NLRP3 at stated chokepoints?

Proposed in: nlrp3-exploit-map.md, gout-deep-dive.md

Protocol: - Use macrophage cell line (THP-1 differentiated with PMA preferred over primary mouse macrophages — the species-gap caveat in supplements-stack.md makes human cells mandatory for translation) - Prime with LPS (Signal 1: NF-κB priming) - Expose to MSU crystals (NLRP3 trigger) - Treat with individual compounds and read out in parallel - Measure endpoints: IL-1β secretion (ELISA), caspase-1 activity, ASC specks (fluorescence), IκBα retention (Western — mechanistic readout for proteasome-pathway inhibitors) - Compare dose-response and mechanistic target (which chokepoint affected)

Priority compounds (ordered by information value of the specific mechanistic claim being tested):

EGCG — highest-priority single-compound assay. The mechanistic claim in egcg.md (proteasome inhibition → IκBα stabilization → unified CP1 + CP1a + CP4 + CP5a coverage) is specific and testable. Readouts: IL-1β ELISA + Western for IκBα retention + TNFSF14-induced IL-6 in HGF co-culture (tests CP1a). If the proteasome mechanism is correct, EGCG should show a steeper dose-response than quercetin or ursolic acid at equimolar concentrations, and IκBα retention should track the proteasome IC50 (86 nM cellular) rather than the reported IKK IC50 (≥10 μM). Phytosome-formulated EGCG recommended alongside free EGCG to test the bioavailability-gated translation question. This brings a falsifiable mechanistic claim to a format that can actually falsify it.
Oridonin — direct NLRP3 NACHT Cys279 covalent binder; 5.18 μM human THP-1 IC50 per ChEMBL. Tests whether the curated human IC50 replicates in our hands.
BHB — tests direct NLRP3 K⁺-efflux-block mechanism; straightforward positive-control-class compound.
Sulforaphane — Nrf2 activator; tests whether the Nrf2/NF-κB crosstalk mechanism translates to MSU-triggered cells at achievable sub-μM doses.
Quercetin — now primarily a CP6a (5-LOX) compound; tests whether the weaker NF-κB/NLRP3 claim holds at μM concentrations.
Carnosine + Lactoferrin — unique mechanism classes (dual UA/NLRP3 and CP5 GSDMD-axis respectively); tests whether the rat/murine evidence translates to human THP-1.

Estimated cost: $5,000–8,000 (cell culture, cytokines, assay kits, Western reagents, compound panel)

Estimated timeline: 8–10 weeks (larger compound panel than original scope)

Dependencies: None

Success criteria: - Confirm >50% IL-1β reduction at stated compound doses; validate chokepoint targets - EGCG-specific: dose-response for IκBα retention tracks the 86 nM proteasome IC50 (falsifies or confirms the proteasome-pathway reframe); dose-response is steeper than quercetin at equimolar (confirms mechanistic difference between direct-proteasome and NF-κB-pathway-modulator compounds)

1.8 EGCG Dose-Escalation on MSU-Stimulated THP-1: TNFSF14-Induced IL-6 Readout (CP1a)¶

Status: Proposed | Cost: $500–800 | Weeks: 3–4 | Phase: 1

Affected wiki: egcg, tnfsf14-gout-target, nlrp3-exploit-map

What it tests: Does EGCG suppress TNFSF14-induced IL-6 in a gout-relevant cell model at sub-μM concentrations — the specific CP1a readout that would validate EGCG's multi-chokepoint coverage story?

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-24 Pass 2 Proposed Experiments #3; complements Experiment 1.7 (NLRP3 pathway validation) with a TNFSF14-specific readout.

Protocol: - THP-1 monocytes differentiated to macrophages with PMA (25 ng/mL, 24h, then rest 24h) - Prime with LPS (10 ng/mL, 4h — Signal 1) - Expose to MSU crystals (100 μg/mL, 6h — Signal 2) - Add recombinant TNFSF14/LIGHT (100 ng/mL, 16h) to stimulate the CP1a axis specifically - Treat with EGCG dose-escalation: 10 nM, 30 nM, 100 nM, 300 nM, 1 μM, 3 μM, 10 μM (spans the 86 nM proteasome IC50) - Positive control: bortezomib (proteasome inhibitor, orthogonal mechanism) - Negative control: DMSO vehicle - Primary readout: IL-6 in supernatant (ELISA) - Secondary readouts: IL-1β (ELISA), IκBα retention (Western blot), HVEM receptor surface expression (flow cytometry)

Estimated cost: $500-800 (THP-1 cells, PMA, LPS, MSU, recombinant TNFSF14, EGCG, ELISA kits for IL-6 and IL-1β, Western reagents)

Estimated timeline: 3-4 weeks (cell differentiation, assay, readouts)

Dependencies: None (can run in parallel with 1.7, or as a focused follow-up)

Success criteria: - IL-6 suppression ≥50% at EGCG ≤1 μM (confirms CP1a activity at achievable concentrations) - Dose-response for IκBα retention tracks the 86 nM proteasome IC50 (falsifies or confirms the proteasome-pathway reframe of EGCG's mechanism) - HVEM downregulation at EGCG ≤1 μM (replicates Hosokawa 2010 HGF finding in a macrophage lineage)

Cross-references: wiki/egcg.md (mechanistic reframe), wiki/tnfsf14-gout-target.md (CP1a chokepoint), wiki/nlrp3-exploit-map.md (CP1a entry)

1.9 Ward 1995 Dual-Cassette Feasibility Test (Koji Endgame Strain Gate) — #1 priority gate¶

Status: Proposed | Cost: $5,265–8,065 (updated 2026-05-17 with Plasmidsaurus QC pipeline + RNA-Seq host-stress readout) | Weeks: 8–12 | Phase: 1

Affected wiki: koji-endgame-strain, lactoferrin, engineered-koji-protocol, aspergillus-oryzae, uricase-variant-selection

What it tests: Can the Ward 1995 A. awamori glucoamylase-KEX2 lactoferrin architecture (>2 g/L submerged, PMID 9634791) be layered with a second expression cassette for A. flavus uricase (uaZ) in the same A. oryzae genetic background on solid-state rice koji — without silencing either cassette or collapsing the native kojic-acid / ergothioneine metabolite program? This is the single feasibility gate for the endgame strain thesis (one A. oryzae strain, 5 NLRP3-pathway chokepoints, 4 molecules — see koji-endgame-strain.md).

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-24 Pass 2 Connection 1 + Proposed Experiment 1; formalized in koji-endgame-strain.md §3. This is the gating experiment that decides whether the endgame strain is engineerable in its one-strain form (go to full development) or needs the two-strain fallback (koji-endgame-strain.md §4.1).

Secondary role — chaperone-framework calibration set (added 2026-05-08): the lactoferrin-alone arm of this experiment is the transferrin-lobe data point in the calibration-set candidate documented in chaperone-orthogonal-stacking.md §3.5.4 (paired with §1.25's DAF SCR1-4 CCP/SCR data point). Pre-registered framework prediction: ≥500 mg/L lactoferrin-alone if the framework's α coefficients transfer to koji; <40 mg/L if PDI-saturation dominates. This calibration role does NOT change §1.9's primary objective or design — it just means the lactoferrin-alone titer should be reported with enough precision to compare against §1.25's DAF SCR1-4 titer under harmonized conditions (same host = NSlD-ΔP10, same format = solid-state shio-koji, same titer units = mg/L mature protein by ELISA).

Protocol: - Construct design. - Cassette A (lactoferrin): [PamyB — glucoamylase — KEX2site (Lys-Arg) — hLf codon-optimized for *A. oryzae* — TamyB]. Matches Ward 1995 architecture. Selection marker: pyrG complementation. - Cassette B (uricase): [PTEF1 — amyB signal peptide — *A. flavus uaZ* codon-optimized — TgpdA]. Distinct promoter (constitutive TEF1) to separate transcriptional program from Cassette A. Selection marker: niaD or amdS. - Host strain. A. oryzae RIB40 or NSAR1 (pyrG-deficient auxotroph). Updated recommendation (post-H01 Killshot #1, 2026-05-05): For the lactoferrin cassette specifically, prefer a protease-deletion chassis (NSlD-ΔP10 or equivalent: ΔtppA ΔpepE ΔnptB ΔdppIV ΔdppV ΔalpA ΔpepA ΔAopepAa ΔAopepAd ΔcpI) over wild-type RIB40. Huynh et al. 2020 (PMC7257131) showed wild-type RIB40 was inadequate for functional antibody production at the titer threshold needed; only the ten-protease-deletion strain reached 39.7 mg/L. RIB40 remains appropriate for the uricase-only Year 1 starting strain. The NSAR1 5-marker platform (Oikawa 2020, PMC7725655) provides 5 simultaneous integration slots — the 2-cassette H01 design uses two, leaving three free for downstream additions. (In Vitro; source: H01-ward-dual-cassette.md) - Transformation. PEG/CaCl₂ protoplast, sequential: Cassette A first → select on pyrG-minus → confirm hLf expression by Western → transform Cassette B into validated hLf clone → select on niaD/amdS. - Fermentation. Solid-state rice koji, 48–60 h at 30°C, 35% moisture. Parallel submerged-culture control (100 mL shake flask, 28°C) to isolate solid-state variable. Add Lf-alone single-cassette arm (no uricase cassette, otherwise identical) to resolve the capacity-vs-titer benchmark ambiguity flagged 2026-05-06 — see "Capacity-vs-titer side-product readout" below. - Readouts. - Uricase activity: spectrophotometric UA-disappearance assay (per engineered-koji-protocol.md §05). - Lactoferrin titer: anti-hLf ELISA + Western blot. - Iron-binding capacity of Lf: UV-Vis at 465 nm (apo-vs-holo); optional CD spectroscopy for fold confirmation. - Native metabolite profile: kojic acid titer (HPLC) + ergothioneine titer (LC-MS) — is WT baseline preserved within 30%? - qPCR for both cassette copy numbers (stability check). - SDS-PAGE to detect any incompletely-processed glucoamylase-hLf fusion (KEX-2 saturation signal).

Capacity-vs-titer side-product readout (added 2026-05-06): The Lf-alone single-cassette arm above resolves a load-bearing benchmark ambiguity in the OE wiki: the chaperone-orthogonal stacking framework calibrates synergy coefficients against the Huynh 2020 antibody capacity ceiling (39.7 mg/L adalimumab in NSlD-ΔP10, 16 disulfides), while koji-endgame-strain.md §3.1 cites Ward 1995 (>2 g/L Lf in A. awamori) as the lactoferrin titer precedent. Both numbers cannot be the binding constraint: 17-disulfide Lf at 2 g/L would be impossible if 16-disulfide adalimumab at 40 mg/L were a hard capacity ceiling. The §1.9 Lf-alone arm directly resolves which baseline applies in the actual §1.9 host (NSlD-ΔP10) and format (solid-state koji) — neither of which matches the original Ward 1995 conditions (A. awamori, submerged). Three actionable readouts:

Lf-alone titer	Implication for chaperone framework	Implication for endgame strain
≥500 mg/L	Huynh ceiling is antibody-architecture-specific; framework's synergy coefficients are systematically conservative for single-chain payloads	Endgame strain dual-cassette in good shape; can stack additional PDI-loaded payloads with confidence
100–500 mg/L	Genuine intermediate regime; framework calibration is approximately right for single-chain payloads	Dual-cassette feasible but third PDI-loaded cassette (e.g., DAF SCR1-4) needs conservative framing
<100 mg/L	Huynh ceiling is approximately the real ceiling regardless of architecture; framework is well-calibrated	Dual-PDI-cassette designs are at higher risk than the Ward 1995 precedent suggests; two-strain co-fermentation fallback (§4.1 koji-endgame-strain.md) becomes more attractive

This is a free byproduct of the §1.9 readout — no additional fermentation cost, only the Lf-alone strain construction (which is already a prerequisite for the dual-cassette construction sequence per "Transformation" above: Cassette A first → confirm hLf expression → transform Cassette B). The Lf-alone titer was previously reported only as part of the construct-validation step; this addendum elevates it to a load-bearing platform readout.

Plasmidsaurus QC pipeline (added 2026-05-17): apply the canonical §05 Plasmidsaurus QC pipeline across the §1.9 build: - Pre-transformation: Whole Plasmid Sequencing of both cassette plasmids before any transformation work ($15 × 2 = $30, 1 day). Catches construct errors before the $500–1,000 cloning/transformation reagent spend. - Post-transformation clone screening (Cassette A round): Genotyping Analysis on 6–10 hLf-alone transformants to pick clean on-target integrants before committing to Western screening ($30 × 8 = $240, 1–2 days). - Post-transformation clone screening (Cassette B round): Genotyping Analysis on 6–10 dual-cassette transformants ($30 × 8 = $240, 1–2 days). Same logic — screen on integration cleanliness before fermentation panel. - Junction PCR sequencing (both rounds): Amplicon Sequencing on 2–4 junction PCRs per integration ($15 × 6 = $90, next-day). - Final platform-strain release: Whole Genome Sequencing on the validated dual-cassette strain (Eukaryotic tier for A. oryzae, $250 + $15 DNA extraction = $265, 3–6 days). This is the "publish-grade" sequence for the open-source-strain-library release.

Plasmidsaurus QC pipeline subtotal: ~$865, ~15% of the §1.9 envelope. Replaces piecemeal Sanger + multiple junction PCRs + qPCR copy-number — the qPCR copy-number assay can be retained as a sanity check or replaced entirely by Whole Genome Sequencing readout from the final-strain step.

Host-stress transcriptome readout via Plasmidsaurus RNA-Seq (added 2026-05-17): the planned readout panel covers known native metabolites (kojic acid, ergothioneine) via HPLC/LC-MS but does not assay genome-wide host stress — UPR activation, secretory-pathway saturation, broader biosynthesis-transcript collapse — which is the empirical signal most directly relevant to chaperone-orthogonal-stacking α-coefficient calibration (chaperone-orthogonal-stacking.md §3.5.4, combined-cp0-systems-model-computational.md comp-029). Plasmidsaurus launched an Illumina-based RNA-Seq service in 2026 priced at $50/sample academic / $80/sample industry, ~3-day turnaround, 10M deduplicated 3' end counting reads from 300 ng purified RNA, with interactive volcano + functional-enrichment outputs. Proposed addendum panel: 4 conditions (WT NSlD-ΔP10, lactoferrin-alone arm, uricase-alone, dual-cassette) × 3 biological replicates = 12 samples = ~$600 academic. Add ~$200 for RNA-extraction reagents (TRIzol or RNeasy) — koji is fungal and Plasmidsaurus does not accept fungal cells directly, only purified RNA at ≥10 ng/μL — total adder ~$800, ~15% of the §1.9 envelope.

α-signature in transcriptome	Implication for chaperone framework
UPR target genes (hac1, bipA, pdiA, ero1) elevated in dual-cassette by <2× vs Lf-alone	α ≥ 0.8 (near-additive); framework predicts dual-PDI stacking scales well
UPR targets elevated 2–5×	α ≈ 0.4–0.6 (intermediate); third PDI-loaded cassette (DAF SCR1-4) needs conservative framing
UPR targets elevated >5× OR ergothioneine biosynthesis transcripts (egt1, egt2) collapsed >50%	α < 0.4 (saturating); strain compromised, two-strain co-fermentation fallback (§4.1 koji-endgame-strain.md) becomes more attractive regardless of titer outcome

Technology caveat: Plasmidsaurus RNA-Seq is short-read Illumina 3' end counting — good for differential expression and transcript abundance, not capable of cryptic-splicing detection, transcript-isoform analysis, or read-through detection. If a load-bearing splicing question emerges post-§1.9 (e.g., heterologous ORF showing antibody-positive Western but no activity), a long-read cDNA service (Oxford Nanopore PromethION, separate vendor) is the right diagnostic — Plasmidsaurus does not currently offer this. The whole-plasmid / whole-genome sequencing line items in engineered-koji-protocol.md §05 are a distinct Plasmidsaurus product and remain unchanged.

Estimated cost: $5,265–8,065 — gene synthesis for two codon-optimized cassettes (~$600–1,000), cloning and transformation reagents ($500–1,000), fermentation consumables ($200–400), ELISA + Western antibodies ($800–1,200), metabolite assay reagents ($500–800), Plasmidsaurus QC pipeline (plasmid + amplicon + genotyping + whole-genome, ~$865), Plasmidsaurus RNA-Seq 12-sample panel + extraction reagents ($800), CRO or academic lab time if outsourced ($1,000–2,000 per batch).

Estimated timeline: 8–12 weeks — 2–3 weeks gene synthesis + construct assembly, 2–3 weeks sequential transformation + clonal screening, 1–2 weeks parallel fermentation (solid-state + submerged), 2–3 weeks full assay suite + write-up.

Dependencies: A. oryzae genetic-engineering lab access. Candidate pathways: (a) a Role 2 (Pharma Translation) collaborator (see team.md) if recruiting converts; (b) commercial CRO specializing in filamentous-fungus engineering (Lonza, Novozymes, Dyadic) — faster but more expensive; © community biolab with protoplast-transformation capability (Genspace NY has precedent on A. oryzae). Global parallel options (Japan / China / Europe) are mapped in ward-1995-lab-access-global.md — the Maruyama lab at the University of Tokyo is the single most important contact globally (origin lab for NSlD-ΔP10, the default chassis per H01 Killshot #1); Jiangnan University (C19 chassis) and DTU Mortensen group (CRISPR toolkit) are the parallel-path options. (source: ward-1995-lab-access-global.md)

Success criteria: - Accept (go to full endgame strain development per koji-endgame-strain.md §7): lactoferrin titer ≥500 mg/L koji pore-fluid equivalent, uricase activity ≥50 μmol/h/OD retained from single-cassette baseline, native kojic acid + ergothioneine titers within 30% of WT. - Iterate (adjust architecture, re-test): lactoferrin 100–500 mg/L OR uricase activity down >30%. Try protease-knockout host strain (Δalp, Δnpr), alternative integration sites, iron supplementation (10–100 ppm FeCl₃), or alternative signal peptides. - Reject (fall back to two-strain co-ferment per koji-endgame-strain.md §4.1): lactoferrin <100 mg/L after two rounds of optimization, OR native metabolite program collapse (kojic acid down >50% vs. WT). The two-strain fallback preserves the coverage matrix at the cost of single-strain elegance.

Computational prior (comp-010, 2026-05-05) — cassette compatibility: Seven sequence-level analyses (codon usage, KEX2 geometry, secretion targeting, disulfide load, N-glycosylation, combined burden, Huynh 2020 comparison) found no blocking cassette-design issues for the proposed asymmetric architecture. Overall cassette-design risk: LOW. Key design notes: (1) Lactoferrin has one moderate-risk internal KEX2 site at mature position 579 (P1'=K) — monitor by SDS-PAGE for a ~67 kDa truncated band; if seen, mutate K597→Q in the codon-optimized gene. (2) Uricase C-terminal SKL resembles a PTS1 peroxisomal signal — verify secretion by anti-uricase ELISA on culture supernatant vs. cell lysate; if misrouted, append 3×Ala C-terminal tag. Combined ER disulfide load = 1.06× Huynh 2020 adalimumab baseline (17 disulfides, all on Lf; uricase contributes zero), within demonstrated NSlD-ΔP10 capacity. The 12.6× titer gap vs. Huynh 2020 (39.7 mg/L adalimumab) is not the correct benchmark for Lf — Ward 1995 >2 g/L is. Full analysis: wiki/cassette-compatibility-computational.md and etc/experiments/comp-010-cassette-compatibility/. Evidence level: Mechanistic Extrapolation (in silico only). (source: cassette-compatibility-computational.md)

Computational prior (comp-022 v2, 2026-05-14) — uricase cassette ranking: ClockBase-style exhaustive enumeration of 43,200 uricase cassette candidates (6 promoters × 12 signal peptides × 10 codon variants × 60 secretion scaffolds). v2 retrofit with ESM2 pseudo-pLDDT (Tier 3 fold-quality proxy) + ViennaRNA 2.7.2 MFE (replacing v1's weak GC-clamp proxy; Spearman rho = 0.241). 71 cassettes pass N-of-5 ≥ 4; 4 cassettes pass N-of-5 = 5. The v1 top cluster (PamyB + amyB SP + 5'-softened codon + direct-secretion + PTS1-blocking C-terminal tag + N191Q glycosylation-sequon ablation) survives v2 at 100%. Three gene-synthesis-time refinements confirmed: (1) 5'-softened codon optimization (low-GC first 30 codons + max-CAI thereafter), (2) PTS1-blocking C-terminal tag (3×Ala or His6), (3) N191Q glycosylation-sequon ablation. All at zero marginal cost. Glucoamylase-KEX2 fusion architecture confirmed as the wrong scaffold for uricase (zero intrinsic disulfides + zero glycosylation = no benefit from a fusion carrier). Full analysis: wiki/uricase-cassette-ranking-computational.md and etc/experiments/comp-022-clockbase-uricase-cassette-ranking/. Evidence level: Mechanistic Extrapolation (in silico only). (source: uricase-cassette-ranking-computational.md)

Computational prior (comp-023, 2026-05-14) — cordycepin cassette metabolic burden: FBA on the Vongsangnak 2008 iWV1314 GEM with dual + cns1-cns2 + carnS + panD scenarios. Verdict: GREEN at the Jeennor 2023 empirical titer (564 mg/L/day). Growth penalty +0.02% vs WT; kojic acid + EGT yield headroom 100% of dual-cassette baseline. Cordycepin demand at 564 mg/L/d consumes ~0.02% of cellular carbon flux. FBA breakpoint ~1,000× the empirical titer. Carnosine + panD third-cassette alternatives also GREEN. Three open follow-up gates: ADA competition (comp-025), dynamic FBA validation (comp-023 v2), multi-cassette induction interference (comp-026). Full analysis: wiki/cordycepin-cassette-burden-computational.md. Evidence level: Mechanistic Extrapolation (in silico only). (source: cordycepin-cassette-burden-computational.md)

Cross-references: koji-endgame-strain.md §3 (full protocol rationale + adjacent literature: Li 2024 PMID 39830075 multi-copy in A. oryzae, Wang 2023 PMID 37807677 multi-locus in A. niger), engineered-koji-protocol.md §16 (starting single-cassette lactoferrin module that this experiment ladders on top of), lactoferrin.md §7 (Open Enzyme feasibility bet), synthesis/ 2026-04-24 Connection 1, cassette-compatibility-computational.md (comp-010 cassette design analysis).

1.10 Heterologous Uricase + Lactoferrin Stability in Shio-Koji Salt-Protease Ferment¶

Status: Proposed | Cost: $600–1,100 | Weeks: 3–4 | Phase: 1

Affected wiki: koji-home-fermentation, engineered-koji-protocol, aspergillus-oryzae, synthesis/, lactoferrin

What it tests: Does the 7–14 day shio-koji salt-protease ferment degrade engineered uricase and/or lactoferrin produced by A. oryzae? Shio-koji's hallmark feature is active native subtilisin-family proteases at room temperature in 15–20% NaCl — this likely degrades any heterologous peptide payload (carnosine, KPV, BPC-157 — Connection #2 in synthesis 2026-04-27) and may plausibly degrade folded proteins despite their higher intrinsic stability. Two proteins are tested in the same run because they have structurally distinct proteolytic vulnerabilities: uricase is a compact ~34 kDa homotetramer (comp-001 finds zero exposed cleavage sites — confirmation experiment); lactoferrin is an 80 kDa glycoprotein with two bilobal domains and N/C-terminal linker regions that are structurally accessible (no computational prior — this arm is a feasibility gate). Resolves the "single highest-stakes open question for the shio-koji dual-use thesis" per Pass 3 review.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-27 Open Question #2 (sweep on commit b7df491). Gates the dual-use product concept that unifies the two project arms (Lynn's EPI track + Brian's gout track) into a single household condiment (engineered-koji-protocol.md §15).

Protocol: - Constructs: Use engineered-koji-protocol.md §6 single-cassette uricase strain + a co-expressing or separate lactoferrin strain if available. If engineered strains not yet available, run pilot by spiking WT A. oryzae shio-koji with: (a) rasburicase (commercial recombinant uricase) as the uricase positive control; (b) bovine lactoferrin (Sigma L9507 research-grade or equivalent) as the lactoferrin positive control — both at physiologically-relevant concentrations (~1–5 µg/mL). - Ferment matrix: Prepare shio-koji per koji-home-fermentation.md standard protocol (15–20% NaCl, room temp 22–25°C). Run in parallel with two control matrices: (a) freshly harvested koji (no salt ferment), (b) amazake-style brief warm hold (55–60°C × 6h followed by RT storage) — heat hold partially inactivates proteases. - Time-course sampling: Aliquot at days 0, 3, 7, 10, 14. Freeze at −80 °C immediately after collection. - Readouts — uricase: - Uricase activity: spectrophotometric UA-disappearance assay at 293 nm per engineered-koji-protocol.md §05 (quantitative). - SDS-PAGE + anti-uricase Western blot: detects intact monomer (~34 kDa) vs. degradation products. Distinguishes "lost activity due to denaturation" from "lost activity due to proteolytic cleavage." - Optional CD spectroscopy on extracted uricase: confirms tetramer fold preservation if activity drops without obvious cleavage on Western. - Readouts — lactoferrin: - Lactoferrin protein integrity: SDS-PAGE + anti-lactoferrin Western blot, detecting intact 80 kDa band vs. characteristic bilobal cleavage products (~40 kDa N-lobe + ~40 kDa C-lobe). Lactoferrin's linker region between the two lobes is the most proteolytically accessible site. - Lactoferrin iron-binding capacity (optional functional assay): iron-binding ELISA or colorimetric ferrozine assay at day 0 and day 14; iron-binding is the functional proxy for intact bilobal structure. - Note: unlike uricase, lactoferrin has no comp-001 computational prior. The Western blot result is the primary feasibility determination. - Salt-concentration sub-experiment: Single-timepoint (day 7) panel at 5%, 10%, 15%, 20% NaCl. Run both proteins in the same panel — determines whether uricase and lactoferrin have different salt-threshold protection profiles, which would inform whether a low-salt variant could preserve one but not the other. - Linker-variant arm — comp-034 multi-variant plate (added 2026-05-16): 4-lane gel comparing WT lactoferrin against three redesigned inter-lobe linker variants from comp-034: - Lane 1: WT lactoferrin (SEEEVAARRAR linker, residues 353–363 / mature 334–344) — baseline / positive control - Lane 2: Primary candidate EEEEPAARRAR (S353E + V357P, 2 substitutions, 82% WT identity, comp-034 4-of-5 metrics, predicted −29% protease cleavage) - Lane 3: Minimum-change SEEEPAARRAR (true single V357P, 91% WT identity, comp-034 3-of-5, predicted −24% cleavage) - Lane 4: MPNN-native STRICT NEEEQQQEEEQ (multi-substitution, 5-of-5 metrics simultaneously, 10.4× cleavage reduction vs WT — 0.039 vs 0.407). Identified by the 2026-05-19 genuine ProteinMPNN rerun (E2 walkthrough); the substitute sampler never proposed this candidate. Swapped in for the originally-planned EEEEPAAPPAP aggressive arm because NEEEQQQEEEQ dominates on all five metrics.

Readout: same SDS-PAGE + anti-Lf Western + iron-binding ELISA as the WT lane, run at day 0 / day 7 / day 14. Outcome: maps comp-034's in silico predictions to wet-lab protease resistance + bilobal-cleavage product pattern. Marginal cost +$1.5–3K (gene synthesis for 3 variants at typical custom-synthesis pricing; reagent costs amortized into the existing §1.10 panel). comp-034 substitute-sampler caveat RESOLVED 2026-05-19: genuine ProteinMPNN rerun (E2 walkthrough; install at tools/ProteinMPNN/) validated that the substitute sampler's 15 GREEN candidates are NOT artifacts (mean MPNN log-likelihood 2.74 GREEN vs 3.74 FAIL — clean separation). Substitute sampler's proline-bias + WT-mix-in heuristic was a coarse but functional proxy for what ProteinMPNN encodes structurally. Genuine MPNN additionally found 3 STRICT (5-of-5) candidates the substitute sampler missed: NEEEQQQEEEQ (Lane 4), NEEEEQQEQEQ, NEEEEEQEQEQ — all 10.4× cleavage reduction. Full rerun report: logs/proteinmpnn-comp-034-rerun-2026-05-19.md. See also etc/bio-ai-tools.md §"Protease-vulnerability-to-redesign workflow" for the generalizable workflow pattern.

Microbial-purity readout via Plasmidsaurus 16S Amplification (added 2026-05-17): the 7–14 day room-temperature shio-koji ferment in 15–20% NaCl is a contamination-permissive format — salt-tolerant Tetragenococcus, Halomonas, and various Staphylococcus species can colonize the matrix and confound the proteolysis readout (any drop in heterologous protein band could reflect contaminant proteases, not A. oryzae native proteases). A cheap microbial-purity check at the day 0 / day 7 / day 14 time-course points uses Plasmidsaurus's 16S Amplification & Sequencing product: $45/sample standard tier (5K Nanopore long-reads, full-length 16S → species-level resolution), +$15 per sample for in-house DNA extraction from raw ferment, 1 business day turnaround. Three time-course points across both the engineered + WT control matrices = 6 samples = ~$360 total (well under 10% of the §1.10 envelope). Output: taxonomic-composition stacked-bar across the time course. Interpretation: dominant A. oryzae signal at day 0 (any other taxa <5% relative abundance), watch for any taxon climbing >10% relative abundance by day 14. If a contaminant climbs, the proteolysis readout for that arm needs to be re-interpreted with the contaminant's known protease profile in mind.

Estimated cost: $2,460–4,460 (post-2026-05-17 16S purity adder; post-2026-05-16 linker-variant arm) — uricase activity assay reagents ($100–200), lactoferrin iron-binding assay reagents ($50–100), SDS-PAGE / Western antibodies for both proteins ($300–500), bovine lactoferrin standard ($50), shio-koji ingredients ($20–50), CD spectroscopy if outsourced ($100–200), comp-034 linker-variant gene synthesis ($1,500–3,000 for 3 variants), Plasmidsaurus 16S microbial-purity panel (~$360).

Estimated timeline: 3–4 weeks — parallel with the active fermentation. Day-by-day sampling continues over the 14-day window; assay batches at days 0/3/7/10/14 are ~2 days each.

Dependencies: No specialized lab access required beyond Western blot capability. Doable in a community biolab (Genspace NY, Counter Culture Labs Oakland) or as a small parallel run during the §1.9 Ward 1995 cassette work. Self-contained.

Success criteria: - Accept dual-use thesis (engineer for shio-koji delivery is viable): >70% uricase activity retained at day 14 vs. day 0; intact monomer band on Western; no major degradation products. - Iterate (try lower-salt or shorter-ferment formats): 30–70% retention. Document the salt-time tradeoff and propose a modified format (e.g., shio-koji variant at 10% NaCl × 7 days). - Reject shio-koji as a delivery format for uricase (fall back to fresh koji, amazake, or lyophilized powder per synthesis 2026-04-27 Connection #2 review): <30% retention. Same logic extends to any peptide payload (carnosine, KPV, BPC-157).

Computational prior (comp-001, 2026-05-05) — uricase only: AlphaFold structural analysis + P1/P1' cleavage-site prediction for all three A. oryzae koji proteases (ALP, NPr, acid protease) under shio-koji conditions found zero exposed recognition sites — all 356 sites across all three proteases map to buried/well-folded regions (100% of residues pLDDT > 80, mean 97.1). ALP is also strongly salt-inhibited (~19% residual activity at 17.5% NaCl). Verdict: LOW structural risk for uricase. This shifts the uricase arm of §1.10 from a feasibility gate to a confirmation experiment. Full analysis: wiki/uricase-protease-stability-computational.md and etc/experiments/comp-001-uricase-shio-koji-protease-stability/.

Computational prior (comp-005, 2026-05-05) — lactoferrin: AlphaFold structural analysis + P1/P1' cleavage-site prediction for the same three koji proteases, with two verdicts: HIGH (full sequence including signal peptide) / MODERATE (mature protein aa 20–710). The HIGH score is driven entirely by the fully disordered signal peptide (aa 1–19, pLDDT 35–54) — all top-5 sites across all three proteases map to signal peptide residues. Mature-protein max risk is 0.188 (ALP, 3 exposed sites). If A. oryzae signal peptidase processes the heterologous signal sequence, operative risk is MODERATE. Signal peptide processing is common for secreted proteins in A. oryzae but not guaranteed for foreign sequences. The lactoferrin arm of §1.10 remains a feasibility gate — unlike the uricase arm, the MODERATE mature-protein verdict is insufficient to reframe this as a confirmation experiment. If wet-lab shows lactoferrin degradation while uricase survives, first diagnostics are: (1) Western blot for ~40 kDa bilobal cleavage products (inter-lobe linker); (2) N-terminal sequencing to determine signal peptide processing status. Full analysis: wiki/lactoferrin-protease-stability-computational.md and etc/experiments/comp-005-lactoferrin-shio-koji-protease-stability/.

Cross-references: synthesis/ 2026-04-27 Open Question #2 + Connection #2; engineered-koji-protocol.md §15 (the dual-use proposal this experiment gates); koji-home-fermentation.md (shio-koji standard protocol); aspergillus-oryzae.md (native protease characterization); uricase-protease-stability-computational.md (comp-001 structural prior); computational-experiments.md.

1.11 Ergothioneine → ABCG2 Induction in Caco-2 (Native Koji Synergy Test)¶

Status: Proposed | Cost: $1,000–1,500 | Weeks: 3–4 | Phase: 1

Affected wiki: abcg2-modulators, aspergillus-oryzae, engineered-koji-protocol, gut-lumen-sink

What it tests: Does ergothioneine — natively produced by A. oryzae at ~20 mg/g dry mass — induce ABCG2 expression in human enterocyte-lineage cells at concentrations achievable from koji-derived dietary intake? Tag: Mechanistic Extrapolation testing a two-step inference (ergothioneine → Nrf2 stabilization → ABCG2 induction). Ergothioneine's "Nrf2 inducer" classification is weaker than canonical activators (sulforaphane, CDDO-Me) — it is more accurately a ROS scavenger that may indirectly stabilize Nrf2. This experiment disambiguates whether the engineered-koji platform has a "free" ABCG2-induction synergy via its native metabolite chorus, or whether the connection is too distant to matter at koji-achievable luminal doses. Verify substrate claim before running: confirm aspergillus-oryzae.md ergothioneine titer (~20 mg/g dry mass) against primary literature; the L223 sweep flagged that pass-2 cited this without a verified primary source.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-27 sweeps (Connection #1, multiple sweep blocks: ergothioneine→Nrf2→ABCG2 chain).

Protocol: - Cells: Caco-2 (ATCC HTB-37), differentiated 21 days on transwell inserts to recapitulate apical/basolateral polarity. - Treatment arms (n=4 wells per arm): - Vehicle control - Ergothioneine at 1, 10, 100 μM (apical) — brackets the koji-luminal-bioavailability range (OCTN1 transport is the rate-limiter) - Sulforaphane at 1 μM (positive control — established Nrf2 → ABCG2 inducer per Xie 2020) - Combination: ergothioneine 100 μM + sulforaphane 0.1 μM (sub-threshold sulforaphane to test additivity) - Time-course: 6, 24, 48 h. - Readouts: - ABCG2 mRNA (qPCR, normalized to GAPDH) - ABCG2 protein (Western, apical-membrane fraction) - Functional efflux (Hoechst 33342 accumulation assay; or urate-direct transport in bidirectional transwell if budget allows — strongly preferred per the L243-area review note that prior assays should ground in urate not just BCRP probe substrates) - Nrf2 nuclear translocation (immunofluorescence, 6 h timepoint) - Substrate-claim verification (parallel, $0): desk-check aspergillus-oryzae.md against primary literature (Cheah & Halliwell 2012, Borodina 2020) before committing wet-lab spend.

Estimated cost: $1,000–1,500 — Caco-2 culture + transwell inserts ($300), ergothioneine + sulforaphane standards ($150), qPCR primers + reagents ($200), Western antibodies for ABCG2 + Nrf2 ($300), Hoechst probe + plate reader time ($100), urate-transport reagents ($150) if pursuing the bidirectional transwell.

Estimated timeline: 3–4 weeks.

Dependencies: None — Caco-2 is a standard cell line. Could pair with §1.13 (limonene) to amortize fixed costs.

Success criteria: - Confirms synergy claim: ABCG2 mRNA and protein induction at koji-achievable ergothioneine concentrations (10–100 μM apical), with functional efflux upregulation. Promotes the "free synergy" claim from speculative to supported in engineered-koji-protocol.md and aspergillus-oryzae.md. - Falsifies / scopes down: No detectable ABCG2 induction at koji-achievable doses. Removes the synergy claim from the platform thesis; positive sulforaphane control remains the canonical ABCG2 inducer route.

Cross-references: synthesis/ 2026-04-27 Connection #1 (multiple sweep blocks); abcg2-modulators.md §2 (Nrf2 transcriptional axis); aspergillus-oryzae.md (native ergothioneine claim — verify before spending).

1.12 Local H₂O₂ Stress in Caco-2 from High Gut-Lumen Uricase¶

Status: Proposed | Cost: $800–1,200 | Weeks: 2–3 | Phase: 1

Affected wiki: uricase, aspergillus-oryzae, gut-lumen-sink, engineered-koji-protocol

What it tests: Does high local uricase activity in proximity to enterocytes generate H₂O₂ flux that exceeds local catalase scavenging capacity, causing oxidative stress / barrier compromise? Uricase generates H₂O₂ stoichiometrically 1:1 with urate consumption. Gut-lumen urate concentrations reach hundreds of μM; near a koji particle expressing uricase, peak local H₂O₂ flux could locally overwhelm host- and microbe-derived catalase. The catalase-neutralization assumption in uricase.md and aspergillus-oryzae.md is currently un-quantified.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-27 Open Question #1 (ergothioneine sweep).

Protocol: - Cells: Caco-2 transwell monolayer, 21-day differentiated. - Treatment arms (n=4): - Vehicle (apical buffer + 500 μM urate, no enzyme) - Uricase apical only (rasburicase or A. flavus recombinant uricase) at 0.1, 1, 10 U/mL - Uricase + catalase apical (1000 U/mL catalase) — tests whether exogenous catalase rescues - Uricase + ergothioneine 100 μM apical — tests whether co-delivered native koji metabolite mitigates - Readouts: - Apical H₂O₂ time-course (Amplex Red probe, fluorescent plate reader, every 5 min × 60 min). - TEER (trans-epithelial electrical resistance) — barrier-integrity readout, baseline + 1, 4, 24 h. - LDH release (apical and basolateral) — cytotoxicity proxy. - Tight-junction protein localization (ZO-1, occludin) by IF after 24 h. - Optional: add an A. oryzae whole-koji-extract arm (delivers uricase + native catalase + ergothioneine simultaneously) to test whether the native chorus is naturally self-buffering.

Estimated cost: $800–1,200 — Caco-2 + transwell ($300), Amplex Red kit ($200), rasburicase (research grade, $100), catalase ($50), TEER electrodes (already standard), IF antibodies ($200), reagents ($150).

Estimated timeline: 2–3 weeks.

Dependencies: Caco-2 cell access. Could co-run with §1.11 (ergothioneine arm transfers directly).

Success criteria: - No barrier compromise at any uricase dose tested in the koji-realistic dose range: removes the open question from the platform-risk register. - Barrier compromise at high doses (TEER drop >25%, LDH increase, ZO-1/occludin disruption): triggers a redesign of the engineered-strain expression cassette toward a regulated/dose-capped uricase output, OR mandates ergothioneine co-delivery as a safety feature, OR informs an enteric-coated dose-limiting formulation strategy.

Cross-references: synthesis/ 2026-04-27 Open Question #1; uricase.md (catalase-neutralization assumption); aspergillus-oryzae.md (native catalase + ergothioneine).

1.13 Limonene → ABCG2 Induction in Caco-2 (Tier 3 Stack Synergy Test)¶

Status: Proposed | Cost: $800–1,200 | Weeks: 3–4 | Phase: 1

Affected wiki: supplements-stack, abcg2-modulators, cannabinoids-terpenes

What it tests: Does limonene induce ABCG2 expression in Caco-2 enterocytes at supplement-relevant doses? Limonene was promoted to Tier 3 in supplements-stack.md based on the Venkatesan 2025 MSU rat model (50 mg/kg ≈ 0.5 g/day BSA-scaled human dose, close to typical supplement range), citing Nrf2 activation as a key mechanism. abcg2-modulators.md independently identifies Nrf2 as an ABCG2 transcriptional inducer (sulforaphane precedent, EC50 = 580 nM). This experiment tests whether limonene's putative Nrf2 activation translates to ABCG2 induction — gating whether the supplements-stack entry should be augmented with a "gut-lumen sink synergy" claim.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-26 Connection #3.

Protocol: - Cells: Caco-2 transwell, 21-day differentiated. - Treatment arms (n=4): - Vehicle - Limonene at 1, 10, 50, 100 μM (DMSO-solubilized; correct for DMSO at <0.1%) - Sulforaphane 1 μM (positive control) - Limonene + sulforaphane combination at sub-threshold doses - Time-course: 24, 48 h. - Readouts: ABCG2 mRNA (qPCR), ABCG2 protein (Western, apical-membrane fraction), functional efflux (Hoechst 33342 or urate-direct in bidirectional transwell).

Estimated cost: $800–1,200 — Caco-2 + transwell ($300), limonene + sulforaphane standards ($100), qPCR ($200), Western antibodies ($300), efflux probe ($100), reagents ($150).

Estimated timeline: 3–4 weeks (parallelizable with §1.11).

Dependencies: Caco-2 access; pairs cleanly with §1.11.

Success criteria: - Confirms synergy claim: ABCG2 induction at supplement-achievable limonene doses. Updates supplements-stack.md limonene entry to include the gut-lumen-sink synergy and promotes the compound from Nrf2-activator-only to Nrf2 + ABCG2-inducer. - Falsifies: No ABCG2 induction at any tested dose. Removes the synergy claim; limonene remains a Tier 3 NLRP3 modulator without the ABCG2 angle.

Cross-references: synthesis/ 2026-04-26 Connection #3; supplements-stack.md limonene entry; abcg2-modulators.md §2.

1.14 Additive ABCG2 Suppression by Androgens + TNFα + Butyrate Rescue + Lactoferrin Synergy¶

Status: Proposed | Cost: $2,300–4,300 (post-2026-05-16 butyrate dose-response arm adder) | Weeks: 4–6 | Phase: 1

Affected wiki: abcg2-modulators, androgen-urate-axis, gut-lumen-sink, supplements-stack, lactoferrin, koji-endgame-strain, purine-degrading-bacteria

What it tests: Four questions in one experiment. (1) Are androgen (DHT) and inflammatory (TNFα) suppression of ABCG2 additive, producing a "worst-case" phenotype for the gut-lumen sink in patients with both elevated androgens and chronic inflammation? (2) Does butyrate co-treatment rescue the suppressed phenotype via PPARγ induction, restoring substrate flow for the engineered uricase? (3) Does lactoferrin co-treatment also rescue the TNFα-suppressed phenotype via TNFα suppression (independent of PPARγ) — testing whether the koji endgame strain's engineered lactoferrin payload would synergize with its co-expressed uricase by relieving the inflammatory brake on ABCG2? (4) Do stack supplements (quercetin, EGCG, curcumin) inhibit ABCG2-mediated urate efflux at supplement-relevant gut-lumen concentrations, and is this antagonism genotype-dependent (Q141K vs. WT)?

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-27 Connection #1 + Proposed Experiment #2 (DHT + TNFα additive ABCG2 suppression); 2026-05-05 Connection #1 (lactoferrin → TNFα → ABCG2 derepression as substrate-supply synergy). Per the Pass 3 review augmentation: bundle the lactoferrin arm into the same Caco-2 factorial rather than queue a parallel experiment — the marginal cost is small relative to running two batches.

Protocol: - Cells: Caco-2 transwell (used in both Xie 2020 and Solbakk 2025 per abcg2-modulators.md), 21-day differentiated. - Treatment arms (3 × 3 + rescue arms, n=4 per arm): - DHT: 0, 10, 100 nM - TNFα: 0, 5, 20 ng/mL - All 9 combinations (DHT × TNFα factorial) - Butyrate rescue arm: repeat the highest-suppression combination (DHT 100 nM + TNFα 20 ng/mL) ± butyrate 1 mM apical. - Butyrate dose-response arm — Q141K concentration-gap resolution (added 2026-05-16): in both WT and Q141K-transfected Caco-2 monolayers, apply butyrate basolaterally at five concentrations (0.05, 0.2, 1, 2, 5 mM) under baseline conditions (DHT 0, TNFα 0). Brackets the published in vitro HDAC-inhibition range (Basseville 2012, PMID 22472121 — 1–5 mM range) and the lower bound of plausible enterocyte-nucleus concentrations after the mucus-layer + epithelial-surface gradient drop from luminal butyrate. Dual readouts (non-optional per Pass 3 tightening): (1) ABCG2 apical-membrane surface expression (membrane-fraction Western) — the trafficking-rescue readout; (2) functional urate efflux (transwell basolateral-to-apical urate flux) — the functional-restoration readout. WT-vs-Q141K comparison is the load-bearing contrast: WT butyrate response is PPARγ-mediated transcriptional induction; Q141K rescue is HDAC-mediated trafficking restoration. The dose-response shape should differ between WT (gradual induction) and Q141K (threshold-like rescue once HDAC inhibition is achieved). Outcome: minimum butyrate concentration that achieves Q141K rescue at the enterocyte nucleus — directly resolves the PDB-butyrate-Q141K concentration gap named in purine-degrading-bacteria.md §"Q141K + PDB-butyrate + HDAC". Marginal cost: ~$500–1,500 (10 conditions × n=4 = 40 wells; antibody reagents shared with existing arms). - Lactoferrin rescue arm: repeat the TNFα-only suppression (TNFα 20 ng/mL, DHT 0) and the worst-case combination (DHT 100 nM + TNFα 20 ng/mL) ± bovine lactoferrin 100 µg/mL basolateral (mimicking gut-lumen-side delivery from the koji endgame strain). Compare to the butyrate rescue arm — lactoferrin's mechanism (TNFα suppression upstream) is mechanistically distinct from butyrate's (PPARγ induction), so the two should not be redundant in the worst-case phenotype. - Supplement ABCG2 antagonism arms (added 2026-05-05, per synthesis Proposed Experiment #1): Using the basal (DHT 0, TNFα 0) monolayer, apply each of the three named stack supplements at supplement-relevant gut-lumen concentrations, apical side: quercetin 10 µM and 50 µM; EGCG 1 µM and 10 µM; curcumin 5 µM and 20 µM. Measure urate flux in all six conditions vs. DMSO vehicle. These concentrations reflect achievable post-oral-dose enterocyte exposure, not plasma concentrations (gut-lumen levels are 10–50× higher than plasma due to incomplete absorption). Note: the Yu 2024 EGCG in vivo data (PMID 38757391) shows net-favorable ABCG2/URAT1/GLUT9 effect in hyperuricemic mice, contradicting the in vitro inhibition story — include both 1 µM and 10 µM EGCG arms to see whether the inhibitory or the inductive effect dominates at supplement-achievable concentrations. Q141K-variant arm: if a Q141K-expressing Caco-2 line or patient-derived matched organoid is available, repeat the highest-effect supplement conditions (quercetin 50 µM + curcumin 20 µM) in both WT and Q141K backgrounds — this directly tests the stratification hypothesis that the contradiction is clinically significant for the highest-risk genotype but manageable for WT. - Time-course: 48 h. - Readouts: ABCG2 mRNA (qPCR), ABCG2 protein (Western, apical-membrane fraction), functional urate efflux (transwell, basolateral-to-apical urate flux — primary readout per Pass 3 critique that expression ≠ function), AR activation (CYP3A4 mRNA as positive control), NF-κB activation (IκBα Western), TNFα abundance in lactoferrin arms (ELISA, confirming that lactoferrin actually suppressed the added TNFα).

Estimated cost: $2,100–3,200 — Caco-2 + transwell ($400), DHT + TNFα + butyrate standards ($200), bovine lactoferrin (research-grade, ~$150 for 1 g), quercetin + EGCG + curcumin standards (~$150 total; all available as research-grade), urate analytics ($400, expanded for supplement arms), qPCR + Western antibodies ($600), TNFα ELISA ($150), assay reagents ($400), labor ($250 for added factorial arms). Original Proposed Experiment #1 ($1,500 parallel Caco-2 assay) is subsumed — shared Caco-2 infrastructure + urate-flux readout amortize fixed costs; this extended factorial is ~$600–700 more than the original §1.14 but replaces a separate experiment.

Computational prior (comp-004, 2026-05-05): IC50 occupancy analysis finds quercetin and curcumin both reach VERY HIGH ABCG2 inhibition at standard supplement doses — 6.8× and 8.3× their IC50 respectively (quercetin IC50 7,250 nM; curcumin IC50 1,630 nM), predicting 87–89% ABCG2 transport inhibition. Curcumin's < 1% bioavailability concentrates > 99% of the dose in the gut lumen, making it the highest-risk compound despite lower lumenal concentration than quercetin. EGCG operates via ABCG2 expression downregulation (24–72h transcriptional effect), not acute transport inhibition — a separate 72h treatment arm with ABCG2 Western blot is needed to capture this mechanism; the 48h transwell assay will miss it. This shifts supplement arms in §1.14 from screening ("is there an effect?") to testing a pharmacologically-predicted effect ("how large is it?"). Full analysis: wiki/supplement-abcg2-antagonism-computational.md and etc/experiments/comp-004-supplement-abcg2-antagonism/.

Computational prior (comp-038, 2026-05-20): Tier 2 butyrate assay audit finds YELLOW for the assay-infrastructure question. No ready-to-adopt simple/home colorimetric or breath-based butyrate assay surfaced. HPLC-UV is a plausible Tier 2-lab path for culture-supernatant butyrate, and electrochemical fecal SCFA profiling is a promising stool-specific future direction, but neither replaces GC-MS for the §1.14 butyrate dose-response arm without matrix validation. This does not change §1.14's priority framing; it keeps concentration verification tied to a Tier 3 analytical anchor if butyrate exposure becomes load-bearing. Full analysis: tier-2-butyrate-assay-audit-computational.md and etc/experiments/comp-038-tier-2-butyrate-assay-audit/.

Estimated timeline: 4–6 weeks (unchanged — supplement arms run in the same batch).

Dependencies: Caco-2 access. Stand-alone or paired with §1.11/§1.13 in the same Caco-2 batch run. Bovine lactoferrin is over-the-counter (Jarrow / NOW supplements work for pilot; research-grade Sigma L9507 for the actual experiment).

Success criteria: - Additive suppression confirmed AND butyrate rescue confirmed AND lactoferrin rescue confirmed: elevates the "dense-downstream + dual gate-opening stack" framing to supported. Strengthens the personalized-medicine case for fiber/butyrate in abcg2-modulators.md. Validates the lactoferrin-as-substrate-supply-synergist hypothesis in lactoferrin.md §4.7 and the koji-endgame-strain.md §2.2 positive-feedback framing — making the case for layering both cassettes (uricase + lactoferrin) substantially stronger than either alone. - Lactoferrin rescues but butyrate doesn't (or vice versa): identifies which gate-opener is operative in which subphenotype — informs whether the koji endgame strain payload is sufficient (lactoferrin built-in) or requires fermentable-fiber adjunct (butyrate-via-microbiome). - Neither rescues the worst-case phenotype: triggers a redesign of the gut-lumen-sink dosing model — uricase output capacity must compensate for unrescuable ABCG2 capping in the male/inflamed subgroup. - Suppression sub-additive (synergistic-suppression rather than additive): triggers same redesign as the no-rescue case.

Cross-references: synthesis/ 2026-04-27 Connection #1 + Proposed Experiment #2; 2026-05-05 Connection #1 (lactoferrin substrate-supply synergy); abcg2-modulators.md §3 (TNFα suppression — Ferrer-Picón 2020 PMID 31211831); androgen-urate-axis.md (AR-mediated ABCG2 suppression); lactoferrin.md §4.1 (Habib 2023 PMID 37926296 — Lf → ↓TNFα in vivo) and §4.7 (substrate-supply synergy framing); koji-endgame-strain.md §2.2.

1.15 Rice-Bran Substrate × Koji Uricase GI Survival¶

Status: Proposed | Cost: $800–1,200 | Weeks: 3 | Phase: 1

Affected wiki: engineered-koji-protocol, aspergillus-oryzae, koji-construct-design, gi-survival-prediction

What it tests: Does substrate composition (white rice vs. rice bran vs. rice bran + soybean) affect GI survival of koji-produced uricase via food-matrix protection — phytic acid, polyphenols, fiber binding to the tetramer, or transit-time effects? digestive-enzyme-optimization.md identifies rice bran as the optimal substrate for native enzyme yield (2,280 U/g lipase vs. ~1,800 U/g on plain rice), but no current experiment tests whether substrate effects propagate to GI survival of heterologous payloads.

Proposed in: synthesis/ (architecture: synthesis/README.md) Pass 2 Connection #7 (rice bran interaction) + Proposed Experiment #3 (rice bran composition impact on uricase GI survival). L829, L1002.

Protocol: - Strain: Wild-type A. oryzae RIB40 (no genetic modification — isolates the substrate variable from construct effects). Optional second arm with engineered uricase strain from §1.5 if available. - Substrate matrix: - Plain white rice (baseline) - Rice bran alone - Rice bran + 10% soybean (full optimization per digestive-enzyme-optimization.md) - Fermentation: 48 h at 30°C, 35% moisture. - Process: Lyophilize, grind to powder. - GI simulation: Resuspend in SGF (pH 2, pepsin, 2 h, 37°C) → SIF (pH 7, trypsin, 2 h, 37°C). Sample at 0, post-SGF, post-SIF. - Readouts: - Uricase activity at each stage (293 nm UV-Vis or rasburicase-style assay) - HPLC quantification of kojic acid, ferulic acid, ergothioneine in each koji type (secondary — does substrate change native metabolite production?) - LC-MS for phytic acid + polyphenol residuals (does rice bran's phytic acid bind divalent cations and affect tetramer stability?)

Estimated cost: $800–1,200 — koji ingredients ($50), assay reagents ($300), HPLC time ($200), LC-MS time ($300), labor ($150).

Estimated timeline: 3 weeks.

Dependencies: Standard fermentation lab + HPLC/LC-MS access.

Success criteria: - Rice bran improves survival ≥10% over plain rice: substrate optimization is a "free" stability lever; lock in rice bran + soybean as the production substrate. - No effect or destabilization: plain rice or other non-bran substrate becomes the production default; rules out bran as a stability variable. - Ferulic acid / phytic acid correlation: if survival tracks specific native metabolites, the variable is identifiable and tunable in future engineered constructs.

Cross-references: synthesis/ Pass 2 Connection #7 + Proposed Experiment #3; engineered-koji-protocol.md §08 (substrate optimization); gi-survival-prediction.md (food-matrix model).

1.16 OPT-1 Disulfide-Engineered Uricase in Koji vs. WT — GI Survival Head-to-Head¶

Status: Proposed | Cost: $1,800–2,500 | Weeks: 6–8 | Phase: 1

Affected wiki: engineered-koji-protocol, uricase-variant-selection, protein-engineering-strategy, gi-survival-prediction

What it tests: Does the OPT-1 engineered uricase variant (A6C + R290C + S119C + C220C + K234E + K236E — disulfide-bond-stabilized) achieve higher GI survival when expressed in A. oryzae koji compared to wild-type A. flavus uricase in the same construct? OPT-1 was designed in uricase-variant-selection.md and validated in S. cerevisiae context; the A. oryzae redox environment differs and disulfide formation may not transfer cleanly. If OPT-1 koji achieves ~55–70% GI survival vs. ~25–35% for WT, koji becomes the preferred platform and obviates parallel yeast fermentation for stability gains.

Proposed in: synthesis/ (architecture: synthesis/README.md) Pass 2 Proposed Experiment #1 (Disulfide-engineered uricase in koji). L948.

Protocol: - Constructs: - WT control: [PamyB — SP — A. flavus uaZ codon-optimized — TamyB] - OPT-1: same construct with the 6-mutation cassette (A6C + R290C + S119C + C220C + K234E + K236E) - Strain background: A. oryzae NSAR1. - Fermentation: Solid-state rice bran (per §1.15 result, or default white rice) 48–60 h. - Readouts: - Titer (HPLC + Western on lyophilized koji) - Thermal stability (Tm by DSF — confirms disulfide formation) - Disulfide bond formation: non-reducing SDS-PAGE + DTNB free-thiol assay - GI survival via SGF → SIF (per §1.6 / §1.10 protocol) - Comparators: Purified engineered yeast OPT-1 from engineered-yeast-uricase-proposal.md; rasburicase positive control.

Estimated cost: $1,800–2,500 — OPT-1 gene synthesis ($600), yeast OPT-1 control purification or vendor ($300), DSF + thermal stability ($200), gel electrophoresis + Western ($300), SGF/SIF reagents ($150), labor ($300).

Estimated timeline: 6–8 weeks.

Dependencies: Engineered koji strain transformation capacity; A. oryzae construction tooling. Could fold into the §1.9 Ward 1995 dual-cassette program if shared infrastructure is available.

Success criteria: - OPT-1 koji ≥55% GI survival AND ≥80% titer vs. WT: koji becomes preferred platform; eliminates need for parallel yeast OPT-1 production. Locks in OPT-1 as the default uricase variant for engineered koji. - Disulfide formation fails (non-reducing gel shows monomer at expected MW): A. oryzae redox environment incompatible with OPT-1's six engineered cysteines. Either revert to WT or design a pH-stability-only variant. - Activity preserved but GI survival not improved: suggests survival is gated by gastric pH not protease, and disulfides don't help enough — pivot to enteric-coated formulation rather than further protein engineering.

Cross-references: synthesis/ Pass 2 Proposed Experiment #1; uricase-variant-selection.md (OPT-1 design rationale); protein-engineering-strategy.md; engineered-koji-protocol.md §02–§05 (uricase construct).

1.17 Quercetin × Ursolic Acid × Carnosine Three-Way Synergy on MSU-Stimulated THP-1¶

Status: Proposed | Cost: $1,500–2,000 | Weeks: 3–4 | Phase: 1

Affected wiki: nlrp3-inhibitor-screen, supplements-stack, carnosine, engineered-koji-protocol

What it tests: Does combining the three Tier-1 NLRP3 modulators (quercetin, ursolic acid, carnosine) produce greater than additive IL-1β suppression in MSU-stimulated human macrophages? If super-additive, the engineered-koji platform should target all three (uricase + carnosine + secondary metabolite cassette for ursolic acid/quercetin precursors). If only one or two compounds carry the signal, simplifies the construct design.

Proposed in: synthesis/ (architecture: synthesis/README.md) Pass 2 Proposed Experiment #2 (synergy testing — three Tier-1 NLRP3 inhibitors). L974.

Protocol: - Cells: THP-1 PMA-differentiated to M1 phenotype (24 h LPS prime). - Stimulus: MSU crystals (100 μg/mL, 4 h post-prime). - Treatment matrix: - Quercetin alone: 5, 10, 20 μM - Ursolic acid alone: 2.5, 5, 10 μM - Carnosine alone: 1, 2, 5 mM - 3-way combinations at IC50 of each compound (single, all pairs, full triplet) - Readouts: - IL-1β (apical + basolateral if transwell) — primary readout, ELISA - Caspase-1 activity (luminescence-based assay) - ASC speck formation (immunofluorescence; manual or automated count) - Loewe combination index computed for all combinations (CI <0.7 super-additive, 0.7–1.3 additive, >1.3 antagonistic)

Estimated cost: $1,500–2,000 — THP-1 + reagents ($300), IL-1β ELISA ($400), caspase-1 luminescence ($200), MSU crystals + LPS ($100), compounds standards ($100), labor ($400).

Estimated timeline: 3–4 weeks.

Dependencies: THP-1 cell culture capacity. Independent or pairs with §1.7 (broader NLRP3 pathway validation).

Success criteria: - 3-way super-additive (CI <0.7): justifies engineering all three into the koji endgame strain. Strengthens the multi-target food-grade pathway-modulator thesis. - 2-way super-additive only: simplifies construct design — drop the redundant compound from the engineering list. - No synergy beyond additive: revert to single-compound prioritization; carnosine is the strongest standalone candidate per evidence tier.

Cross-references: synthesis/ Pass 2 Proposed Experiment #2; nlrp3-inhibitor-screen.md (Tier-1 candidates); carnosine.md (URAT1/GLUT9 angle).

1.18 Native Koji Enzyme SGF Survival — Free Extract vs. Whole Biomass (2-Arm)¶

Status: Proposed | Cost: $300–500 | Weeks: 2 | Phase: 1

Affected wiki: koji-home-fermentation, engineered-koji-protocol, gi-survival-prediction, digestive-enzyme-optimization

What it tests: A 2-arm sharpening of §1.6: does cell-wall encapsulation in intact mycelium provide food-matrix protection that free enzyme extract lacks? Resolves the Koji-S vs. Koji-I default question for native koji enzymes (lipase, protease, amylase) in one experiment rather than two. Per the L81 Pass 3 review augmentation, both arms must be run in parallel.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-27 Proposed Experiment #3 (Simulated GI survival assay of native koji enzymes — 2-arm augmentation). L81.

Protocol: - Material: Wild-type A. oryzae fermented on rice (or rice bran per §1.15 result), 48 h. - Two parallel arms: - Arm A — Free extract: Buffer-extract koji enzymes (sodium phosphate, 4°C, 30 min). Clarify by centrifugation. Measure activity in supernatant. - Arm B — Whole biomass: Lyophilize whole koji, grind to powder. Resuspend at equivalent enzyme load to Arm A. - GI simulation: Both arms through SGF (pH 2, pepsin, 2 h) → SIF (pH 7, pancreatin, 2 h). - Readouts at each stage: - Lipase: pNPP hydrolysis or tributyrin titration - Protease: azocasein assay - Amylase: starch-iodine or DNS reducing-sugar - Positive control: Pancrelipase (Creon) at equivalent enzyme load.

Estimated cost: $300–500 — pNPP, azocasein, starch ($100), Creon control ($30), SGF/SIF reagents ($50), labor ($150).

Estimated timeline: 2 weeks.

Dependencies: Standard wet-lab. Pairs cleanly with §1.6 (extends it to the 2-arm design) — could replace §1.6 outright if budget is tight.

Success criteria: - Whole biomass survival ≥30% AND free extract survival <10%: cell-wall encapsulation is the protective mechanism; Koji-I (intracellular) is the default for engineered constructs. Updates engineered-koji-protocol.md §06. - Both arms survive ≥30%: extract-vs-biomass distinction doesn't matter for native enzymes; substrate or food-matrix is the driver. Decouples the construct decision. - Both arms <10%: native enzyme delivery via koji is inherently limited to pre-ingestion (marinade) effects; engineered delivery requires enteric coating regardless of intracellular vs. secreted strategy.

Cross-references: synthesis/ 2026-04-27 Proposed Experiment #3; engineered-koji-protocol.md §06 (Koji-S vs. Koji-I trade-off); digestive-enzyme-optimization.md §4 (native enzyme activity); enzyme-quantification-protocol.md §3 + §5 (assay methodology + sample-prep for the readouts above).

1.19 Methodological Standard — Rodent Cellular IC50 Translation Caveat¶

Status: Standing | Cost: $0 | Weeks: ongoing | Phase: 1 (methodology)

Affected wiki: nlrp3-inhibitor-screen, chembl-cross-check, supplements-stack, nlrp3-exploit-map, all per-compound pages citing rodent IC50 values.

Standard (not an experiment — methodology): Rodent cellular IC50 values for NLRP3 inhibitors and other inflammasome-pathway compounds may diverge from human cellular IC50 by up to 3 orders of magnitude. Anchoring example: dapansutrile IC50 = 1 nM in mouse J774A.1 vs. 1,000 nM (1 μM) in human MDM under LPS+nigericin stimulation (ChEMBL v34). Apply across the wiki:

Tag every rodent-derived IC50 citation with the species and assay format. Do not present rodent IC50 as if it were a clinical-grade potency claim.
Prefer human-cell data (THP-1, U937, primary human MDM, PBMC) over rodent cellular data when evaluating new compound candidates.
For mouse-only compounds (β-caryophyllene, BHB rodent ketogenic-diet gout model, ursolic acid Kawasaki mouse, carnosine hyperuricemia rat), propose human-cell follow-up assays before promoting from animal to clinical evidence tier.
For compounds with no curated human IC50, plan species-bridging experiments (THP-1 MSU IC50 head-to-head with rodent benchmark) as part of the validation queue rather than relying on rodent extrapolation.
Counter-example to flag: repurposing candidates with strong adjacent-indication human data (zileuton, disulfiram, avacopan) may translate cleaner than a compound with strong rodent gout data — species-gap failures stack, while existing human safety + PK data skip the failure mode.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-23 Connection #2 (dapansutrile species-gap). L584.

Cross-references: chembl-cross-check.md (curated ChEMBL evidence per compound), nlrp3-inhibitor-screen.md §"Species-gap caveat" line 38, every per-compound wiki page citing rodent data.

1.20 Lactoferrin + EGCG CP1a Super-Additivity Assay (THP-1 Macrophage 2×3 Dose Matrix)¶

Status: Proposed (gated on §1.9) | Cost: $1,500 | Weeks: 3–4 | Phase: 1

Affected wiki: lactoferrin, egcg, nlrp3-exploit-map, supplements-stack, koji-endgame-strain

What it tests: Does combining lactoferrin (LPS sequestration upstream of TLR4 — CP1a input-blocking) with EGCG (20S proteasome inhibition at IC50 = 86 nM, ChEMBL v34 — IκBα stabilization downstream of NF-κB activation, CP1a output-blocking) produce super-additive IL-1β suppression in MSU-stimulated human macrophages? Tag: In Vitro (EGCG 86 nM proteasome target) + Mechanistic Extrapolation (super-additivity prediction from independent-barrier cascade logic). The textbook conditions for super-additivity in a cascade are two independent barriers to the same output — lactoferrin neutralizes the input (LPS) before signal-1 priming can occur; EGCG blocks the output (NF-κB nuclear translocation) regardless of upstream signal. The operationally load-bearing question is dosing: EGCG carries a hepatotoxicity ceiling at ~600 mg/day (well-established; see egcg.md, disulfiram.md for the hepatic-stress stacking concern). If the combination is super-additive, dosing both compounds at sub-maximal individual amounts beats either at maximum, keeping EGCG below the liver ceiling while still hitting the CP1a target. If only additive (CI 0.7–1.3), no dosing flexibility is gained. The result changes both the supplement-stack recommendations and the koji-endgame-strain priority list.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-24 sweep (25-file v1.2 batch), Connection #4 + Proposed Experiment #2.

Protocol: - Cells: PMA-differentiated THP-1 macrophages (or equivalent human macrophage source — primary MDM if available). - Stimulus: LPS prime (signal 1) + MSU crystals (NLRP3 trigger, signal 2). - Treatment matrix (2×3 + combination arm, n=4 per arm): - Lactoferrin: 0, low, high (apo or holo recombinant; bracket plasma-achievable and koji-luminal-achievable concentrations) - EGCG: 0, low, high (bracket the 86 nM proteasome IC50) - Mid-range combination arm at the IC50 of each compound (tests for super-additivity at the response midpoint where Loewe analysis is most sensitive) - Readouts: - IL-1β ELISA (primary endpoint) - IκBα Western blot (mechanistic — confirms the EGCG arm is engaging the proteasome target; IκBα retention should track the 86 nM cellular IC50) - LPS-binding assay on lactoferrin-treated medium (mechanistic — confirms the lactoferrin arm is sequestering LPS rather than acting through an off-target mechanism) - Analysis: Compute Loewe combination index across the matrix. CI <0.7 super-additive; 0.7–1.3 additive; >1.3 antagonistic.

Estimated cost: $1,500 — THP-1 cells + reagents (~$300), recombinant lactoferrin apo or holo form (~$400), EGCG standard (~$50), LPS + MSU (~$100), IL-1β ELISA kit (~$300), Western antibodies for IκBα (~$200), labor/materials (~$150).

Estimated timeline: 3–4 weeks (THP-1 differentiation 1 wk + assay 1–2 wk + analysis 1 wk).

Dependencies: Gated on §1.9 Ward 1995 dual-cassette feasibility test. Per V4-Pro peer review (2026-04-25), this assay is "premature before feasibility": if the engineered koji platform cannot co-express both lactoferrin and uricase in one strain, the platform-level synergy claim collapses — Brian would source supplement-grade lactoferrin separately, which still works for the experiment in isolation but removes the engineered-strain motivation. Independent of §1.7 (broader NLRP3 panel), but the IL-1β readout can fold into §1.7 if both run together to amortize THP-1 differentiation and ELISA fixed costs.

Success criteria: - Super-additive (CI <0.7): justifies dosing both compounds together at sub-maximal individual doses, keeping EGCG under the ~600 mg/day hepatotoxicity ceiling while achieving full CP1a coverage. Strengthens the case for engineering both into the koji endgame strain (and conversely, the §1.9 dual-cassette result becomes operationally consequential, not just architecturally elegant). - Additive (CI 0.7–1.3): no dosing flexibility gained. Stack-level recommendation: dose each at its individual optimum if both are tolerated; no specific synergy claim added to supplements-stack.md. - Antagonistic (CI >1.3): unexpected — investigate whether the lactoferrin matrix interferes with EGCG bioavailability or proteasome access. Plausible mechanism: iron–EGCG chelation. Lactoferrin is a high-affinity iron-binding protein and EGCG is a known iron chelator; the apo vs. holo form of lactoferrin should differentiate iron-mediated antagonism from a direct interaction. Likely indicates one compound should be dosed alone, not in combination.

Cross-references: synthesis/ 2026-04-24 Connection #4 + Proposed Experiment #2; lactoferrin.md §3 (LPS/CD14 sequestration mechanism); egcg.md (20S proteasome 86 nM target, hepatotoxicity ceiling); nlrp3-exploit-map.md v1.2 CP1a (independent input/output barrier framing); supplements-stack.md (current standalone entries for both compounds); koji-endgame-strain.md (downstream engineering implication, gated on §1.9).

1.24 Carnosine Co-Expression Validation in A. oryzae (Koji Endgame Optional Third Cassette)¶

Status: Proposed | Cost: $1,500–2,500 | Weeks: 4–6 | Phase: 1

Affected wiki: koji-endgame-strain, engineered-koji-protocol, carnosine, androgen-urate-axis

What it tests: Can Lactobacillus carnosine synthase (CarnS, ATP-grasp family, ~460 aa) co-expressed in A. oryzae with bacterial aspartate decarboxylase (panD, ~140 aa, for β-alanine supply) produce carnosine at ≥500 mg/L in koji pore fluid — the threshold needed to deliver 1–1.5 g carnosine/day at 10–15 g dry koji/day? This is the gating experiment for the optional third cassette in the koji endgame strain, specifically targeting the androgen-driven URAT1 upregulation axis that the primary uricase + lactoferrin dual-cassette does not address. (source: engineered-koji-protocol.md §15; koji-endgame-strain.md §2.5)

Proposed in: engineered-koji-protocol.md §15 — Carnosine Co-Expression Module, Proposed Validation Experiment section.

Protocol: - Transform A. oryzae RIB40 (or NSAR1 for auxotrophic selection) with single-copy [PTEF1–CarnS–TamyB] cassette integrated at a characterized neutral locus (specific locus TBD; see koji-construct-design.md and engineered-koji-protocol.md §03 for current standard choices). Selection marker: separate auxotrophic marker from uricase cassette (e.g., niaD or adeA if uricase uses pyrG). - Ferment 100 mL on polished rice at 30°C, 48–60 h at 35% moisture. - If β-alanine bottleneck is suspected after first pass, add a second construct with [PTEF1–panD–TamyB] and re-test. - Primary readout: Carnosine titer by LC-MS (OPA/FMOC derivatization, quantify against a carnosine standard curve; β-alanine and histidine pools measured in the same run). Accept: ≥500 mg/L in pore fluid. Reject: <100 mg/L. - Secondary readouts: Uricase titer (if dual-cassette strain; spectrophotometric urate-degradation assay at 293 nm), growth rate vs. parental strain (radial extension on PDA at 30°C), kojic acid baseline (HPLC), β-alanine and histidine pool sizes (LC-MS), carnosine stability through standard workup (measure before and after lyophilization + grinding).

Estimated cost: $1,500–2,500 — gene synthesis (CarnS codon-optimized, ~1.4 kb; plus optional panD, ~420 bp; ~$600–1,000), HPLC carnosine standards ($150), β-alanine/histidine standards ($100), fermentation consumables ($200), LC-MS time ($400), labor ($150–500).

Estimated timeline: 4–6 weeks end-to-end.

Dependencies: A. oryzae transformation capacity (same infrastructure as §1.9 Ward 1995 dual-cassette test). Can be run in parallel with §1.9 if lab access permits, or sequentially after §1.9 confirms the dual-cassette architecture is viable.

Success criteria: - Promote to combined strain if carnosine ≥500 mg/L AND uricase titer unchanged AND growth rate within 10% of parental. Move carnosine cassette into the production uricase-expressing strain. - Add β-alanine supply module if carnosine 100–500 mg/L AND β-alanine pool appears limiting. Re-test with panD co-expression. - De-prioritize koji track for carnosine if <100 mg/L after panD co-expression. Fall back to S. cerevisiae as the carnosine production host. - Re-engineer the cassette if base koji phenotype is impaired. Options: swap PTEF1 → PamyB (inducible, lower metabolic burden baseline), try an alternative neutral locus, or reduce cassette copy number.

Strategic context: Carnosine is the highest-priority optional third cassette for a male/high-androgen product configuration because its URAT1/GLUT9 downregulation is mechanistically mirror-image to androgen-driven URAT1 upregulation — the dominant driver of hyperuricemia in the platform's primary demographic (male gout patients, TRT/SERM/AAS users). The uricase + lactoferrin dual-cassette does not address this renal reabsorption axis; carnosine is the natural extension. (source: koji-endgame-strain.md §2.5; androgen-urate-axis.md)

Cross-references: koji-endgame-strain.md §2.5 (carnosine as optional third cassette, androgen-axis alignment); engineered-koji-protocol.md §15 (full co-expression protocol, decision point, format constraints); carnosine.md (mechanism, gout-specific evidence, bioavailability); androgen-urate-axis.md (URAT1 upregulation mechanism).

1.21 Natural-Product C5aR1 Antagonist Screening — Computational Pass (Closes the CP0 Fermentable-Coverage Question)¶

Status: Closed (negative result, 2026-04-27) | Cost: $0 | Weeks: 0.5 | Phase: 1 (computational, complete)

Affected wiki: complement-c5a-gout, nlrp3-exploit-map (CP0), open-enzyme-vision (CP0 gap statement).

What it tests: The Open Enzyme platform has a structural gap at CP0 — the complement-priming chokepoint where MSU crystals → classical-pathway activation → C5a → C5aR1 binding on neutrophils/macrophages → non-transcriptional NLRP3 priming. CP0 is the upstream-most chokepoint in the gout cascade, and the engineered koji / yeast / supplements stack has zero coverage at this step (see complement-c5a-gout.md §9 for the full gap analysis and open-enzyme-vision.md "CP0 gap — honest acknowledgment"). Avacopan (Tavneos, FDA-approved 2021 for ANCA vasculitis, oral C5aR1 allosteric antagonist) is the pharma adjunct here — and it is a synthetic small molecule, not a natural-product analog. This experiment runs a fast, free computational scan to either (a) surface a natural-product C5aR1 antagonist worth wet-lab triage — opening a fermentable lead at CP0 — or (b) definitively close the door on natural-product CP0 coverage and lock in "CP0 requires a pharma adjunct" as the platform thesis. The hit-rate prior was low: known C5aR1 antagonists are dominated by synthetic constrained peptides (PMX-53 series, JPE-1375) and synthetic small-molecule allosterics (avacopan, NDT-9513727, JNJ-27141491); the binding pocket is not a typical plant-secondary-metabolite scaffold target. Negative result was the expected and operationally useful outcome.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-24 sweep (25-file v1.2 batch), Connection #2 + Proposed Experiment #3. Run on 2026-04-27.

Protocol — what was actually run:

ChEMBL target confirmation and bioactivity pull. Query ChEMBL REST API for target CHEMBL2373 (confirmed: human C5AR1, UniProt P21730, "C5a anaphylatoxin chemotactic receptor 1", G-protein-coupled receptor, single protein, Homo sapiens). Total bioactivity records at CHEMBL2373: 4,873 (April 2026 query). Filter the curated potent tail at pChEMBL ≥ 6 (sub-μM IC50, Ki, or EC50 against human receptor).
Manual classification of the potent tail. Walk the top ~20 highest-pChEMBL entries; classify each as synthetic vs. natural-product by inspecting molecule_type, structure_type, pref_name, and the natural_product flag on each ChEMBL molecule record. Distinguish "natural-product-derived synthetic peptide" (e.g., C5a C-terminal mimics) from true small-molecule natural products.
Cross-database verification. Search NPASS (Natural Products Activity & Species Source) and LOTUS (Naturally Occurring Chemical Compounds Storage) for any curated natural-product entry at C5AR1. Search NPAtlas for microbial natural products with reported C5aR1 activity.
Open Targets cross-check. Pull the C5AR1 known-drugs list from the Open Targets Platform (target ENSG00000197405) — surfaces clinical/preclinical compounds that ChEMBL may not have indexed yet, plus any natural-product-derived clinical assets.
Targeted primary-literature sweep. PubMed-via-WebSearch queries for: "C5aR1" antagonist plant, "C5aR1" natural product flavonoid OR terpenoid OR alkaloid, "C5a receptor" inhibitor flavonoid IC50 cell-based, "C5aR1" inhibitor marine fungus. Catches any plant- or microbe-source antagonist reported in primary literature without ChEMBL curation.
Avacopan structural-class check. Quick SwissSimilarity / pharmacophore scan against avacopan's cyclohexanecarboxamide / piperidine motif — most plant secondary metabolites won't share this scaffold but worth a fast pass. (Skipped after step 5 returned <5 candidates — see "what was not run" below.)

What was not run, and why: AlphaFold + AutoDock Vina docking against a curated natural-product library was deferred. The protocol gates docking on ≥5 wet-lab-validated or strongly-prior-supported natural-product candidates emerging from steps 1–5; the actual count was 0 wet-lab-validated natural-product C5aR1 antagonists, with only 2 computational-only docking hits and 1 indirect "neutraligand" surfacing in the literature (detailed below). At <5 candidates, docking adds no signal — it would either re-derive the existing computational hits (already published) or surface novel docking-only leads of the same evidence tier as those already discounted. The wet-lab triage gate is the binding constraint, and there is nothing to triage.

Result:

Total ChEMBL bioactivities at human C5AR1 (CHEMBL2373): 4,873 (April 2026; up from the 506 figure cited in the existing complement-c5a-gout.md §10.1 — that older count was likely distinct compounds at a higher-confidence cutoff or an earlier ChEMBL release, not total bioactivity records; see cross-reference correction note in §10.1 follow-up).
Curated natural-product hits at human C5AR1 with wet-lab functional or binding data: 0. No compound flagged natural_product=1 in ChEMBL appears in the sub-μM potency tail. The full pChEMBL ≥ 6 list at CHEMBL2373 is dominated by synthetic cyclic peptides (PMX-53/PMX-205 series, 1995–2006 BMCL/JMC papers, IC50 18–60 nM in [125I]-C5a binding or PMN glucosaminidase release), synthetic imidazolidinones / piperazines / piperidines (the CO13 binding-competition series, IC50 25–450 nM), and clinical-stage allosteric small molecules in the avacopan structural class.
Apparent peptide hit, not a natural product: CHEMBL217378 (sequence ISHKDMQLGR, EC50 1.3 nM in PMN polarization) initially looked natural-product-flavored at the sequence level but is curated as molecule_type: "Protein", natural_product: 0, pref_name: "ISHKDMQLGR" — a synthetic decapeptide derived from C5a's own C-terminal sequence, designed as a receptor-engagement probe, not an isolated natural product.
Computational-only natural-product candidates from primary literature (no wet-lab confirmation):
Acteoside (verbascoside; phenylethanoid glycoside; plant natural product widely distributed in Olea europaea, Plantago, Verbascum, Rehmannia, Lamiales generally) — Shaikh & Siu 2016, Med Chem Res 25:1564–1573 (PMID 27499603). Homology model of C5aR1 (Glide XP docking + MM-GBSA), ΔG_bind = −113.9 kcal/mol, XP GScore = −12.4 kcal/mol. Authors explicitly state: "biological experiments to validate this inhibitor are being planned as a future work." No follow-up validation has been published in the decade since. Evidence level: Computational / homology-model docking only.
Toxicarioside (cardiac glycoside from Antiaris toxicaria, the upas tree; latex traditionally used as a dart poison in Southeast Asia) — same Shaikh & Siu 2016 paper, ΔG_bind = −90.1 kcal/mol. Not pursuable on safety grounds: the A. toxicaria cardenolides (toxicariosides J/K/L/O, antiarin) are cytotoxic Na+/K+-ATPase inhibitors at sub-μM doses; this is a fundamentally toxic scaffold, fermentable or not. Evidence level: Computational only.
Resveratrol — Mishra et al. 2020, J Biomol Struct Dyn (PMID 32131707). Molecular dynamics + automated docking + MM-GBSA + circular dichroism + steady-state fluorescence biophysics. Critically, resveratrol binds hC5a (the ligand), not C5aR1 (the receptor) — a "neutraligand" approach that prevents C5a from engaging C5aR1 by sequestering the soluble anaphylatoxin. Mechanistically distinct from receptor antagonism (the question this scan was framed around) but tangentially relevant. No reported potency in standard inhibitor units; the biophysics suggest binding but do not establish a functional IC50 on C5a-driven C5aR1 signaling. Evidence level: Computational + cell-free biophysical binding; no functional assay. Resveratrol is already on Brian's near-term radar for SIRT1 activation / NLRP3 modulation but is not promoted on this CP0-related signal alone.
Open Targets known-drugs list at C5AR1 (ENSG00000197405): Avacopan (CCX-168, FDA-approved 2021, oral C5aR1 antagonist, 30 mg BID dosing, the canonical pharma reference) plus the upstream C5-binding biologics (eculizumab, ravulizumab, zilucoplan) which are not C5aR1-directed. No natural-product-derived clinical or preclinical asset.
NPASS / LOTUS: No curated natural-product entries at C5AR1 / CHEMBL2373 surface in either database (queried 2026-04-27). NPASS contains 222,092 NP-target pairs across 5,863 targets; the absence of C5AR1 in this corpus is itself informative — it means that across the full curated natural-product activity landscape, C5AR1 has not been assayed with sufficient hit confirmation to merit a database entry.
Plant flavonoid CH50 literature: As already documented in complement-c5a-gout.md §10.2, broad complement-pathway inhibition (CH50, AP50) by quercetin, EGCG, baicalein, curcumin, resveratrol falls in the 50–500 μM range — 100–1000× weaker than synthetic C5aR1 antagonists, multi-target rather than C5aR1-selective, and not pursuable as CP0 coverage at dietary or supplement-achievable doses.

Conclusion — CP0 fermentable coverage is closed for natural products. The scan returned zero wet-lab-validated natural-product C5aR1 antagonists. The two computational-only plant hits (acteoside, toxicarioside) have not been functionally validated in the decade since publication despite the original authors' stated plans, and toxicarioside is non-pursuable on safety grounds anyway. Resveratrol's hC5a binding is mechanistically distinct (neutraligand, not antagonist) and biophysically weak. Avacopan remains the pharma adjunct at CP0; the engineered koji / yeast / supplements stack does not have, and structurally is unlikely to acquire, fermentable CP0 coverage. This is a useful negative result — it converts the existing CP0 gap statement from "we don't have natural-product coverage at CP0" to "we ran the scan; here is exactly what we found and exactly why avacopan is the answer," removing this question from the platform's open backlog.

Re-open conditions: (a) a new ChEMBL release (v35+) curates a sub-μM natural-product C5aR1 antagonist with primary-literature wet-lab confirmation; (b) a primary-literature paper reports a fermentable C5aR1 antagonist with functional cell-based or in vivo evidence; © avacopan loses regulatory or supply availability, raising the value of even weak fermentable backups; (d) the Shaikh & Siu 2016 group (or an independent group) publishes the long-promised in vitro validation of acteoside on C5aR1-expressing cells. Until one of these triggers, the CP0 question stays closed and the platform thesis stays "Open Enzyme covers crystal elimination upstream of CP0 + downstream chokepoints CP1–CP6; avacopan covers CP0 itself."

Cross-references: complement-c5a-gout.md §9 (CP0 platform gap) + §10 (natural-product modulator literature); nlrp3-exploit-map.md (CP0 chokepoint); open-enzyme-vision.md ("CP0 gap — honest acknowledgment"); synthesis/ 2026-04-24 Connection #2 + Proposed Experiment #3. Source: ChEMBL CHEMBL2373 (April 2026); Open Targets ENSG00000197405; Shaikh F, Siu SWI. Med Chem Res 25:1564–1573 (2016, PMID 27499603); Mishra et al. J Biomol Struct Dyn 2020 (PMID 32131707).

1.22 Gut-Selective Food-Grade HDAC Inhibitor Screen for Q141K-ABCG2 Trafficking Rescue¶

Status: Proposed | Cost: $5,000–8,000 | Weeks: 8–10 | Phase: 1

Affected wiki: abcg2-modulators, supplements-stack, gut-lumen-sink

What it tests: The Q141K variant of ABCG2 (~12% population allele frequency; ~25% of East Asian, ~4% of European populations) produces a misfolded protein that is retained in the endoplasmic reticulum rather than trafficked to the apical membrane. HDAC inhibition (specifically class I HDACs — HDAC½/3) rescues this trafficking defect by upregulating Hsp90 chaperoning via HSF1 activation (Basseville et al. 2012, PMID 22472121). Butyrate (sodium butyrate, food-grade) is the known food-grade class I HDACi that rescues Q141K ABCG2 trafficking at ~1 mM concentrations achievable in the colon via fermentable fiber. However, butyrate's efficacy depends on microbiome composition and fiber intake — there is no reliable way to deliver a specific dose from diet. This experiment screens alternative food-grade HDACi candidates for (a) class I HDAC selectivity over HDAC6, (b) gut-enriched activity (Caco-2 ≥ hepatocyte potency), © trafficking-rescue efficacy at concentrations achievable via food or supplement, and (d) absence of hepatotoxicity signal (the reason vorinostat/SAHA remains oncology-restricted).

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-05-05 Proposed Experiment #3. Per the Pass 3 review: the design must include a tissue-selectivity assay (Caco-2 vs. hepatocyte HDAC activity as primary screen discriminator) and explicit HDAC½/3 isoform focus; HDAC6 inhibition is off-target for this purpose and is a pan-tissue toxicity risk. Original cost estimate ($5,000) was flagged as optimistic if the selectivity criterion is operationalized; revised to $5,000–8,000 to include paired Caco-2/hepatocyte HDAC activity assays.

Background on Q141K mechanism: ABCG2-Q141K's ATP-binding domain folds incorrectly at the NBD2 interface → ERAD (ER-associated degradation) retention → reduced apical transporter density → impaired urate efflux. HDACi → Hsp90α/β upregulation + HSF1 nuclear translocation → ↑chaperone-assisted folding of the misfolded NBD2 → partial membrane-trafficking rescue. Cells transfected with Q141K ABCG2 show ~30–50% restoration of surface expression at butyrate 1 mM (Basseville 2012). The clinical relevance: Q141K homozygotes on clomid/TRT with low fermentable-fiber intake are the hardest-to-rescue subgroup; a direct food-grade HDACi supplement would be meaningful.

Protocol:

Stage 1 — In silico candidate selection ($500): - Compile known food-grade or GRAS-adjacent compounds with documented HDAC inhibition: butyrate/short-chain fatty acids (the known benchmark), sulforaphane (indirect via Nrf2/keap1, class I-relevant), allyl mercaptan (garlic-derived, reported class I HDACi), phenethyl isothiocyanate (PEITC, cruciferous), hydroxycinnamic acids (caffeic acid, ferulic acid), diallyl disulfide (DADS). - Screen each candidate against: class I HDAC (HDAC½/3) IC50 from ChEMBL / primary literature; HDAC6 IC50 (if known — selectivity check); Caco-2 permeability / gut-lumen-achievable concentration estimate; reported hepatotoxicity signal (LD50 or NOAEL from TOXNET / EFSA). - Select top 5–7 candidates by gut-enriched concentration × class I HDAC potency ratio.

Stage 2 — Paired Caco-2 / hepatocyte HDAC activity assay ($2,000–3,000): - Cell lines: Caco-2 (enterocyte model) and HepG2 or primary human hepatocytes (hepatocyte model). The primary screen discriminator is Caco-2 HDAC activity ÷ hepatocyte HDAC activity for each candidate at matched concentrations. Gut-selective candidates have ratio > 2 (more HDAC inhibition in enterocytes than hepatocytes). - Readout: Fluorometric HDAC activity assay (FLUOR DE LYS-based or equivalent) in nuclear extracts from each cell type + 24h candidate treatment. - HDAC½/3 vs. HDAC6 isoform specificity: use a class I-selective substrate (acetylated H3K9/H4K12 peptide) and a HDAC6-selective substrate (acetylated tubulin peptide) to distinguish isoform selectivity within the Caco-2 data.

Stage 3 — Q141K ABCG2 trafficking rescue in HEK293T or Caco-2 Q141K-transfected cells ($2,500–4,500): - Transfect cells with ABCG2-Q141K-GFP construct (standard overexpression assay, as in Basseville 2012). - Treat with top 3 candidates (from Stage 2) at Caco-2-achievable concentrations ± butyrate 1 mM (positive control). - Readouts: ABCG2 surface expression (flow cytometry / confocal — ratio of membrane-localized to total GFP signal), urate efflux (transwell if Caco-2-based), ABCG2 protein abundance (Western — total vs. glycosylated mature form).

HDAC isoform note: HDAC½/3 (class I, nuclear) → histone deacetylation → Hsp90/HSF1 → Q141K rescue. HDAC6 (class IIb, cytoplasmic) → tubulin deacetylation → autophagy regulation. Pan-HDAC inhibitors (vorinostat, romidepsin) hit HDAC6 → actin dysregulation, cardiac ion-channel effects → cardiotoxicity. Any candidate that shows Caco-2 vs. hepatocyte selectivity AND class I >> HDAC6 selectivity is safe to advance; pan-inhibitors are excluded regardless of efficacy.

Estimated cost: $5,000–8,000 (in silico $500 + Caco-2/HepG2 HDAC assay $2,000–3,000 + trafficking rescue $2,500–4,500). Original synthesis proposal ($5,000) was optimistic for a design that includes paired tissue-selectivity assay; $8,000 covers the paired hepatocyte arm + Q141K-transfected cell assay.

Estimated timeline: 8–10 weeks.

Success criteria: - A food-grade HDACi candidate that outperforms butyrate on selectivity (higher Caco-2:hepatocyte ratio AND HDAC½/3 >> HDAC6) AND rescues Q141K surface expression ≥20%: advances to Q141K-targeted supplement protocol, potentially as a co-expression candidate in the koji endgame strain. - No candidate outperforms butyrate on selectivity: confirms butyrate as the best available food-grade Q141K-rescue agent and locks in the fermentable-fiber adjunct recommendation for Q141K carriers. - A candidate with class I selectivity and hepatocyte-sparing profile emerges but doesn't rescue trafficking: updates the Q141K rescue model (suggests additional misfolding mechanism beyond class I HDAC).

Stage 1 results (comp-007, 2026-05-05): In silico screen completed. Composite scoring (potency × HDAC6 selectivity × gut-enrichment proxy) across 7 candidates ranked: Butyrate (0.374, HIGH confidence — confirmed 167× HDAC6 selectivity, biochemical IC50 data from ChEMBL/ACS Med Chem Lett 2011) >> Sulforaphane (0.090, LOW — estimated IC50, HDAC6 profile uncharacterized) > PEITC (0.060, LOW — estimated IC50 by analogy with SFN). Caffeic acid and ferulic acid score 0 (no isoform-specific IC50 available). Advancing to Stage 2: Butyrate, Sulforaphane, PEITC. Stage 2 must include HDAC6 isoform-selective substrate assay for SFN and PEITC; butyrate's HDAC6 selectivity is confirmed. Full analysis: etc/experiments/comp-007-food-grade-hdaci-screen/. Interpretive wiki: wiki/food-grade-hdaci-screen-computational.md. Evidence level: Mechanistic Extrapolation.

Cross-references: abcg2-modulators.md §6 (butyrate + PPARγ/HDACi mechanism; Basseville 2012 PMID 22472121); supplements-stack.md §"Q141K-personalized recommendations"; gut-lumen-sink.md; synthesis/ 2026-05-05 Proposed Experiment #3; food-grade-hdaci-screen-computational.md.

1.23 Androgen × MSU × NLRP3 in Macrophages — Tiered Mechanistic Protocol¶

Status: Proposed | Cost: Tier 1: $5–10K; full T1+T2+T3 cascade $105–160K | Weeks: Tier 1: 6–8; full cascade ~12 months | Phase: 1

Affected wiki: androgen-urate-axis §"Beyond transporters: direct androgen effects on NLRP3 priming", nlrp3-inflammasome, koji-endgame-strain, self-experiment-protocol §11 (Tier 4 n=1)

What it tests: Whether testosterone/DHT directly modulates MSU-crystal-induced NLRP3 inflammasome activation in macrophages — the gout-relevant cell type and stimulus combination. The 2026-05-05 androgen × NLRP3 literature scan (androgen-urate-axis.md §"Beyond transporters") confirmed that this exact intersection has zero indexed papers despite both halves (androgen × macrophage NLRP3 with TLR4/LPS priming; MSU × macrophage NLRP3 in gout) being independently well-characterized. The general-tissue literature direction is anti-inflammatory (DHT → AR → ↓NF-κB → ↓TLR4 → dampened priming; Norata 2006 in vitro on human macrophages), but the cardiac-tissue exception (testosterone → ↑NLRP3 in cardiac macrophages, the explanation for male-skewed myocarditis) shows the effect is tissue-context-dependent. Whether synovial / gout-relevant macrophages follow the general-tissue or the cardiac pattern is unknown, and the answer matters for: (a) whether androgen-elevated patients (elevated endogenous T, clomid, TRT, AAS users) need a heavier anti-inflammatory layer in the gout stack, (b) whether the male-skew of gout incidence has a direct-inflammation contribution beyond the well-documented transporter contribution.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-05-05 Open Question #2 (androgen axis × NLRP3) — actioned by lit scan (Option A: section in androgen-urate-axis.md). The promotion criteria stated in that section (≥3 convergent mechanistic studies, OR ≥1 in vivo dose-response, OR clear human evidence) are exactly what this experiment generates if positive.

Background on the gap: The reason this intersection has not been studied is sociological, not technical. Gout immunology funding flows to clinical-translational drug studies (canakinumab, MCC950, dapansutrile). Sex-hormone × innate-immunity research is a separate community focused on autoimmune disease using LPS/TLR4 as the prototypical priming stimulus. The two communities have not overlapped. The assays themselves are standard.

Protocol — Tiered, gating logic:

Tier 1 — THP-1 macrophage in vitro screen ($5,000–10,000; 6–8 weeks): - Cell line: THP-1 monocytes differentiated to macrophages with PMA (50–100 nM, 48–72 hr). - Pre-treatment: ± DHT at 1 nM, 10 nM, 100 nM, 1 μM (physiological → supraphysiological) × 24–72 hr. Vehicle control (ethanol or DMSO matched). Androgen receptor antagonist arm (flutamide 1 μM or enzalutamide 1 μM) for AR-dependence. - Challenge: MSU crystals (50–200 μg/mL × 6 hr; ATP 5 mM × 30 min as orthogonal NLRP3 trigger control). - Readouts: IL-1β secretion (ELISA, primary endpoint); caspase-1 cleavage (Western, p20/p10); ASC speck formation (immunofluorescence, % cells with specks); NLRP3 mRNA (qPCR baseline + post-priming); pyroptosis (LDH release). - Success criterion (Tier 1 → Tier 2): ≥30% modulation of MSU-induced IL-1β by DHT pre-treatment at any concentration AND AR-dependence confirmed by antagonist arm. Either direction (suppression or amplification) is interpretable; null result closes the question without needing Tier 2.

Tier 2 — Primary human PBMC-derived macrophages, donor-stratified ($20,000–30,000; 12 weeks; gated on Tier 1 positive): - Cells: PBMC-derived macrophages from male donors stratified by serum total + free testosterone (high-T quartile vs. low-T quartile, n=8 per group). - Same MSU challenge protocol as Tier 1. - Readouts: IL-1β + IL-18 (gout-relevant cytokines); donor-stratified comparison rather than dose-response (the donor T levels are the dose). - Success criterion (Tier 2 → Tier 3): Donor T-quartile correlates with MSU-induced IL-1β response in the same direction as Tier 1 immortalized-line signal, with effect size ≥20%. Null in primary cells closes the question; positive Tier 1 + null Tier 2 indicates immortalized-line artifact and is itself useful. - Ethics note: Donor recruitment and consent through standard IRB-approved protocols; serum T measurement is non-invasive standard-of-care.

Tier 3 — Murine MSU air-pouch model ± castration ± T add-back ($80,000–120,000; 6 months; gated on Tier 2 confirmation): - Animals: Male C57BL/6 mice. Three arms: intact, castrated + vehicle, castrated + T replacement (low-dose ~physiological, high-dose ~supraphysiological). - Standard gout model: Subcutaneous air pouch raised over 6 days; MSU crystal injection (3 mg in PBS); 6-hr or 24-hr lavage. - Readouts: Lavage neutrophil count (primary endpoint — this is the standard gout-model readout); IL-1β + cytokine cascade (IL-6, CXCL1, KC); pouch-tissue NLRP3 / ASC / caspase-1 by Western. - Success criterion: Causal demonstration that manipulating circulating T modulates MSU-induced gouty inflammation in vivo. Establishes whether the male-skew of gout has a direct-inflammation contribution, with a quantified effect size suitable for translating to recommendations. - Outcome: Positive Tier 3 → publishable as a single mechanistic paper with clinical implications; updates the OE platform's anti-inflammatory layer dosing recommendation for androgen-elevated patients.

Tier 4 (n=1, parallel and independent) — Brian's ex vivo PBMC MSU challenge: see self-experiment-protocol.md §11. Cost $500–1,000 per panel as quarterly add-on. Does not prove causality but provides a low-cost personal signal of whether clomid-elevated T associates with hotter MSU-induced inflammation in his own cells.

Estimated cost (full cascade): Tier 1 $5–10K → +Tier 2 $20–30K → +Tier 3 $80–120K = $105–160K total if all tiers fire. Tier 1 alone is the entry cost; Tier ⅔ only proceed if signal warrants.

Estimated timeline (full cascade): Tier 1: 6–8 weeks. + Tier 2: +12 weeks (gated). + Tier 3: +6 months (gated). Best case (early null at Tier 1): 8 weeks. Worst case (full cascade): ~12 months.

Success criteria (overall): - Direct-inflammation androgen contribution confirmed (positive Tier 1 + Tier 2 + Tier 3): Updates platform recommendations — androgen-elevated patients (clomid, TRT, AAS, high-endogenous-T) get an elevated anti-inflammatory layer (BHB, oridonin, lactoferrin) in the stack. Adds a section to koji-endgame-strain.md male-skew framing. Falsification card H02 (engineered LBP) gains a new use case (LBP-delivered NLRP3 silencing for high-T subgroup). - Null at Tier 1: Closes the open question. The transporter-axis male-skew is the only confirmed driver. No platform changes needed. Negative result is publishable as a clear gap-fill. - Tier 1 positive but Tier 2 null: Indicates immortalized-line artifact; updates the literature scan and closes the in vivo escalation. No platform changes.

Limitations: - Tier 1 uses an immortalized line — known limitations of THP-1 vs. primary cells (stable phenotype, possibly less responsive to MSU than monocyte-derived primary cells). - Tier 2's donor stratification will have confounders (BMI, fiber intake, baseline inflammation). Statistical power calculation needed before recruitment. - Tier 3's murine air-pouch model is the standard gout model but is acute, not chronic. Translating to chronic-flare biology requires additional model considerations. - All three tiers focus on the priming + activation step. They do not address resolution (SPM pathway) or aggregated-NET amplification — those would be separate experiments.

Cross-references: androgen-urate-axis.md §"Beyond transporters: direct androgen effects on NLRP3 priming" (the lit scan section that surfaced this gap); nlrp3-inflammasome.md; self-experiment-protocol.md §11 (Tier 4 n=1 ex vivo PBMC); koji-endgame-strain.md (male-demographic ceiling framing); synthesis/ 2026-05-05 Open Question #2.

1.25 DAF/CD55 SCR1-4 Truncated Single-Cassette Expression in A. oryzae (CP0 Engineering Candidate Wet-Lab Gate)¶

Status: Proposed | Cost: $4,445–6,745 (two-arm RIB40 + NSlD-ΔP10; re-scoped 2026-05-16; Plasmidsaurus QC pipeline added 2026-05-17) | Weeks: 6–8 | Phase: 1

Affected wiki: daf-cd55-scr14-truncated-computational, hypotheses/H05-daf-scr14-cp0-thesis, chaperone-orthogonal-stacking, koji-endgame-strain, complement-c5a-gout, modality-chokepoint-matrix

What it tests: Can engineered A. oryzae (RIB40 or NSlD-ΔP10) secrete the truncated DAF/CD55 SCR1-4 construct (aa 35–285, residues immediately following the signal peptide cleavage site through the end of SCR4 — see comp-012) as a correctly-folded, complement-regulatory-active soluble protein? This is the wet-lab gate for the CP0 closure thesis: comp-012 confirmed protease stability (LOW risk in shio-koji), but expression + correct disulfide folding + retained CCP-regulatory activity have to be demonstrated empirically before the construct becomes a real platform component.

Single-cassette expression, NOT triple-cassette. Per the chaperone-orthogonal stacking framework's triple-cassette prediction (§5.5, refined 2026-05-06), the triple combination (uricase + lactoferrin + DAF SCR1-4) lands in the architecture-adjusted synergy range 0.35–0.65 (central 0.45–0.55) — firmly below the 0.6 decision gate. Recommended platform direction is separate-strain routing for DAF SCR1-4 (or routing to the engineered LBP chassis as a parallel peer track per engineered-lbp-chassis.md). This experiment validates the single-cassette feasibility step; if positive, the DAF strain becomes either (a) a sister koji strain co-fermented with the uricase + lactoferrin endgame strain, or (b) a candidate payload for the LBP chassis once that peer track matures.

Co-primary role — chaperone-framework calibration set (re-scoped 2026-05-16, mandatory): this experiment is the CCP/SCR data point in the calibration set documented in chaperone-orthogonal-stacking.md §3.5.4 (paired with §1.9's lactoferrin transferrin-lobe data point). Pre-registered framework prediction: ≥100 mg/L DAF SCR1-4 if the framework's α coefficients transfer to koji — substantially higher per-cassette titer than lactoferrin because of the lower α (CCP/SCR 0.3–0.6 vs. transferrin-lobe 1.5–2.5). The NSlD-ΔP10 calibration arm is now mandatory (was "optional" through 2026-05-15; re-scoped 2026-05-16 after the riskiest-assumption verdict named the framework's α coefficients as the single load-bearing belief least supported by the corpus — see chaperone-orthogonal-stacking.md §8 item 6 for the framework's own calibration uncertainty). Calibration-arm conditions: matching host = NSlD-ΔP10, matching format = solid-state shio-koji, matching promoter as §1.9, matching titer units (mg/L mature protein by ELISA). Without this arm under harmonized conditions, the host/format mismatch confounds the §1.9 + §1.25 comparison and the framework cannot recalibrate α — leaving every downstream architecture decision (separate-strain DAF routing, triple-cassette feasibility, single-strain endgame thesis) resting on un-validated coefficients. The RIB40 arm runs in parallel as the primary CP0 engineering candidate validation; the two arms together satisfy both §1.25's original objective and the framework calibration role.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-05-05 sweep block 487fad3 Pass 2 Proposed Experiment 2 (gated on the comp-012 in silico LOW verdict, which landed same session). Held during the 2026-05-05 walkthrough due to patent-agent batch collision; landed 2026-05-06 with the disulfide count corrected from the original "12" to the verified 8 (per comp-012 §1.5 correction note anchored to UniProt P08174).

Background on the gating context: comp-012 (2026-05-05) confirmed the SCR1-4 truncated construct is shio-koji protease-stable (LOW verdict, max risk score 0.039 — identical to uricase, 10× drop from the comp-006 full ectodomain HIGH verdict driven by removing the Ser/Thr-rich stalk aa 286–353). H05 stub (2026-05-05) registered the CP0 closure thesis as a falsification card with three named wet-lab unknowns: (1) does SCR1-4 retain complement-regulatory activity without the stalk, (2) can A. oryzae fold 8 intrachain disulfides per molecule (corrected from 12, per UniProt P08174 DISULFID feature annotations: Cys36-Cys81, Cys65-Cys94 [SCR1]; Cys98-Cys145, Cys129-Cys158 [SCR2]; Cys163-Cys204, Cys190-Cys220 [SCR3]; Cys225-Cys267, Cys253-Cys283 [SCR4]), and (3) does the construct express at therapeutic-relevant titer. This experiment addresses all three.

Effective PDI load context (from chaperone framework refinement, 2026-05-06): 8 disulfides × CCP/SCR architecture coefficient α=0.3-0.6 = effective PDI load 2.4-4.8 disulfide-equivalents — substantially lighter than the 17 (or 16, per Notari 2023 corrected count) lactoferrin transferrin-lobe load of 24-40 effective. Single-cassette DAF SCR1-4 expression should be well within demonstrated A. oryzae secretion capacity even on wild-type RIB40 — the 8 vs. 12 disulfide-count correction (Item 2 of the 2026-05-06 walkthrough) shifts the "can A. oryzae fold this" question from "uncertain" to "highly probable."

Protocol:

Construct design.
Cassette: [PamyB — *A. oryzae* α-amylase signal peptide — DAF SCR1-4 mature sequence (aa 35–285 of UniProt P08174, codon-optimized for *A. oryzae*) — TamyB]. Direct secretion via amyB SP, no glucoamylase fusion (DAF SCR1-4 has no internal KEX2 sites that would require glucoamylase-KEX2 architecture). Selection marker: pyrG complementation (food-grade, no antibiotic).
Codon optimization: full optimization for A. oryzae codon table — DAF/CD55 native codon preferences are mammalian (high-GC) and broadly compatible with A. oryzae (~54% GC) but standard gene synthesis optimization captures any remaining suboptimal codons. Cost: ~$300-500 for codon-optimized gene synthesis (~750 bp).
Disulfide assessment design: the 8 disulfides form 2 per SCR domain in the canonical sushi/CCP fold (Cys1-Cys3, Cys2-Cys4 motif within each ~60-aa domain). Misfolding modes to detect: (a) intermolecular disulfide-linked aggregates (would show up as high-MW bands on non-reducing SDS-PAGE), (b) within-domain mis-pairing (would not show up on SDS-PAGE but would compromise CCP-regulatory activity), © mature protein with reduced free Cys (would show up as smaller MW on non-reducing SDS-PAGE indicating fewer than 8 disulfides formed). All three are detectable with the Western + activity assay readouts below.
Host strain — two parallel arms (re-scoped 2026-05-16; both mandatory).
RIB40 arm (genome-sequenced reference) — primary CP0 engineering candidate validation. Per the chaperone framework, single-cassette DAF SCR1-4 (effective PDI load 2.4–4.8) should be well within RIB40's secretion capacity; this arm carries the §1.25 primary objective.
NSlD-ΔP10 arm (10-protease-deletion via Maruyama lab path per operations/ward-1995-lab-access.md) — chaperone-framework calibration arm, mandatory. Run under matching solid-state shio-koji format and matching promoter as §1.9 so the §1.9 + §1.25 titer comparison is the framework's α-recalibration measurement. The reason this arm is mandatory (not "optional pending RIB40 results") is that recalibration only works on harmonized-condition data; RIB40-only execution forfeits the calibration role even if RIB40 succeeds on the engineering objective.
Transformation. PEG/CaCl₂ protoplast, single-step transformation → select on pyrG-minus → confirm cassette integration by PCR + qPCR for copy number stability across 5 serial passages.
Fermentation. Solid-state rice koji, 48–60 h at 30°C, 35% moisture (the project's standard koji condition; matches §1.9 dual-cassette fermentation conditions for downstream comparability). Parallel submerged-culture control (100 mL shake flask, 28°C) to isolate solid-state vs. submerged variable.
Readouts.
Secretion + apparent MW: SDS-PAGE under reducing AND non-reducing conditions on culture supernatant. Reducing condition: detect monomeric ~28 kDa band (predicted from 251-aa mature protein × ~110 Da/aa average + glycosylation if any). Non-reducing condition: confirm intramolecular disulfide formation (band shifts to slightly lower apparent MW vs. reducing) AND absence of high-MW aggregation bands (absence = no intermolecular Cys mis-pairing). Western blot with anti-DAF/CD55 antibody (commercial — Abcam ab1422 or similar) to confirm identity.
Quantitative titer: anti-DAF/CD55 ELISA on culture supernatant. Target: ≥50 mg/L pore-fluid equivalent (mirroring the H01 lactoferrin floor scaled for the smaller protein).
Disulfide folding fidelity: mass spectrometry (MALDI-TOF or LC-MS) on purified protein under non-reducing conditions to confirm correct disulfide pairing (8 expected) vs. mispaired isoforms. This is the load-bearing readout for the CP0 thesis — protease-stable + secreted ≠ functionally folded.
CCP-regulatory activity assay: zymosan-activation assay measuring C5a generation in human serum + purified recombinant DAF SCR1-4 vs. control (heat-denatured DAF SCR1-4 + buffer-only). Target: ≥30% C5a-generation inhibition vs. control at therapeutically-plausible DAF concentration (rough target ~1-10 μg/mL based on literature soluble DAF activity ranges). This is the H05 third wet-lab unknown — does SCR1-4 retain complement-regulatory activity without the stalk?
Native metabolite profile (carryover check): kojic acid titer (HPLC) + ergothioneine titer (LC-MS) — confirm WT baseline preserved within 30% on the engineered strain (i.e., the heterologous DAF cassette doesn't perturb the native koji metabolite chorus that contributes to the CP1a + CP1b coverage per koji-endgame-strain.md §1).

Plasmidsaurus QC pipeline (added 2026-05-17): apply the canonical §05 Plasmidsaurus QC pipeline across both arms (RIB40 + NSlD-ΔP10): - Pre-transformation: Whole Plasmid Sequencing of the single DAF SCR1-4 cassette plasmid ($15 × 1 = $15, 1 day). - Post-transformation clone screening (per arm): Genotyping Analysis on 6–10 transformants per arm to pick clean on-target integrants ($30 × 8 × 2 arms = $480, 1–2 days each). - Junction PCR sequencing (per arm): Amplicon Sequencing on 2–4 junction PCRs per integration ($15 × 4 × 2 arms = $120, next-day each). - Final platform-strain release (per arm): Whole Genome Sequencing on each validated arm strain (Eukaryotic tier, $250 + $15 extraction = $265 × 2 = $530, 3–6 days each). Both arms get publish-grade sequences for the open-source-strain-library release since the dual-arm framework-calibration role means both are platform-relevant outputs.

Plasmidsaurus QC pipeline subtotal: ~$1,145, ~25–35% of the §1.25 envelope. Higher fraction than §1.9 because §1.25 has two parallel arms (mandatory per the 2026-05-16 re-scope) each requiring its own full QC pass.

Estimated cost ($4,445-6,745 breakdown, updated 2026-05-17): - Codon-optimized gene synthesis: $300-500 - Cloning + transformation reagents: $400-600 - Fermentation consumables: $200-300 - Anti-DAF antibody (commercial): $400-600 - ELISA reagents + Western consumables: $500-700 - Mass spec analysis (outsourced to core facility): $300-500 - Zymosan + complement activity assay reagents: $200-400 - Plasmidsaurus QC pipeline (both arms: plasmid + amplicon + genotyping + whole-genome): ~$1,145 - CRO or academic lab time if outsourced: $1,000-2,000 (otherwise embedded in lab partnership)

Estimated timeline (6-8 weeks breakdown): - 2-3 weeks: gene synthesis + construct assembly + cloning verification - 2 weeks: transformation + clonal screening + copy-number stability check - 1 week: parallel fermentation (solid-state + submerged controls) - 2 weeks: full assay suite (SDS-PAGE + Western + ELISA + MS + activity assay) + write-up

Dependencies: Same lab-access pathway as §1.9 — a Role 2 (Pharma Translation) collaborator (per etc/team.md) if recruiting converts; commercial CRO specializing in filamentous-fungus engineering (Lonza, Novozymes, Dyadic); community biolab with protoplast-transformation capability (Genspace NY has A. oryzae precedent). Global parallel options mapped in operations/ward-1995-lab-access.md. This experiment shares lab-access infrastructure with §1.9 — both are A. oryzae protoplast transformation + solid-state koji fermentation + standard mammalian-protein readout assays. If §1.9 is running in a partner lab, §1.25 is a natural co-batch experiment with marginal infrastructure cost (sequential transformations on the same host, parallel fermentations under the same conditions).

Success criteria: - Accept (proceed to integration with platform — sister-strain co-ferment with uricase + Lf endgame strain, OR queue for LBP-chassis transfer): secreted titer ≥50 mg/L pore-fluid equivalent + correct apparent MW on non-reducing SDS-PAGE + ≥40% native disulfide-folded form on mass spec + ≥30% C5a-generation inhibition vs. control at therapeutically-plausible DAF concentration + native metabolite program preserved within 30% of WT. - Iterate (adjust architecture, re-test): titer 10-50 mg/L OR 20-40% native folded form OR 10-30% C5a inhibition. Try NSlD-ΔP10 host (extracellular protease deletion), alternative integration sites, alternative signal peptide (TamyG or glaA SP). - Reject (DAF SCR1-4 not viable in koji chassis; route to LBP chassis or shelve CP0 closure thesis): titer <10 mg/L after two optimization rounds, OR <20% native folded form, OR no detectable CCP-regulatory activity, OR native metabolite program collapse (kojic acid down >50% vs. WT). Reject outcome triggers H05 falsification card update (Killshot #1 fired) and re-routing of CP0 closure to the engineered-lbp-chassis.md peer track or the soluble-Factor-H-fragment alternative documented in complement-c5a-gout.md.

Computational priors that informed this design: - comp-012 (2026-05-05) — protease stability LOW verdict for the SCR1-4 construct; gates the wet-lab feasibility question - chaperone-orthogonal-stacking framework §3.5 + §4 (refined 2026-05-06) — per-architecture α coefficient for CCP/SCR fold (0.3-0.6) gives effective PDI load 2.4-4.8 for single-cassette DAF SCR1-4, well within demonstrated A. oryzae capacity even on wild-type RIB40 - chaperone-orthogonal-stacking framework §5.5 (refined 2026-05-06) — triple-cassette prediction lands below 0.6 decision gate, supporting the separate-strain (single-cassette) routing decision encoded in this experiment design - comp-030 (2026-05-15) — exhaustive cassette ranking (43,200 candidates; 6 promoters × 12 SP × 10 codon variants × 60 scaffolds). Top cluster: PamyB + SPamyB + max-CAI codon variant + direct-secretion scaffold (His6 or no C-term tag) + no propeptide. §1.25 baseline survives; one gene-synthesis-time refinement warranted: use max-CAI codon optimization (NOT 5'-softened — DAF SCR1-4's first-30 aa generate favorable 5' MFE under max-CAI; 5'-softening is target-specific to uricase). α-coefficient CORROBORATED: ESM2 pseudo-pLDDT mean = 88.8, std = 0.5, 100% of 720 protein-distinct candidates above pseudo-pLDDT 80 — consistent with CCP/SCR fast-folding, α = 0.3–0.6. (Mechanistic Extrapolation; in silico only.) Full analysis: wiki/daf-cd55-scr14-cassette-ranking-computational.md.

Limitations: - Single-cassette test does not directly answer whether DAF SCR1-4 can co-express with uricase + Lf in a triple cassette (that would be a separate, gated experiment if the chaperone framework's prediction proves too pessimistic in the §1.9 readout) - Mass spec disulfide-pairing analysis assumes high-quality purification; if the purification step is suboptimal, mis-paired isoforms may be undercounted - CCP-regulatory activity assay measures one specific complement readout (C5a generation in zymosan-activation); doesn't directly measure C3 convertase decay-acceleration (the canonical DAF activity) — that would be a follow-up assay if C5a-arm is positive - No in vivo gut-lumen activity readout in this experiment — that's a Phase 2 / Phase 3 follow-up gated on positive in vitro result

Cross-references: daf-cd55-scr14-truncated-computational.md (comp-012, the in silico prior); hypotheses/H05-daf-scr14-cp0-thesis.md (the falsification card this experiment addresses); chaperone-orthogonal-stacking.md §5.5 (the triple-cassette prediction that motivated single-cassette routing); koji-endgame-strain.md (sister-strain co-fermentation context); engineered-lbp-chassis.md (alternative chassis if reject outcome); complement-c5a-gout.md (the CP0 chokepoint biology); operations/ward-1995-lab-access.md (lab-access shared with §1.9); synthesis/ 2026-05-05 487fad3 Pass 2 Proposed Experiment 2.

1.26 Cordycepin × Pentostatin × GLPP — Five-Arm ADA Half-Life Assay (ADA Chokepoint Synergy Validation)¶

Status: Proposed | Cost: $1,500–2,500 | Weeks: 3–4 | Phase: 1

Affected wiki: medicinal-mushroom-complement-track, gout-pathophysiology, medicinal-mushroom-compound-mapping-computational

What it tests: Does combining ADA inhibitors from two independent biochemical mechanisms (pentostatin = small-molecule competitive inhibition; GLPP = polysaccharide-peptide binding) extend cordycepin's in-vitro half-life enough to make a fermentable, food-grade urate-lowering protocol viable at sub-multi-gram daily dosing? Specifically: does the two-organism combination (whole-fermentate Cordyceps militaris + Ganoderma lucidum GLPP) outperform either single-organism preparation?

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-05-08 sweep block e842754 Connection 1 + Proposed Experiment 1; Pass 3 review (GPT-5.5) flagged the original 4-arm design as incomplete because it tested purified pairings and whole-fermentate alone but NOT the two-organism combination — fifth arm added per Pass 3's specific recommendation.

Background — the ADA chokepoint: Adenosine deaminase (ADA) is the enzyme that rapidly deaminates cordycepin (3'-deoxyadenosine) to its inactive metabolite, limiting cordycepin's half-life and forcing impractical multi-gram daily doses for therapeutic urate-axis effects. Two natural ADA inhibitors are documented: pentostatin (small-molecule, FDA-approved as Nipent for hairy-cell leukaemia, NATIVELY co-produced with cordycepin in C. militaris per the Xia 2017 BGC characterization PMID 29056419) and GLPP polysaccharide-peptide from G. lucidum (mechanism orthogonal to pentostatin — polysaccharide binding rather than competitive nucleoside-mimetic inhibition). Whole-fermentate Cordyceps delivers cordycepin + pentostatin in their natural ratio; supplementing with GLPP adds a second, mechanistically orthogonal ADA blockade. See medicinal-mushroom-complement-track.md §"Combined / synergy candidates" for the full thesis.

Protocol — Five-arm in-vitro design:

Arm	Composition	Tests
1. Cordycepin alone	Recombinant human ADA (Sigma A6535) + cordycepin standard (Sigma C3394, 100 µM) in PBS pH 7.4, 37°C	Baseline ADA-driven cordycepin deamination kinetics
2. Cordycepin + pentostatin	Arm 1 + research-grade pentostatin (Sigma P3650, 1 µM and 10 µM dose-response)	Pentostatin's quantitative ADA-inhibition contribution at gut-relevant concentrations
3. Cordycepin + GLPP	Arm 1 + GLPP-enriched fraction from a SEC-MALS-characterized G. lingzhi dual-decoction extract (per SOP-1, 100 µg/mL polysaccharide-peptide)	GLPP's ADA-inhibition contribution alone, mechanistically distinct from pentostatin
4. Whole-fermentate Cordyceps	Total water/ethanol-coextract from C. militaris (GYS60 strain or commercial fruiting-body extract; cordycepin-equivalent dose normalized to 100 µM via SOP-2 HPLC quantification)	Whole-fermentate co-delivery of cordycepin + native pentostatin in their natural ratio — single-organism baseline
*5. Whole-fermentate Cordyceps* + GLPP** (added per Pass 3)	Arm 4 + GLPP from Arm 3	The two-organism combination — does adding mechanistically-orthogonal GLPP-mediated ADA inhibition further extend cordycepin half-life beyond what whole-fermentate's native pentostatin already delivers?

Primary readout: cordycepin remaining at t = 0, 15, 30, 60, 120, 240 min, measured by HPLC (per SOP-2 cordycepin quantification — calibrated reference standard). Compute half-life per arm. Loewe combination index for arms ⅔/5 vs. additive expectation.

Secondary readout: ADA enzyme activity (residual deamination rate) measured directly via commercial ADA assay kit (Diazyme, 1064-330) — confirms the ADA-inhibition mechanism rather than off-target cordycepin protection.

Success criteria: - Promote two-organism stack to mouse PK study if Arm 5 shows ≥2× cordycepin half-life extension over Arm 4 (whole-fermentate alone) AND the half-life extension correlates with ADA activity reduction in the secondary readout. This would justify a follow-on PO HUA mouse study testing the combination at therapeutic dose. - Drop GLPP from the cordycepin-targeting protocol if Arm 5 ≈ Arm 4 (no meaningful improvement over native pentostatin) — implies GLPP's ADA inhibition is redundant with pentostatin in whole-fermentate context, and the simpler whole-fermentate-alone preparation is the right consumer product. - Reframe the platform thesis if Arm 4 ≈ Arm 1 (whole-fermentate's native pentostatin is too dilute to matter at gut-relevant concentrations) — implies cordycepin needs supplemental purified pentostatin or GLPP regardless of preparation, and the "single-organism whole-fermentate" framing in medicinal-mushroom-complement-track.md needs revision.

Limitations: - In vitro ADA assay does not capture gut-microbiome metabolism of cordycepin (which may matter for in vivo half-life). The half-life extension demonstrated here is necessary but not sufficient for clinical effect. - Recombinant human ADA (Sigma A6535) is the standard substrate but doesn't model intestinal mucosa-localized ADA dynamics. Mouse PK study (queued as gated follow-on) is the next-step de-risker. - GLPP fraction quality is load-bearing — Tier 3 SEC-MALS characterization per SOP-1 is non-negotiable. Generic "reishi extract" cannot substitute. Per the structure-dependent β-glucan caveat, wrong-fraction substitution would produce uninterpretable results.

Cross-references: medicinal-mushroom-complement-track.md §"Combined / synergy candidates" (Item 1 of the 2026-05-08 walkthrough — the two-organism synergy bullet); gout-pathophysiology.md §"ADA (Adenosine Deaminase) — Purine Catabolism Chokepoint Candidate"; medicinal-mushroom-compound-mapping-computational.md (comp-014 Phase 2, where ADA was first surfaced); synthesis/ 2026-05-08 sweep Connection 1 + Proposed Experiment 1.

Sixth-arm extension — engineered-koji cordycepin + GLPP (added 2026-05-15; Deprioritized 2026-05-16; gated on strain availability)¶

Deprioritized 2026-05-16 — koji-cordycepin engineering removed from active cassette stack. Walkthrough Item 7 strategic call. The sixth arm tests engineered-koji cordycepin + GLPP for ADA half-life protection; with the koji-cordycepin engineering effort deprioritized (full reasoning at koji-endgame-strain.md §3.5), the §1.26 base assay (Arms 1–5) stands as the canonical ADA-protection investigation — those arms use whole-fermentate Cordyceps and purified compounds, all available via the cultivation track. Sixth arm is moot until/unless koji-cordycepin engineering is re-prioritized.

Status: Proposed extension to §1.26 base | Cost: ~$500–1,000 adder | Weeks: same as §1.26 base | Phase: 2 | Hard gating: engineered-koji cordycepin strain must exist (downstream of §1.9-extended design + comp-025 ADA-competition GREEN + comp-028 three-axis GREEN)

What it tests: Can koji-track cordycepin (lacking the native pentostatin that C. militaris co-produces from the same BGC) achieve ADA half-life protection equivalent to whole-fermentate Cordyceps by leveraging GLPP's polysaccharide-binding ADA inhibition? Specifically: does engineered-koji cordycepin extract + GLPP match the whole-fermentate Cordyceps native arms (§1.26 Arms 4 + 5) on ADA half-life?

Why a sixth arm: the §1.26 base tests purified cordycepin, pentostatin, GLPP, whole-fermentate Cordyceps, and whole-fermentate Cordyceps + GLPP. The koji-track equivalent of the cordycepin + ADA-inhibitor pair — koji cordycepin + GLPP — is the synergy named in medicinal-mushroom-complement-track.md §"Combined / synergy candidates" but never assayed against the whole-fermentate baseline. Without the sixth arm, the koji-track cordycepin strain ships without empirical ADA-protection data; the strain's deliverable falls back to pairing with whole-fermentate Cordyceps (per §2.7's cross-chassis stability test) rather than the cleaner GLPP route.

Distinction from §2.7 (Item 19's Koji × Cordyceps Co-Formulation Stability Test): §2.7 tests engineered-koji cordycepin + whole-fermentate C. militaris (native pentostatin) for co-formulation stability. The §1.26 sixth arm tests engineered-koji cordycepin + GLPP (polysaccharide-binding ADA inhibitor — different ADA-inhibitor source). Both inform the koji-track ADA-protection strategy from different angles; together they decide which co-product (whole-fermentate Cordyceps OR purified GLPP) is the preferred pairing for the engineered koji.

Arm 6 protocol: identical to §1.26 base — ADA challenge (recombinant human ADA, Sigma A6535) at defined enzyme concentration, sampling at 0/15/30/60/120/240 min, LC-MS cordycepin vs. 3'-deoxyinosine quantification — but the substrate is engineered-koji cordycepin extract (cns1+cns2 strain, post-fermentation extraction per medicinal-mushroom-extract-sops.md SOP-2) co-administered with Tier 3-anchored GLPP (per SOP-1 SEC-MALS characterization).

Success criteria (sixth arm → next phase): - GREEN: sixth-arm cordycepin half-life ≥ 70% of Arm 4 (whole-fermentate Cordyceps) AND ≥ 90% of Arm 5 (whole-fermentate + GLPP). → koji cordycepin + GLPP is a viable two-organism deliverable independent of C. militaris cultivation; update medicinal-mushroom-complement-track.md to promote this from synergy candidate to validated route. - YELLOW: sixth-arm cordycepin half-life 50–70% of Arm 4. → koji cordycepin + GLPP partially protects; needs higher GLPP dose OR co-formulation with whole-fermentate Cordyceps per §2.7. Decision deferred to per-dose cost analysis. - RED: sixth-arm cordycepin half-life < 50% of Arm 4. → GLPP alone is insufficient ADA protection for the koji cordycepin route; the koji track depends on either (a) co-formulation with whole-fermentate Cordyceps (per §2.7) or (b) pentostatin co-engineering (higher cassette complexity per comp-024-class follow-up).

Estimated cost: $500–1,000 adder - Engineered-koji cordycepin extract preparation (one-time, gated on strain): ~$200 - Additional LC-MS quantification samples (1 arm × 6 timepoints × 3 replicates = 18 samples × $35 ≈ $630) - Tier 3-anchored GLPP reagent (shared with §1.26 base): negligible adder

Estimated timeline: same as §1.26 base — sixth arm runs in parallel with Arms 1–5 once the strain exists; no incremental wall-clock time.

Limitations:

Same in-vitro-ADA limitation as §1.26 base — recombinant human ADA doesn't model gut-microbiome metabolism of cordycepin.
The cordycepin extract from engineered koji may have different impurity profile than whole-fermentate Cordyceps extract; this affects interpretation only if impurities themselves modulate ADA activity (unlikely but flagged).
GLPP fraction quality is the same load-bearing requirement as §1.26 base — Tier 3 SEC-MALS characterization per SOP-1 non-negotiable.

Cross-references: §1.26 base (parent five-arm assay); §2.7 (sister Tier 2 stability test on engineered-koji + whole-fermentate Cordyceps pairing — different ADA inhibitor source); medicinal-mushroom-complement-track.md §"Combined / synergy candidates" (the koji + GLPP entry this sixth arm validates); cordycepin-cassette-burden-computational.md (comp-023 engineering thread); computational-experiments.md comp-025 (ADA × cns1 kinetic gate — must clear before this experiment runs).

1.27 Ergothioneine + Lactoferrin Combination ROS Assay in MSU-Stimulated THP-1 Macrophages (Cross-Track ROS / CP1b Additivity Validation)¶

Status: Proposed | Cost: $1,500–2,500 | Weeks: 3–4 | Phase: 1

Affected wiki: gout-pathophysiology.md (multi-track coverage map ROS / CP1b row), lactoferrin.md, medicinal-mushroom-complement-track.md, koji-endgame-strain.md

What it tests: Do ergothioneine (mushroom track, direct thiol scavenging of hydroxyl radicals + peroxynitrite) and apo-lactoferrin (koji track, iron-sequestration Fenton suppression) operate as mechanistically orthogonal ROS-reduction routes in a gout-relevant cell model — and if so, do they produce additive or synergistic suppression of NLRP3 priming when combined?

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-05-07 77d0f6e Connection 3 + Proposed Experiment 2; Pass 3 review (Opus 4.7) added two refinements (extended Lf dose range to koji-pore-fluid-achievable; apo vs holo Lf comparison to confirm iron-sequestration mechanism). This is the wet-lab gate that would promote the gout-pathophysiology.md ROS / CP1b coverage row (added 2026-05-08, Item 22 walkthrough) from speculative to supported.

Sequencing: gated on §1.20 (Lactoferrin + EGCG CP1a Super-Additivity Assay), which itself is gated on §1.9. Run §1.27 after §1.20 to share THP-1 macrophage + MSU stimulation + IL-1β ELISA infrastructure.

Protocol:

Cells: THP-1 monocytes differentiated to macrophages (PMA, 100 nM × 24h then rest 24h). Human cells chosen to avoid the rodent-IC50 translation gap per §1.19 standing methodology.
Priming: LPS (100 ng/mL × 4 h).
Stimulation: MSU crystals (250 µg/mL × 6 h) — gout-relevant inflammasome trigger.
Treatment arms (treatment 1 h before MSU, continued through readout):
Vehicle control
Ergothioneine alone: 1, 10, 100 µM (brackets dietary-achievable plasma range ~5–25 µM per P. citrinopileatus correction in medicinal-mushroom-complement-track.md Phase 7-1c)
Apo-lactoferrin alone: 10, 100, 500 µg/mL (Pass 3 refinement — extended from original 10–100 µg/mL range to test koji-pore-fluid-achievable concentrations)
Holo-lactoferrin (iron-loaded) at 500 µg/mL — apo-vs-holo comparator arm (Pass 3 refinement — Fenton-suppression mechanism is apo-specific; any apo-lactoferrin additivity that disappears in holo confirms the iron-sequestration mechanism rather than a generic anti-inflammatory effect)
Combination: ergothioneine 10 µM + apo-lactoferrin 100 µg/mL (mid-range × mid-range, Loewe-index reference point)
Primary readout: IL-1β ELISA (gold-standard NLRP3 activation readout)
Secondary readouts: intracellular ROS (DCFDA fluorescence), NF-κB priming (IκBα Western blot)
Analysis: Loewe combination index for ROS and IL-1β. CI < 1 = synergy; CI ≈ 1 = additive; CI > 1 = antagonism. Apo-vs-holo comparison: if apo-Lf-additivity disappears in holo arm, mechanism is iron-sequestration-specific (the platform-relevant story).

Success criteria:

Promote ROS / CP1b coverage row from speculative to supported in gout-pathophysiology.md multi-track coverage table if Loewe CI ≤ 1.0 for IL-1β at the mid-range × mid-range combination, AND apo-Lf-driven additivity is greater than holo-Lf in the apo-vs-holo comparator (mechanism confirmed iron-sequestration-specific). This is the Item 22 wet-lab gate.
Strengthen the case for combining koji + mushroom tracks beyond urate-transporter rationale, providing an anti-inflammatory additivity argument for the multi-track product strategy.
Drop the orthogonal-ROS framing if apo-Lf additivity is no greater than holo (mechanism is generic anti-inflammatory, not Fenton-iron-specific) OR if Loewe CI ≫ 1 (compounds antagonistic rather than additive).

Limitations: - THP-1 is a single human macrophage line; primary human MDM (monocyte-derived macrophage) replication would strengthen translation but doubles cost. - LPS + MSU stimulation is a two-signal model that doesn't capture all in vivo gout-flare priming pathways. - Fenton-iron mechanism in cell culture vs. in vivo gut lumen has different iron-availability conditions; cell-culture additivity may not translate to gut-luminal additivity.

Cross-references: gout-pathophysiology.md §"Multi-track urate transporter coverage" ROS / CP1b row (the speculative claim this experiment gates); lactoferrin.md §4.1 (Fenton-iron mechanism); medicinal-mushroom-complement-track.md (P. citrinopileatus EGT source); validation-experiments.md §1.19 (rodent-IC50 species-gap discipline); validation-experiments.md §1.20 (sister CP1a super-additivity assay sharing THP-1 + MSU infrastructure); synthesis/ 2026-05-07 77d0f6e Connection 3 + Item 22 walkthrough closure.

1.28 Tier 2 Colorimetric Cordycepin Assay Validation (added 2026-05-15)¶

Status: Proposed | Cost: ~$200 (reagents + cordycepin reference standard + Tier 3 anchor) | Weeks: 2 | Phase: 1

Affected wiki: medicinal-mushroom-extract-sops.md SOP-6 (the speculative-marked assay this validates); quantification-ladder.md (the Tier-2 framework this anchors); self-experiment-protocol.md §12 (the genotype-informed-supplement-quantification workflow that depends on home-quantification of cordycepin); cordycepin-cassette-burden-computational.md (the cordycepin engineering thread); medicinal-mushroom-complement-track.md (cordycepin-bearing co-products).

What it tests: Whether the diazo-coupling colorimetric assay proposed in medicinal-mushroom-extract-sops.md SOP-6 — currently marked Speculative with the explicit "do not commit until primary-literature confirmation" caveat — is viable for Tier 2 home / community-biolab cordycepin quantification, or whether UV 260 nm absorbance must be used as the fallback. This is the gating wet-lab gate for cordycepin home quantification; load-bearing for self-experiment-protocol.md §12 (genotype-informed supplement quantification workflow surfaced 2026-05-15 Item 17) and for the broader medicinal-mushroom-complement-track.md §"Phase 7 follow-ups" #3 + #7 (extract characterization SOPs + dose-grounding pass).

Proposed in: 2026-05-14 sweep Experiment 2 (synthesis/done/2026-05-14-experiment-2-tier-2-colorimetric-cordycepin-assay-validation-diazo.md).

Background on the gap: SOP-6 proposes a Bratton-Marshall-style diazo-coupling colorimetric assay for cordycepin (3'-deoxyadenosine — a nucleoside analog with a primary aromatic amine accessible under hydrolysis conditions). The mechanism is plausible by analogy to nitrite-based colorimetric detection of aromatic amines (sulfanilamide, dapsone, etc.), but no primary-literature precedent for cordycepin-specific diazo-coupling has been verified. Until validated, the SOP carries the speculative caveat. UV 260 nm absorbance is the conservative fallback — cordycepin absorbs at λmax ~260 nm with ε ~14,500 M⁻¹·cm⁻¹, comparable to adenosine — but requires no derivatization and gives lower specificity (any 260-nm-absorbing contaminant interferes).

Protocol:

Reference standard: Cordycepin reference standard (Sigma-Aldrich C3394 or equivalent, ≥98% purity, ~$50–80 for 10 mg). Prepare calibration series at 1, 5, 10, 25, 50, 100 µg/mL in 10% methanol/water (mirrors expected extract matrix).
Arm A — Diazo-coupling colorimetric: Per SOP-6 draft — acid hydrolysis (1 N HCl, 60 °C, 30 min) to expose the primary amine, neutralize, then react with sodium nitrite + N-(1-naphthyl)ethylenediamine (NEDA) per the standard Bratton-Marshall procedure. Read absorbance at 540–560 nm. Record: linearity (R² of standard curve), LoD (signal:noise ≥ 3), LoQ (signal:noise ≥ 10).
Arm B — UV 260 nm fallback: Direct absorbance at 260 nm in 10% methanol/water. Same calibration series. Same metrics.
Cross-validation: Send 3 calibration concentrations (low, mid, high) to a Tier 3 anchor (HPLC-UV, contract lab e.g. Eurofins or university analytical service, ~$50/sample × 3 = $150). Compare Tier 2 result (both arms) vs. Tier 3 ground truth.
Specificity check: Spike each calibration point with 100 µg/mL adenosine (the most likely cross-reactant — also a primary-amine-bearing nucleoside that diazo-couples). Quantify cross-reactivity: < 5% interference = clean; 5–20% = needs hydrolysis-condition optimization or column cleanup before diazo step; > 20% = method-fail for crude Cordyceps extracts (which contain orders-of-magnitude more adenosine than cordycepin by mass).

Success criterion (test → next phase):

Diazo-coupling GREEN: linearity R² ≥ 0.98 across 1–100 µg/mL, LoD ≤ 2 µg/mL, adenosine cross-reactivity < 20%, Tier 2 vs. Tier 3 agreement within 20% on all three concentrations. → Promote SOP-6 from Speculative to Validated; update medicinal-mushroom-extract-sops.md to remove the caveat.
Diazo-coupling YELLOW: linearity + LoD pass but adenosine cross-reactivity is 20–50%. → Investigate hydrolysis-condition optimization or simple C18 SPE cleanup before assay. Iterate.
Diazo-coupling RED (linearity < 0.95 OR adenosine cross-reactivity > 50% OR Tier 2 vs. Tier 3 disagreement > 30%): use UV 260 nm fallback. Update SOP-6 to explicitly recommend UV 260 nm + downgrade the diazo path to "experimental, not for production quantification."

Estimated cost: ~$200 (cordycepin reference standard $50–80; diazo + UV reagents $20; Tier 3 anchor HPLC-UV $150; misc consumables $20).

Estimated timeline: 2 weeks (1 week reagent procurement + calibration; 1 week assay runs + Tier 3 turnaround).

Limitations:

The Bratton-Marshall-style diazo-coupling mechanism's applicability to cordycepin specifically is the speculative element this experiment tests. If literature surfaces a published precedent during execution, that may obviate the experimental validation step; check PubMed (English) + CNKI / J-STAGE per Open Enzyme/CLAUDE.md §"Global-multilingual research by default" before running.
Adenosine cross-reactivity is the most likely failure mode. If detected, the workflow may require a brief solid-phase cleanup (C18 SPE cartridge separates polar adenosine from less-polar cordycepin) before diazo, adding ~$5/sample.
Tier 3 HPLC-UV anchor cost is vendor-variable; $50/sample is a mid-range estimate. Verify quoting before committing.
The validation is on pure cordycepin reference standard. Real-world extract performance (cordycepin in a C. militaris fermentate matrix) is a separate downstream question — typically the next experiment after a clean reference-standard validation.

Cross-references: medicinal-mushroom-extract-sops.md SOP-6 (the speculative-marked SOP this experiment validates); quantification-ladder.md (Tier-2 framework); self-experiment-protocol.md §12 (genotype-informed-supplement-quantification workflow); cordycepin-cassette-burden-computational.md (comp-023 engineering thread); medicinal-mushroom-complement-track.md §"Combined / synergy candidates" (cordycepin-bearing co-products); §2.7 (sister Tier 2 assay — ADA-challenge stability test for engineered-koji + cultivated-Cordyceps co-formulation).

1.29 Cordycepin × Pentostatin × Substrate Matrix (added 2026-05-19, source: substrate-engineering lit scan)¶

Status: Proposed | Cost: ~$2,500–4,000 (4 cultivation arms × HPLC quantification) | Weeks: 8–12 | Phase: 1

Affected wiki: medicinal-mushroom-complement-track.md §"Substrate engineering as the most-accessible cultivation lever" (the Platform Principle 9 anchor); medicinal-mushroom-extract-sops.md §SOP-2 (cordycepin + pentostatin HPLC quantification — directly extensible to this experiment); §SOP-7 (substrate-engineering protocol matrix this validates).

What it tests: How substrate composition modulates the cordycepin × pentostatin ratio in C. militaris fermentate. The Xia 2017 BGC co-production finding (PMID 29056419) is established — cordycepin and pentostatin come from the same biosynthetic gene cluster — but no primary paper measures the pentostatin:cordycepin ratio under different substrate conditions. This experiment resolves the whole-fermentate-vs-purified clinical positioning gap that has been open in the wiki.

Why this matters platform-wide: the natural ADA-inhibitor pairing (pentostatin co-produced with cordycepin in fermented C. militaris) is the safeguard against cordycepin deamination that purified cordycepin lacks (per medicinal-mushroom-complement-track.md §"Combined / synergy candidates" Phase 6 thesis). If substrate composition shifts the pentostatin:cordycepin ratio, this changes: - Whole-fermentate dose-effectiveness (high-pentostatin batches deliver more durable cordycepin) - Clinical positioning (whole-fermentate vs. purified cordycepin + separate pentostatin) - Substrate selection for distributed cultivators (which substrate gives the optimal natural ratio)

Protocol — four-arm substrate matrix:

Arm A: L-alanine 12 g/L in PDA (Yu 2024 PMC11698586 protocol; expected 3× cordycepin via Cns2/Cns3 upregulation — pentostatin response unknown)
Arm B: Corn steep liquor hydrolysate 1.5 g/L + peptone 3.5 g/L (Chang 2024 PMC10931215 protocol; expected 4.83× cordycepin — pentostatin response unknown)
Arm C: Oleic acid 1.0 g/L substrate supplementation (Turk 2022 PMC9627333 mechanism; expected 1.5–3× cordycepin via fatty-acid-driven Cns1/Cns2 upregulation — pentostatin response unknown)
Arm D: Standard rice-grain solid-state baseline (reference batch; published cordycepin:pentostatin ratio anchor)

Each arm: parallel small-scale liquid (Arms A-C) or solid (Arm D) cultivation; harvest at peak cordycepin (~14d for liquid, ~28d for solid); ethanolic extraction; SOP-2 HPLC-UV quantification of both cordycepin (3'-deoxyadenosine, λmax 260 nm) and pentostatin (2'-deoxycoformycin, λmax 282 nm) against pure reference standards.

Decision rules: - If pentostatin:cordycepin ratio stays stable across substrates (within ±20% of reference): the natural ADA-inhibitor pairing is substrate-robust; whole-fermentate positioning remains the canonical platform path independent of substrate optimization. Substrate choice optimizes for cordycepin yield alone. - If pentostatin:cordycepin ratio shifts substantially (>2×) across substrates: substrate selection becomes a second engineering lever — distributed cultivators optimize jointly for cordycepin yield AND pentostatin-protective ratio. New SOP guidance required. - If pentostatin drops disproportionately under cordycepin-boosting substrates: the high-cordycepin yields come at the cost of the natural ADA-inhibitor safeguard, weakening the whole-fermentate positioning. Purified cordycepin + separate pentostatin becomes the cleaner clinical default.

Success criteria: - All four arms yield detectable cordycepin (≥50 mg/L liquid or ≥0.5 mg/g DW solid) and pentostatin (≥1 mg/L liquid or ≥0.05 mg/g DW solid). - HPLC quantification reproducibility ±15% across triplicate runs per arm. - Reference batch (Arm D) cordycepin and pentostatin levels are within published range (per Kontogiannatos 2021 PMC8621325 cordycepin range 30–8570 mg/L liquid / 0.6–77.4 mg/g DW; Xia 2017 pentostatin co-production anchor).

Dependencies: SOP-2 HPLC infrastructure (cordycepin + pentostatin reference standards from Sigma C3394 + Cayman 10009152); C. militaris working strain with ITS-verified provenance (per SOP-5).

Cross-references: medicinal-mushroom-complement-track.md §"Combined / synergy candidates" (Phase 6 whole-fermentate vs. purified-cordycepin positioning); medicinal-mushroom-extract-sops.md §SOP-2 (HPLC infrastructure) + §SOP-7 (substrate-engineering protocol matrix); logs/substrate-engineering-mushroom-cultivation-lit-scan-2026-05-19.md (the lit scan that surfaced this gap).

Phase 2: Animal Model Validation¶

2.1 Gnotobiotic Mouse Colonization with Engineered S. boulardii¶

Status: Proposed | Cost: $5,000–15,000 | Weeks: 8–12 | Phase: 2

Affected wiki: engineered-yeast-uricase-proposal, gut-lumen-sink, team

What it tests: Can engineered probiotic yeast survive and function in the mouse gut? What dosing is needed?

Proposed in: engineered-yeast-uricase-proposal.md (§4.d)

Protocol: - Colonize germ-free mice with engineered S. boulardii expressing uricase - Measure: - Fecal yeast counts daily for 14 days (CFU/g) - Fecal and cecal uricase activity assay - Serum uric acid in Uox-knockout mice (or potassium oxonate-hyperuricemic model) - Compare: engineered strain vs. wild-type S. boulardii vs. untreated controls

Estimated cost: $5,000–15,000 (gnotobiotic mouse facility time, staff, housing, assays)

Estimated timeline: 8–12 weeks

Dependencies: - Requires optimized S. boulardii uricase strain from Phase 1 - Requires access to a gnotobiotic facility — ideally via a Role 1 (Gut Microbiome / In Vivo Validation) collaborator, if recruiting converts

Success criteria: - Maintain >10⁶ CFU/mL fecal yeast counts through day 7 - Achieve measurable cecal uricase activity - Reduce serum uric acid by ≥20% vs. controls

2.2 Hyperuricemic Rat Model: Engineered Yeast Efficacy¶

Status: Proposed | Cost: $8,000–12,000 | Weeks: 6–8 | Phase: 2

Affected wiki: engineered-yeast-uricase-proposal, gout-deep-dive, uricase

What it tests: Does oral administration of engineered yeast reduce systemic uric acid in a whole-organism model?

Proposed in: engineered-yeast-uricase-proposal.md (§5)

Protocol: - Induce hyperuricemia in Sprague-Dawley rats using oxonic acid + allopurinol (standard model) - Administer engineered yeast strain (lyophilized powder in capsules) daily for 14 days at varying doses - Measure: - Serum uric acid (HPLC or uricase-catalase assay) - Urinary uric acid excretion (24h collection) - Fecal uric acid (as proxy for gut lumen degradation) - Kidney function markers (BUN, creatinine) - Compare: treated vs. vehicle control vs. allopurinol positive control

Estimated cost: $8,000–12,000 (animal costs, housing, blood assays, LC-MS analysis)

Estimated timeline: 6–8 weeks

Dependencies: Requires Phase 1 optimization of yeast strain

Success criteria: - Achieve serum uric acid reduction of ≥30% vs. vehicle - Increase fecal uric acid by ≥50% vs. vehicle - Non-inferior to allopurinol in serum uric acid reduction

2.3 Engineered Koji Efficacy in Digestive Enzyme-Deficient Model¶

Status: Proposed | Cost: $6,000–10,000 | Weeks: 8–10 | Phase: 2

Affected wiki: engineered-koji-protocol, digestive-enzymes, enzyme-deficit-deep-dive

What it tests: Does engineered koji effectively supplement digestive enzymes in vivo?

Proposed in: engineered-koji-protocol.md

Protocol: - Use pancreatic lipase knockout mice (or pancreatectomized mice as EPI model) - Administer koji fermented on rice (whole food) as supplement (10% dietary w/w) for 14 days - Measure: - Fat absorption (coefficient of fecal fat; <7g/day = normal) - Protein digestion (fecal nitrogen) - Starch digestion (breath hydrogen test) - Intestinal inflammation markers (fecal calprotectin) - Compare: engineered koji vs. wild-type koji vs. no supplement vs. commercial enzyme supplement (Creon)

Estimated cost: $6,000–10,000 (genetically modified mice, housing, specialized assays)

Estimated timeline: 8–10 weeks

Dependencies: Requires koji strain from Phase 1

Success criteria: - Normalize fat absorption to >92% (vs. <50% in untreated EPI) - Non-inferior to commercial enzyme supplement

2.4 NLRP3 Inflammasome Inhibition in MSU Crystal Arthritis Model¶

Status: Proposed | Cost: $10,000–15,000 | Weeks: 10–12 | Phase: 2

Affected wiki: nlrp3-exploit-map, nlrp3-inflammasome, gout-deep-dive, supplements-stack

What it tests: Do proposed NLRP3 inhibitor compounds reduce gout flare severity in vivo?

Proposed in: nlrp3-exploit-map.md, gout-deep-dive.md

Protocol: - Induce acute gout in C57BL/6 mice by intra-articular MSU crystal injection into knee - Treat with compounds or combinations: - Individual compounds (BHB via ketogenic diet, oridonin oral gavage, sulforaphane) - Multi-compound stack (BHB + oridonin + sulforaphane) - Positive control: colchicine - Negative control: vehicle - Measure: - Joint swelling (calipers measurement, MRI) - Pain behavior (weight bearing on affected limb, mechanical hyperalgesia) - Inflammatory cytokines in joint lavage (IL-1β, TNF-α, IL-6 by multiplex assay) - Histology: neutrophil infiltration, synovial inflammation score - Timeline: measure at 4h, 24h, 48h, 72h post-injection

Estimated cost: $10,000–15,000 (transgenic mice, surgical arthritis induction, imaging, cytokine assays)

Estimated timeline: 10–12 weeks (including 2-week ketogenic diet adaptation)

Dependencies: Requires Phase 1 validation of NLRP3 pathway

Success criteria: - Reduce peak joint swelling by ≥40% vs. vehicle - Reduce joint IL-1β by ≥50% vs. vehicle - Reduce neutrophil infiltration by ≥30% vs. vehicle

2.5 PULSE Probiotic Validation in Hyperuricemic Mice¶

Status: Proposed | Cost: $5,000–8,000 | Weeks: 8 | Phase: 2

Affected wiki: gout-deep-dive, gout-clinical-pipeline, gut-lumen-sink

What it tests: Can PULSE system (urate-responsive engineered E. coli) maintain uric acid homeostasis?

Proposed in: gout-deep-dive.md (Section 8)

Protocol: - Colonize Uox-knockout mice with PULSE engineered E. coli Nissle 1917 - Administer at varying doses and dosing frequencies (daily vs. every 3 days) - Measure: - Fecal E. coli counts and uric acid-responsive biosensor activity (reporter assay) - Serum uric acid over 28 days (weekly measurements) - Response to acute uric acid challenge (potassium oxonate injection) - Off-target metabolite accumulation (allantoin, oxaluric acid) - Compare: PULSE vs. wild-type E. coli Nissle vs. untreated controls

Estimated cost: $5,000–8,000 (transgenic mice, E. coli handling, weekly blood draws, biomarker assays)

Estimated timeline: 8 weeks

Dependencies: Requires PULSE strain (Source: Cell Reports Medicine 2025 reference)

Success criteria: - Maintain serum uric acid within 2.0–4.0 mg/dL range (homeostatic) - Self-regulate in response to acute uric acid load - Clear allantoin without accumulation

2.6 GLPP + Cordycepin Synergy in Hyperuricemic Mice — 4-Arm Wet-Lab Gate (Phase 7-4 Stub)¶

Status: Proposed (stub — full protocol pending chemistry collaborator) | Cost: $8,000–15,000 | Weeks: 10–14 | Phase: 2

Affected wiki: medicinal-mushroom-complement-track, hypotheses/H06-medicinal-mushroom-complement-track, medicinal-mushroom-extract-sops, medicinal-mushroom-compound-mapping-computational, modality-chokepoint-matrix

What it tests: The Phase 6 GLPP+cordycepin synergy hypothesis — does combined administration achieve URAT1 modulation at lower individual doses than either alone, with acceptable PK/PD? Refined to 4-arm comparison after Phase 7-1b strain scan surfaced that C. militaris natively co-produces pentostatin from the same BGC as cordycepin (Xia 2017, PMID 29056419) — pentostatin is the natural ADA-inhibitor that protects cordycepin from deamination. Whole-fermentate Cordyceps preparations have the synergy built in; purified cordycepin lacks it.

Why this matters: validates whether the medicinal-mushroom-complement track delivers a real platform contribution. Per H06 Dimension 3, replication of GLPP 40.6% UA reduction (PMID 36385640) within 2× of published effect size is the load-bearing claim — if the published effect doesn't replicate at higher methodological rigor, the track is not viable in a way no protocol-improvement fixes.

Proposed in: medicinal-mushroom-complement-track.md §"Six Phase 7 follow-ups queued" #4 (committed 2026-05-06); refined by Phase 7-1b strain scan pentostatin discovery; framed as 4-arm via comp-014 Phase 6 triage.

Protocol (stub-level — full design pending chemistry collaborator): - Model: PO+HX hyperuricemia mouse (potassium oxonate + hypoxanthine), C57BL/6 or matching PMID 36385640's strain (verify via Phase 5b CNKI dive of Chinese-language strain rationale) - Sample size: n=8/arm × 4 arms + 8 healthy controls = 40 mice (powered for 25% SUA reduction, α=0.05, 80% power, based on PMID 36385640 effect 40.6% with 15% SD) - 4 arms: 1. Whole-fermentate C. militaris (top strain GYS60 per Phase 7-1b, brown-rice SSF per Phase 7-2 SOP) — natural cordycepin + pentostatin pairing 2. Purified cordycepin alone (commercial ≥98% HPLC, Sigma C9881 or equivalent) 3. Purified cordycepin + GLPP (GLPP from ITS-verified G. lingzhi per SOP-1; GLPP serves as alternative ADA inhibitor) 4. Purified cordycepin + pentostatin (FDA-approved drug, regulated research-use sourcing; positive control for ADA-inhibitor-mediated cordycepin protection) - Doses: equimolar cordycepin across arms 2-4; whole-fermentate dosed to deliver matched cordycepin (1-25 mg/g DW per Phase 7-1b); GLPP at PMID 36385640 top dose (400 mg/kg PO); pentostatin low pharmacological dose (~0.5 mg/kg) - Duration: 14 days PO daily dosing - Primary endpoint: SUA reduction at d14 - Secondary endpoints: cordycepin + 3'-deoxyinosine plasma PK at d1/d7/d14 (does ADA inhibition extend cordycepin t½?); URAT1 mRNA/protein in kidney; GLUT9 + OAT1 mRNA (GLPP pathway); ADA activity in serum + intestinal mucosa; safety (ALT/AST, BUN/Cr, body weight)

Estimated cost ($8,000-15,000): mice $1,500-3,000; vivarium $1,200-2,000; cordycepin standard $400-600; pentostatin (license + small qty) $1,500-3,000; GLPP source $500-1,500; whole-fermentate Cordyceps $200-500; assays (SUA, cordycepin PK, transporter expression) $2,000-3,500; CRO/lab labor $500-1,500.

Estimated timeline (10-14 weeks): 3-4 wk source acquisition; 1 wk dose validation HPLC; 4-5 wk in vivo arm; 2-3 wk assay completion + analysis.

Dependencies: - SOP-1 GLPP fractionation drafted to operational state — currently stub-level; gated on Phase 5b CNKI dive of Lin Zhanxi Juncao methods (TODO-2 in scope page) - Pentostatin research-use sourcing (FDA-approved drug, restricted access) - Wet-lab access — same recruiting target as §1.25 (Role 2 / Pharma Translation collaborator per team.md; alternatively CRO with rodent metabolic-disease capability) - ITS-verified G. lingzhi strain (Mycelia.bvba M9724 per Phase 7-1a, ~$50-100)

Success criteria: - Accept (H06 Dimension 3 passes): arm 1 SUA reduction ≥20% (within 2× of 40.6%); arm 2 < arm 1 due to BA collapse; arms ¾ recover toward arm 1 (mechanism validated). Cordycepin t½ ≥3× longer in arms ⅓/4 vs arm 2. - Iterate: arms 1+3 work but arm 4 (pentostatin) shows toxicity at therapeutic-equiv dose — reprioritize whole-fermentate + GLPP-paired routes over purified-cordycepin+pentostatin commercial-pharma route. - Reject (H06 Dimension 3 fails): all 4 arms <10% SUA reduction OR cordycepin t½ unchanged by ADA inhibitor co-treatment. Triggers H06 falsification — published effect sizes don't replicate at controlled methodological rigor; medicinal-mushroom-complement track narrows to ergothioneine-only (Phase 5 redox-as-Nrf2-priming subset) or de-prioritizes.

Computational priors: comp-014 Phase 4 ranked candidates; Phase 5 deep-reads; Phase 6 triage; Phase 7-1b strain scan (pentostatin BGC co-production finding).

Limitations: - Mouse strain may interact with cordycepin metabolism — verify via Phase 5b CNKI dive - Pentostatin research-use sourcing may add 3-6 weeks if license framework not pre-established - GLPP MW resolution (2026-05-06 grep-verify gate): 520 kDa = bulk crude prep (sister paper PMC11351902 confirms); 31-42 kDa = post-DEAE sub-fractions (PMID 37852403 + 29541200); Lin 2022 HUA paper itself does not specify which sub-fraction it used. SOP-1 SEC-MALS will resolve which fraction the HUA mechanism load-bears on. Not a blocker for §2.6 — dose math anchors on whole-extract per published g/kg, not on MW. - Xia 2017 (PMID 29056419) cordycepin:pentostatin natural ratio is paywalled and not in open-access secondary sources (mechanism is robustly verified via 3 independent secondary citations; only the absolute COR:PTN ratio number is unavailable). Non-blocking for the 4-arm design — pentostatin is sourced separately at FDA-approved-drug clinical-equivalent dose (~0.5 mg/kg), not at the natural ratio. Documented for completeness; if a future arm requires the natural ratio explicitly, primary-source access will be needed. - 14-day duration captures acute effect, not chronic durability — separate follow-up if positive

Cross-references: medicinal-mushroom-complement-track.md (parent scope); H06 Dimension 3; SOP-1 (gating dependency); §1.25 DAF SCR1-4 (sister wet-lab gate sharing lab-access infrastructure).

Phase 7-4b follow-up — koji × mushroom additivity arm (queued, gated on §2.6 base results, added 2026-05-06)¶

Status: Queued (gated on §2.6 base study confirming mushroom synergy) | Cost adder: ~$1.5–2.5K | Weeks adder: 1–2 wk if run as scope expansion of §2.6; 6+ months as standalone follow-up

What it tests: does the multi-track urate transporter coverage map (per gout-pathophysiology.md §"Multi-track urate transporter coverage") compose additively when koji and mushroom tracks are combined, or is there a ceiling effect where additional mechanisms stop reducing serum urate? The §2.6 base study (4 arms) tests cordycepin × GLPP × pentostatin within the medicinal-mushroom track only; it does NOT test koji × mushroom combinations. This follow-up adds a 5^th arm explicitly designed to answer the additivity question.

Why this matters: the multi-track coverage map is currently an emergent designed-coverage pattern (each track chosen for an independent therapeutic mechanism, multi-node coverage fell out as accident). Whether the implied "stack the tracks for additive serum-urate reduction" recommendation actually holds is a load-bearing assumption for any consumer-product framing combining engineered koji + cultivated mushroom extracts. If additivity holds → multi-track stacking is a real platform-level differentiator; if a ceiling effect dominates → tracks should be presented as alternatives, not stack.

Proposed in: 2026-05-06 sweep Open Question 2 + Item 5 multi-track coverage subsection synthesis. Reviewer recommended promoting from Open Question to Priority Action; chosen Option B (queued follow-up gated on §2.6 base) over Option A (concurrent 5^th arm) to preserve clean attribution in the §2.6 base study and avoid §1.9-strain-readiness dependency.

Proposed protocol (stub-level, fires on §2.6 success gate): - Arm 5 (added): best-performing arm from §2.6 (likely arm 1 whole-fermentate Cordyceps + GLPP based on Phase 6 triage prior) + engineered-koji uricase strain (per koji-endgame-strain.md, delivered as koji-condiment in food matrix, dose-matched to deliver gut-luminal uricase activity comparable to Huynh 2020 baseline) - n=8 (matches §2.6 arm sizing; powered for 25% incremental SUA reduction over arm 1) - Same model (PO+HX hyperuricemia mouse), same readouts (SUA d14, cordycepin PK, URAT1/GLUT9/OAT1 mRNA), same duration (14 days) - Additional readout: kidney-side urate dynamics (incremental gut-lumen sink contribution measurable as d14 urinary urate excretion increase relative to arm 1)

Success criteria: - Additivity confirmed: arm 5 SUA reduction ≥ arm-1 reduction + 8% (incremental ≥⅓ of arm-1 effect, mechanism-independent gut-lumen sink contribution); urinary urate d14 elevated vs. arm 1 (consistent with luminal degradation pulling serum urate into gut) - Ceiling effect dominates: arm 5 SUA reduction within ±5% of arm 1 (no incremental benefit) → multi-track stacking should NOT be presented as platform-level differentiator; tracks become alternatives, not stack - Synergy (rare but possible): arm 5 SUA reduction > arm-1 + 15% (greater than mechanism-independent additivity; investigate gut-axis interaction, e.g., uricase-degraded urate metabolites affecting transporter expression)

Decision gate to fire this follow-up: §2.6 arm 1 (whole-fermentate Cordyceps) achieves ≥20% SUA reduction. If §2.6 base mushroom synergy fails (<10% across arms), this follow-up is moot — no point spending $2K to confirm "still doesn't work." If §2.6 succeeds at ≥20%, Phase 7-4b becomes the next-cycle priority for the medicinal-mushroom track.

Limitations: - Engineered-koji uricase strain readiness: gated on Ward 1995 §1.9 (#1 priority dual-cassette feasibility test). If §1.9 hasn't returned positive results by §2.6 conclusion, Phase 7-4b waits for §1.9 OR uses a documented surrogate (Huynh 2020 koji-uricase strain reproduction). - 14-day duration captures acute additivity, not chronic durability — long-term follow-up separate experiment if positive. - Mouse strain consistency with §2.6 base must be maintained (no cross-cohort comparisons).

Cross-references: gout-pathophysiology.md §"Multi-track urate transporter coverage" (the coverage map this follow-up tests); §2.6 base (parent study); §1.9 Ward 1995 (engineered-koji-uricase-strain dependency); koji-endgame-strain.md (koji track context).

2.7 Koji × Cordyceps Co-Formulation Stability Test — ADA-Challenge Assay (added 2026-05-15; Deprioritized 2026-05-16)¶

Deprioritized 2026-05-16 — koji-cordycepin engineering removed from active cassette stack. Walkthrough Item 7 strategic call. This experiment was a gate for the engineered-koji cordycepin route + cross-chassis pentostatin protection; with the koji-cordycepin engineering effort deprioritized (full reasoning at koji-endgame-strain.md §3.5), the experiment is moot — the cultivation route already delivers cordycepin + pentostatin together at the natural co-evolved ratio, and no engineered-koji cordycepin product is being developed for the gate to evaluate. Section retained for traceability; do not execute. Re-open only if the koji-cordycepin engineering thesis is re-prioritized (new evidence on therapeutic-dose achievability or a chokepoint that koji-engineered cordycepin uniquely addresses).

Status: ~~Proposed~~ Deprioritized | Cost: $1,500–3,000 | Weeks: 3–4 | Phase: 2 (low-cost, low-friction)

Affected wiki: medicinal-mushroom-complement-track §"Combined / synergy candidates"; cordycepin-cassette-burden-computational.md §"Impact on experimental priorities"; computational-experiments.md comp-025 (ADA × cns1 kinetic modeling); koji-endgame-strain.md cordycepin arm.

What it tests: Does whole-fermentate C. militaris extract (providing native pentostatin) protect engineered-koji-produced cordycepin from ADA-mediated deamination when the two are co-formulated? If yes, the cross-chassis pairing (engineered koji handles bulk cordycepin production at scale; cultivated C. militaris extract provides ADA-protecting pentostatin from native co-evolved chemistry) becomes a minimal-complexity delivery strategy that avoids the additional cassette OR ADA-knockout work that comp-024 / comp-025 would otherwise gate. If no, the co-formulation strategy fails and the platform routes through full-BGC engineering OR ADA knockout OR purified pentostatin co-supplementation.

Proposed in: 2026-05-14 sweep Connection 4 (synthesis/done/2026-05-14-connection-4-cordycepins-ada-vulnerability-creates-a-two-organism.md).

Background on the gap: comp-023 confirmed engineered cns1+cns2 cordycepin production in koji is metabolically feasible (GREEN at Jeennor 2023 564 mg/L/d). But cordycepin is rapidly deaminated by adenosine deaminase (ADA) to its inactive 3'-deoxyinosine form. Native C. militaris solves this by co-producing pentostatin (a clinical-grade ADA inhibitor) from the same BGC as cordycepin (Xia 2017, PMID 29056419). The minimal-complexity workaround for engineered koji: don't engineer pentostatin; pair the koji fermentate with a small co-formulated dose of cultivated C. militaris extract. This experiment tests whether the pairing actually delivers ADA protection or whether the formulation context (mixing solid-state koji + dried Cordyceps extract) compromises pentostatin's activity.

Protocol:

Test article preparation:
Arm A (negative control): engineered-koji cordycepin fermentate alone, no ADA inhibitor
Arm B (positive control — native): whole-fermentate C. militaris alone (intrinsic cordycepin + pentostatin from native BGC)
Arm C (cross-chassis pairing — the test): engineered-koji cordycepin fermentate + dried C. militaris extract at pentostatin dose calibrated to match Arm B's pentostatin content
Arm D (purified-pentostatin reference): engineered-koji cordycepin fermentate + commercial pentostatin (Nipent or research-grade)
ADA challenge assay:
Spike each arm with bovine intestinal ADA (or human recombinant ADA) at a defined enzyme concentration
Sample at t = 0, 15 min, 30 min, 60 min, 120 min, 240 min
Quantify cordycepin vs. 3'-deoxyinosine (the ADA product) by LC-MS at each timepoint
Readout: cordycepin half-life under ADA challenge for each arm; comparison vs. Arm A baseline (no ADA inhibition)
Stability check: Arm C cordycepin + pentostatin content at 0, 7, 14 days post-co-formulation (room temperature + 4°C storage) to verify the co-formulation doesn't degrade pentostatin
Success criterion (test → next phase): Arm C cordycepin half-life ≥ 50% of Arm B's half-life. (Arm B is the native co-evolved benchmark; co-formulation reaching half of native protection is meaningful evidence the strategy works.)

Estimated cost: $1,500–3,000 - C. militaris cultivation (~2 weeks home or community-biolab) + dried extract preparation: ~$200–400 - Engineered-koji cordycepin fermentate (or comp-023-feasibility-proxy via Jeennor 2023 reference batch): ~$500 if outsourced; gated on engineered-koji-cordycepin strain availability - LC-MS quantification ($25–50/sample × 4 arms × 6 timepoints × 3 replicates = 72 samples × $35 ≈ $2,500) - Bovine ADA reagent: ~$100

Estimated timeline: 3–4 weeks (2 weeks Cordyceps cultivation + 1 week assay run + 1 week LC-MS turnaround)

Success criteria (overall): - Arm C cordycepin half-life ≥ 50% of Arm B (native co-evolved): the cross-chassis pairing works as a minimal-complexity ADA-protection route. Update medicinal-mushroom-complement-track.md to promote the pairing from "synergy candidate" to "validated route"; update koji-endgame-strain.md cordycepin-arm framing to note this avoids pentostatin co-engineering complexity. - Arm C half-life < 50% of Arm B: the co-formulation strategy fails. Route through pentostatin co-engineering (additional cassette in koji) OR ADA knockout (host engineering) OR purified pentostatin co-supplementation. Comp-024 / comp-025 outcomes determine which.

Limitations:

In vitro ADA challenge does not capture gut-lumen-realistic conditions (mixed flora, gut-wall ADA distribution, pH variation). Use the in vitro result as a go/no-go for whether the cross-chassis pairing is mechanistically possible, not as a guarantee of in vivo performance.
Pentostatin dose-matching across Arm B (native) and Arm C (co-formulated) requires accurate quantification of pentostatin in the dried C. militaris extract. Use an HPLC-UV anchor measurement per medicinal-mushroom-extract-sops.md or send to a Tier 3 vendor for absolute quantification before the assay.
Engineered-koji cordycepin fermentate availability is gated on the cns1+cns2 cassette being expressed in koji. Until that happens, this experiment uses Jeennor 2023's C. militaris fermentate as a stand-in cordycepin source (with the native pentostatin removed via chromatographic purification before re-spiking).

Cross-references: medicinal-mushroom-complement-track.md §"Combined / synergy candidates" (originating section); cordycepin-cassette-burden-computational.md §"Impact on experimental priorities" (cordycepin engineering-feasibility prior); comp-025 ADA × cns1 substrate competition (computational gate that informs whether this experiment is needed); §2.6 (4-arm whole-fermentate vs. purified comparison — sister experiment); Xia 2017 PMID 29056419 (native pentostatin co-production primary source).

Phase 3: Human Self-Experimentation and Biomarker Tracking¶

3.1 Brian: Engineered Yeast Uricase — Serum Uric Acid & Flare Tracking¶

Status: Proposed | Cost: $200–400 | Weeks: 20 | Phase: 3

Affected wiki: engineered-yeast-uricase-proposal, self-experiment-protocol, open-enzyme-vision

What it tests: Does daily oral engineered yeast reduce serum uric acid and gout flare frequency in the primary user?

Proposed in: engineered-yeast-uricase-proposal.md (§5), etc/open-enzyme-vision.md (§8)

Protocol: - Brian (primary user with gout) takes engineered yeast supplement daily - Baseline: 4 weeks pre-intervention (establish flare frequency, serum urate baseline) - Intervention: 12 weeks daily supplementation with engineered yeast (dose TBD from animal studies) - Biomarkers measured weekly: - Serum uric acid (HPLC or uricase-catalase assay) - Inflammatory markers (CRP, IL-6 if available) - Gout flare frequency and severity (patient-reported, validated scale) - Tissue urate (tophi size if present, via ultrasound) - Control: 4-week washout period after intervention

Estimated cost: $200–400 (blood assays, home kit supplies)

Estimated timeline: 20 weeks (4 baseline + 12 intervention + 4 washout)

Dependencies: - Requires Phase 1 & 2 validation - Requires medical oversight (likely rheumatologist or primary care)

Success criteria: - Reduce serum uric acid by ≥15% vs. baseline - Reduce flare frequency by ≥50% vs. baseline period - No adverse events

3.2 Brian: NLRP3 Inflammasome Suppression Stack — Biomarker Panel¶

Status: Proposed | Cost: $700–1,400 | Weeks: 20 | Phase: 3

Affected wiki: nlrp3-exploit-map, supplements-stack, self-experiment-protocol, open-enzyme-vision

What it tests: Does the multi-compound NLRP3 stack reduce inflammatory markers and flare severity?

Proposed in: nlrp3-exploit-map.md, etc/open-enzyme-vision.md (§9)

Protocol: - Brian takes NLRP3 suppression stack (BHB/exogenous ketones + KPV nasal spray + BPC-157 nasal spray + sulforaphane + oridonin + omega-3 + NAC, dosed per [[supplements-stack]]) - Baseline: 4 weeks pre-intervention - Intervention: 12 weeks daily stack - Biomarkers measured weekly: - Serum IL-1β (high-sensitivity ELISA) - Serum CRP, calprotectin, and fibrinogen - Blood ketone bodies (BHB) if using exogenous ketones - Joint pain (VAS scale, validated) - Gout flare frequency - Control: 4-week washout post-intervention

Estimated cost: $300–600 (supplement costs) + $400–800 (blood assays)

Estimated timeline: 20 weeks

Dependencies: - Requires Phase 1 NLRP3 pathway validation - Can run in parallel with 3.1 (same subject, complementary endpoints) - Requires medical oversight

Success criteria: - Reduce IL-1β by ≥30% vs. baseline - Reduce CRP by ≥25% vs. baseline - Reduce flare frequency by ≥40% vs. baseline

3.3 Lynn: Wild-Type Koji Digestive Enzyme Supplementation¶

Status: In Progress (PERT-timing phase active 2026-04-19 → present) | Cost: $600–1,000 | Weeks: 12 | Phase: 3

Affected wiki: engineered-koji-protocol, digestive-enzymes, sibo, open-enzyme-vision, koji-home-fermentation, digestive-enzyme-optimization

What it tests: Does traditional koji effectively supplement digestive enzymes in EPI/SIBO?

Proposed in: engineered-koji-protocol.md, etc/open-enzyme-vision.md (§4); practical protocol in koji-home-fermentation.md (koji-kin → koji rice → shio-koji / amazake). (source: koji-home-fermentation.md)

Interim findings — PERT-timing sub-experiment (2026-04-19 → present, ~30 meals tracked): A structured self-experiment on BoulderBio (wild-type A. oryzae OTC, 40,000 FIP lipase per capsule) dose and timing has been running in parallel. Evidence level: Clinical n=1, single subject, unblinded, uncontrolled. Suggestive only. (source: digestive-enzyme-optimization.md) - 1 cap at first bite (label-default): insufficient for any meal >15 g fat. - 2 caps at first bite: markedly improved; 2026-04-25 breakfast produced a clear decoupling of liquid-stool from pain against a long-stable baseline — a meaningful efficacy signal for the platform's mechanism of action even before any engineering. - 1+1 split (1 cap at first bite + 1 at ~10 min): successful for >25 g fat meals. - Pre-emptive enzyme during long cooking sessions: cooking-and-tasting = small-meal eating; enzyme at start of cook prevented pre-dinner symptom buildup. - Working dose framework (n=1): <5 g fat → no enzyme; 15–25 g fat → 2 caps at first bite; >25 g fat or extended eating → 1+1 split; long cook-and-taste → 1 cap at start. - Confound flagged: Lying flat <90 min post-meal is a strong contributor to overnight episodes; must be controlled separately from enzyme-dose effects. - Tolerability: No adverse reactions across 30+ meals; no allergic response. - Implication for protocol: The formal koji trial should use 2-cap-equivalent dosing (not label-default 1 cap) as the comparator, and should track fat content per meal as a covariate. Split-dose arm should be included for high-fat meals.

Protocol: - Lynn (EPI/SIBO patient) takes traditional koji fermented on rice daily; shio-koji marinade is the highest-leverage format for EPI (pre-digests protein in marinade phase before food reaches the eater; see koji-home-fermentation.md §Stage 2A) (Mechanistic Extrapolation; source: koji-home-fermentation.md) - Baseline: 2 weeks pre-intervention (establish GI symptom baseline, stool frequency/consistency) - Intervention: 8 weeks daily koji consumption (10–20g dried koji powder or equivalent rice koji) - Biomarkers measured weekly: - GI symptom score (abdominal pain, bloating, diarrhea on validated scale) - Stool frequency, consistency (Bristol Scale) - Fat absorption assessment (72h fecal fat collection or non-invasive fat absorption test) - Inflammatory markers: fecal calprotectin, serum CRP - Microbiome composition (stool 16S rRNA at baseline, week 4, week 8 if budget allows) - Crossover: 2-week washout, then repeat with engineered koji (once available from Phase 1)

Estimated cost: $200–400 (koji ingredients, fecal tests) + $400–600 (optional microbiome analysis)

Estimated timeline: 12 weeks

Dependencies: - Requires wild-type koji protocol - Once Phase 1 complete, can compare vs. engineered koji

Success criteria: - Reduce abdominal pain/bloating score by ≥50% vs. baseline - Normalize stool frequency to 1–2× daily - Reduce fecal calprotectin by ≥30% (if elevated at baseline)

3.4 Joint Trial: Engineered Koji (Both Users)¶

Status: Proposed | Cost: $300–500 | Weeks: 14 | Phase: 3

Affected wiki: engineered-koji-protocol, open-enzyme-vision, self-experiment-protocol

What it tests: Does engineered koji providing both digestive enzymes and uricase work as a dual-purpose therapeutic food?

Proposed in: engineered-koji-protocol.md, etc/open-enzyme-vision.md (§4, dual-enzyme vision)

Protocol: - Both Brian and Lynn take engineered koji daily for 12 weeks - Brian measures: - Serum uric acid, gout flare frequency (as in 3.1) - GI tolerance (stool frequency, abdominal symptoms) - Lynn measures: - GI symptom score, stool characteristics (as in 3.3) - Serum uric acid (as secondary endpoint; she may have mild hyperuricemia) - Inflammatory markers - Both: - Palatability/adherence assessment - Adverse event monitoring - Serum inflammatory panel (CRP, IL-6)

Estimated cost: $300–500 (koji production, bioassays)

Estimated timeline: 14 weeks (2 week prep + 12 week trial)

Dependencies: - Requires Phase 1 completion of engineered koji with both enzyme activities validated - Requires both 3.1 and 3.3 baseline data for comparison

Success criteria: - Brian: ≥15% reduction serum uric acid, ≥50% reduction flare frequency - Lynn: ≥50% improvement GI symptoms, normalized stool, ≥30% reduction fecal calprotectin - Both: tolerate koji at therapeutic doses with >80% adherence - No safety signals in 12-week course

3.5 Biomarker Tracking: Long-term Flare Prevention (Brian, 6-month extension)¶

Status: Proposed | Cost: $400–600 | Weeks: 26 | Phase: 3

Affected wiki: open-enzyme-vision, self-experiment-protocol, gout-deep-dive

What it tests: Does uricase supplementation provide sustained reduction in gout flares?

Proposed in: etc/open-enzyme-vision.md (§8)

Protocol: - After Phase 3.1 completes successfully, continue engineered yeast supplementation for additional 6 months - Measure monthly: - Serum uric acid - Gout flare frequency and severity - Tophi size (if present, ultrasound at months 1, 3, 6) - Joint function/mobility scores - Adherence and side effect monitoring

Estimated cost: $400–600 (monthly blood assays, ultrasound imaging)

Estimated timeline: 6 months

Dependencies: Requires successful completion and validation of Phase 3.1

Success criteria: - Sustain serum uric acid reduction over 6-month period - Maintain ≥40% reduction in flare frequency from baseline - No tophi growth; ideally small reduction in tophi size - Continued >80% adherence

3.6 Brian: Urinary LTB4 Assay — Validating Quercetin's 5-LOX (CP6a) Mechanism In Vivo¶

Status: Proposed | Cost: $150–300 | Weeks: 12 | Phase: 3

Affected wiki: self-experiment-protocol, nlrp3-exploit-map, nlrp3-inhibitor-screen, synthesis/

What it tests: Does the current supplement stack suppress 5-LOX/LTB4 activity in vivo in Brian specifically? This directly validates quercetin's CP6a mechanism (5-LOX IC50 = 300 nM from ChEMBL, now the stack's most potent curated 5-LOX activity) as the operative mechanism — rather than its weaker NF-κB/NLRP3 effects that currently dominate the stack rationale.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-24 Pass 2 Proposed Experiment #1 and New Connection #3. Brian's 2026-04-24 annotation: "do it. also, i have recent extensive labs that i can add to the project."

Protocol: - Add urinary LTB4 assay to existing self-experiment timepoints in self-experiment-protocol.md: baseline, week 4, week 12 (three measurements total). - Collect first-morning urine (~20 mL), freeze at -80°C until shipment (standard for eicosanoid stability). - Ship to a commercial lab offering LTB4 ELISA or LC-MS/MS (e.g., Cayman Chemical assay kit format via CLIA lab, or direct Mayo Clinic / ARUP specialty testing). - No additional study visit required — piggybacks on the existing self-experiment draw schedule. - Compare with hs-CRP and urate trajectories at the same timepoints to separate "stack is working" (hs-CRP drop) from "stack is working via CP6a" (urinary LTB4 drop).

Estimated cost: $50-100 per assay × 3 timepoints = $150-300 total

Estimated timeline: No additional study time — piggybacks on the existing 12-week self-experiment. Results available ~2 weeks after each draw.

Dependencies: Existing self-experiment infrastructure (wiki/self-experiment-protocol.md). No new study visits or logistics beyond adding a urine collection to existing draws.

Success criteria: - Measurable baseline urinary LTB4 (confirms the assay is sensitive at Brian's baseline state) - ≥30% reduction at week 4 or week 12 relative to baseline → suggests CP6a engagement in vivo - No change in LTB4 despite hs-CRP improvement → suggests stack effect is via other chokepoints (NF-κB, NLRP3 assembly), not 5-LOX

Cross-references: wiki/self-experiment-protocol.md (baseline/week 4/week 12 timepoints), wiki/nlrp3-exploit-map.md (CP6a), wiki/nlrp3-inhibitor-screen.md (quercetin 5-LOX IC50 = 300 nM)

3.7 Brian: Serum C5a Baseline + Week 12 — Validating CP0 Complement Priming Status¶

Status: Proposed | Cost: $300–400 | Weeks: 12 | Phase: 3

Affected wiki: complement-c5a-gout, nlrp3-exploit-map, self-experiment-protocol

What it tests: Documents complement priming status (C5a, the dominant NLRP3 priming signal per Cumpelik 2016 PMID 26245757 + Khameneh 2017 PMID 28167912) before and after the 12-week supplement stack. The stack currently covers CP1-CP5a but not CP0 — this experiment tests whether it modulates complement at all, and establishes a baseline for future CP0-targeted interventions (e.g., avacopan, flavonoid C5aR1 antagonists per wiki/complement-c5a-gout.md).

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-24 Pass 2 Proposed Experiment #2 and New Connection #3.

Protocol: - Add serum C5a to the baseline and week 12 blood panels in wiki/self-experiment-protocol.md. - Alternative marker: sC5b-9 (soluble terminal complement complex) — often more stable in serum than free C5a and available on standard commercial panels. - LabCorp (Complement C5a by enzyme immunoassay, test code 142046) or Quest (sC5b-9 panel) both offer this as a routine specialty test with physician order. - No new study visit — piggybacks on the already-planned week 0 and week 12 draws. - Cross-reference with CBC, urate, hs-CRP at the same timepoints.

Estimated cost: $150-200 per C5a or sC5b-9 test × 2 timepoints = $300-400 total

Estimated timeline: No additional study time. Results available ~1 week after draw.

Dependencies: Existing self-experiment infrastructure; rheumatologist or primary-care order for the specialty test.

Success criteria: - Measurable baseline C5a (confirms assay sensitivity; establishes whether Brian is a "high-complement-priming" or "low-complement-priming" gout patient — relevant for stack design) - Predicted: minimal change at week 12, since the stack doesn't cover CP0. This is a negative-control-type experiment: if C5a drops significantly, that tells us something unexpected is happening and CP0 is engaged. If C5a doesn't change, that validates the wiki's claim that CP0 is an uncovered chokepoint needing dedicated interventions. - Either result informs next-phase stack design.

Cross-references: wiki/self-experiment-protocol.md (week 0 and week 12 panels), wiki/complement-c5a-gout.md (CP0 chokepoint), wiki/nlrp3-exploit-map.md (CP0 entry)

3.8 Brian: DHA vs. EPA Split Omega-3 Crossover — Resolving the Gout-Specific SPM Precursor Question¶

Status: Proposed | Cost: $550–700 | Weeks: 9 | Phase: 3

Affected wiki: spm-resolution-pathway, supplements-stack, tnfsf14-gout-target, self-experiment-protocol

What it tests: Is DHA or EPA the optimal omega-3 precursor for gout flare prevention in Brian's specific case? The 2026-04-24 synthesis pass identified a contradiction between the cardiovascular literature (EPA-dominant) and the gout-specific SPM evidence (DHA-derived RvD1 and MaR1 both show direct MSU animal-model efficacy; DHA also inversely associates with circulating TNFSF14/LIGHT per Mendelian randomization). The supplements-stack.md currently recommends 2:1 or 3:1 EPA:DHA for gout, which may be a cardiovascular-biased extrapolation.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-24 Pass 2 Proposed Experiment #4 and New Connection #2 ("DHA should be preferentially dosed over EPA for gout").

Protocol: - Phase A (4 weeks): High-EPA protocol. 3 g EPA + 0.5 g DHA daily (≈6:1 ratio — commercial high-EPA omega-3 formulations like Nordic Naturals ProEPA or Minami Platinum-Plus EPA). - Washout (1 week): No omega-3 supplementation. Continue rest of base stack. - Phase B (4 weeks): High-DHA protocol. 3 g DHA + 0.5 g EPA daily (≈6:1 ratio DHA-dominant — e.g., Nordic Naturals ProDHA or Life Extension Mega EPA/DHA adjusted by dropping EPA capsules). - Biomarkers measured at baseline, end of Phase A, end of washout, end of Phase B: - Urinary LTB4 (from 3.6 above; tests whether DHA or EPA better suppresses 5-LOX/LTB4 output) - hs-CRP (generic inflammation marker) - Serum SPM panel (RvD1, RvE1, MaR1 metabolites if a CLIA lab offers this — otherwise spot-measure via Cayman Chemical research kit through a lab contact) - Gout flare count and severity (daily log) - Washout rationale: 7-day omega-3 washout is short relative to RBC phospholipid half-life (~8 weeks) but sufficient to allow downstream SPM levels to decay. Accept the limitation — n=1 study, not a clinical trial.

Estimated cost: $200 (supplement differentials across 9 weeks) + $300 (SPM panel) + $50-100 × 2-3 additional LTB4 assays = $550-700 total on top of 3.6

Estimated timeline: 9 weeks (4 + 1 + 4), concurrent with the existing self-experiment or as a post-experiment extension.

Dependencies: - Experiment 3.6 (urinary LTB4 assay infrastructure) - Availability of a lab offering SPM metabolite measurement (Mayo Clinic has an eicosanoid panel; research-grade SPM kits from Cayman require a CLIA lab partnership) - Brian's flare calendar (existing self-tracking)

Success criteria: - Clear directional effect: one phase (either EPA or DHA) produces lower urinary LTB4, higher serum RvD1 or RvE1, and fewer flares than the other. - Ambiguous result (both phases similar): the ratio doesn't matter clinically for Brian; revert to a balanced 1:1 or the cheaper formulation. - Directional toward DHA: revises supplements-stack.md and confirms the 2026-04-24 synthesis recommendation. - Directional toward EPA: the current stack recommendation was right; synthesis flagged a literature signal that doesn't translate for Brian.

Cross-references: wiki/spm-resolution-pathway.md (RvD1/MaR1 DHA-derived), wiki/supplements-stack.md (omega-3 entry, currently EPA-leaning), wiki/self-experiment-protocol.md (integration with the existing protocol), wiki/tnfsf14-gout-target.md (DHA-TNFSF14 Mendelian randomization link), wiki/nlrp3-exploit-map.md (CP5b SPM entry)

3.9 Brian: Zileuton Off-Label Trial — Pharma-Grade CP6a Inhibition in Flare-Prevention Protocol¶

Status: Proposed | Cost: ~$500 | Weeks: 16 | Phase: 3

Affected wiki: zileuton, gout-clinical-pipeline, nlrp3-exploit-map, self-experiment-protocol

What it tests: Does the FDA-approved 5-LOX inhibitor zileuton (Zyflo / Zyflo CR, asthma indication) abort or prevent gout flares in Brian's specific case? This is the pharma-grade equivalent of quercetin's CP6a mechanism — cleaner readout, stronger effect size expected. Cross-references the wiki/zileuton.md dossier (in progress per synthesis queue).

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-24 Pass 2 Proposed Experiment #5 and New Connection #5 ("Zileuton is the closest pharma-grade CP6a analog to quercetin, and has never been tested in gout"). Brian's 2026-04-24 annotation: "yes add it to the clinical pipeline and also let's do a wiki page about it."

Protocol: - Phase 1: Physician conversation. Request off-label prescription from rheumatologist or primary-care physician with the CP6a mechanistic rationale. Key talking points: - Zileuton (Zyflo CR) is FDA-approved for asthma, dosed 1200 mg BID, generic available, ~$50/month. - 5-LOX is mechanistically upstream of neutrophil chemotaxis in gout (LTB4 is a potent neutrophil chemoattractant; colchicine blocks microtubule-dependent chemotaxis downstream). - No published gout efficacy trials; this is a genuine off-label novelty. - Safety profile: liver enzyme elevation is the primary monitoring concern (~2% patients); monthly LFTs for the first 3 months standard. - Duration: 12 weeks, consistent with the existing self-experiment window. - Phase 2: Baseline documentation. Brian's colchicine-era flare frequency (available from existing medication history). 4-week pre-zileuton observation window if feasible. - Phase 3: Zileuton 1200 mg BID × 12 weeks. Continue base supplement stack (including quercetin — zileuton does not contraindicate quercetin and any additive effect is informative). - Biomarkers: - Urinary LTB4 at baseline and week 12 (from 3.6 — direct pharmacodynamic confirmation) - Gout flare count and severity (primary endpoint; daily log) - LFTs (AST, ALT) at baseline, week 2, week 4, week 8, week 12 (safety) - hs-CRP at baseline and week 12

Estimated cost: $150-200/month × 3 months = $450-600 (prescription) + existing LFT coverage via insurance + $0 additional lab cost (piggybacks on 3.6 and insurance-covered LFTs). Net additional: ~$500.

Estimated timeline: 12 weeks active treatment + 4-week follow-up for post-treatment flare rate. Single additional physician conversation to set up.

Dependencies: - Rheumatologist or primary-care physician willing to prescribe off-label. The mechanistic rationale + clean safety profile + low cost should clear this bar. - Completion of wiki/zileuton.md dossier (in progress; synthesis queue item) for Brian to share with the prescribing physician. - Experiment 3.6 (urinary LTB4 as pharmacodynamic confirmation)

Success criteria: - Urinary LTB4 ≥50% reduction at week 12 (confirms pharmacodynamic engagement — zileuton's on-target effect) - Flare frequency reduced ≥50% vs. colchicine-era baseline (clinical efficacy signal) - LFTs remain within normal range throughout (safety) - Negative result (no flare reduction despite LTB4 drop) is also informative: suggests LTB4/neutrophil-chemotaxis is not rate-limiting for Brian's flare biology, and colchicine's mechanism (microtubule → chemotaxis) is doing more work than expected.

Cross-references: wiki/zileuton.md (to be created), wiki/gout-clinical-pipeline.md (mechanistic gap entry), wiki/nlrp3-exploit-map.md (CP6a), wiki/self-experiment-protocol.md (integration with existing protocol)

3.10 Brian: Fructose Challenge Test as Acute n=1 Uricase Efficacy Readout¶

Status: Proposed | Cost: ~$50 | Weeks: 0.1 per run (single 2-hour session); ~4 wk gap between baseline and post-intervention | Phase: 3

Affected wiki: fructose-connection, self-experiment-protocol, synthesis/, open-enzyme-vision

What it tests: Whether engineered uricase is active in the gut in real-time, using a fructose bolus as a predictable acute UA challenge. Per fructose-connection.md, oral fructose loads generate a serum UA spike within 60–120 min via the unregulated KHK pathway. A blunted post-fructose UA spike after starting koji therapy directly validates uricase action in the gut — without waiting weeks for baseline UA to drift on chronic monitoring.

Proposed in: synthesis/ (architecture: synthesis/README.md) 2026-04-27 Proposed Experiment #1 (sweep on commit b7df491). Pass 3 review: highest insight-per-dollar experiment in the queue, elevated to Priority Action status. Within-subject before/after design controls for most confounders (genetics, kidney function, baseline diet) — the only systematic variable changing between runs is the koji intervention.

Protocol: - Subject: Brian (n=1). - Pre-load conditions: 8-hour fasted; baseline UA established (UASure home meter or equivalent, duplicate readings at each timepoint per Pass 3 review to manage UASure CV ~10–15%). - Challenge: 50 g fructose load (oral) — standardized matrix (water-dissolved); record exact dose and dissolution medium. - Sampling: Fingerstick UA at t = 0, 30, 60, 90, 120 minutes. Duplicate at each timepoint. Record peak UA delta from baseline. - Run #1 (baseline): Before any engineered-koji intervention. Establishes Brian's individual fructose-induced UA spike profile under current stack. - Run #2 (post-intervention): After ≥4 weeks of stable koji therapy (engineered when available; wild-type baseline as interim per the multi-vendor metabolite campaign). Same protocol exactly. - Optional Run #3 (washout): Off-koji washout after the post-intervention run to confirm reversibility (rules out baseline drift or concurrent variable shifts).

Estimated cost: ~$50 — UASure meter ~$25, strips ~$15 for the panel (10 readings × 2 runs = 20 strips minimum), fructose ~$5, miscellaneous.

Estimated timeline: 2 hours per session; ~4 weeks elapsed between baseline and post-intervention runs (matches stable plateau on a new koji regimen).

Dependencies: No specialized lab access. Self-administered. Slots cleanly into the operational backlog tracked separately on the personal-health side.

Success criteria: - Validates engineered uricase activity: post-intervention UA spike at t = 60–90 min is ≥30% reduced vs. baseline run, with the koji intervention as the only changed variable. Effect size scales with how much of the fructose-derived urate is degraded by gut-lumen uricase before systemic absorption. - Null result: spike unchanged. Possible interpretations: insufficient uricase expression / activity, fructose absorbs faster than uricase can degrade the resulting urate, or the koji format isn't delivering active enzyme to the lumen. Triages next experimental questions (e.g., §1.10 stability, §1.6 enzyme survival). - Adverse: spike worsens — suggests run-to-run variance dominated by other factors. Add additional baseline runs to characterize variance before re-interpreting.

Caveats and confounds: - UASure CV ~10–15% — duplicate readings + ≥30% effect-size threshold helps separate signal from noise. - Brian's clomid taper is in flight (UA mobilization risk during T transition). Schedule the runs to either bracket or sit firmly inside one phase of that taper to avoid confounding. - Hydration status confounds UA: standardize water intake (e.g., 500 mL on waking, no other fluids during the 2-hour window). - Recent flares within 4 weeks change baseline UA dynamics — defer until 4+ weeks post-flare.

Cross-references: synthesis/ 2026-04-27 Proposed Experiment #1; fructose-connection.md; self-experiment-protocol.md.

Cross-Experiment Dependencies and Sequencing¶

Phase 1 (In Vitro)
├─ 1.1: Gene performance [weeks 1-6] ─────┬─→ 1.2, 1.3, 1.5, 1.6
├─ 1.2: Secretion vs. intracellular ──────┤
├─ 1.3: Beer survival ──────────────┬─────→ 2.2 (yeast efficacy)
├─ 1.4: Drying stability ───────────┤ ────→ 3.1 (yeast formulation)
├─ 1.5: Koji expression ────────────┬─────→ 1.6, 1.7 (koji validation)
├─ 1.6: Koji digestive stability ───┤────→ 2.3 (EPI model)
├─ 1.7: NLRP3 pathway validation ───┤────→ 2.4 (MSU arthritis model)
│
├─→ Phase 2 (Animal Models)
    ├─ 2.1: Gnotobiotic S. boulardii [weeks 12-20] ──┬─→ 3.1
    ├─ 2.2: Hyperuricemic rat model [weeks 10-16] ───┤─→ 3.1
    ├─ 2.3: EPI koji model [weeks 12-18] ───────────┬─→ 3.3
    ├─ 2.4: MSU arthritis model [weeks 14-22] ──────┬─→ 3.2
    └─ 2.5: PULSE E. coli probiotic [weeks 12-18] ──┤

    ├─→ Phase 3 (Human Self-Experimentation)
        ├─ 3.1: Yeast uricase (Brian) [weeks 24-44] ──┬─→ 3.5
        ├─ 3.2: NLRP3 stack (Brian) [weeks 24-44] ────┼─→ parallel with 3.1
        ├─ 3.3: Koji enzymes (Lynn) [weeks 20-32] ────┤─→ 3.4
        ├─ 3.4: Engineered koji (both) [weeks 36-50] ─┤
        └─ 3.5: Long-term flare prevention [weeks 45-71]

Success Metrics Summary¶

Phase	Experiment	Primary Endpoint	Target Threshold
1	Gene performance	Uricase specific activity	>50 μmol/h/OD
1	Secretion	Bioavailable enzyme fraction	>30% extracellular
1	Beer survival	Enzyme activity retention	>30% post-fermentation
1	Drying	Lyophilization stability	>40% activity retained
1	Koji expression	Secreted uricase activity	>20 μmol/h/OD
1	Koji digestive pH	Duodenal survival	>20% activity post-transit
1	NLRP3 pathway	IL-1β reduction	>50% at stated doses
2	S. boulardii colonization	Fecal yeast counts	>10⁶ CFU/mL by day 3
2	Yeast efficacy (rat)	Serum uric acid reduction	≥30% vs. vehicle
2	Koji EPI model	Fat absorption	>92% (vs. <50% baseline)
2	MSU arthritis	Joint swelling reduction	≥40% vs. vehicle
2	PULSE homeostasis	Uric acid range maintained	2.0–4.0 mg/dL
3	Yeast uricase (Brian)	Flare frequency reduction	≥50% vs. baseline
3	NLRP3 stack (Brian)	IL-1β reduction	≥30% vs. baseline
3	Koji enzymes (Lynn)	GI symptom improvement	≥50% vs. baseline
3	Engineered koji (both)	Tolerability + efficacy	>80% adherence + dual benefit
3	Long-term prevention	Sustained flare reduction	≥40% reduction sustained 6mo
1	EGCG CP1a (1.8)	IL-6 suppression at ≤1 μM EGCG	≥50%
3	Urinary LTB4 (3.6)	Stack effect on 5-LOX in vivo	≥30% reduction vs. baseline
3	Serum C5a (3.7)	CP0 priming documentation	Measurable baseline; informative either direction
3	DHA vs. EPA (3.8)	Directional omega-3 preference	Clear winner or confirmed null
3	Zileuton off-label (3.9)	LTB4 reduction + flare reduction	≥50% LTB4 drop, ≥50% flare reduction
1	Carnosine co-expression (1.24)	Carnosine titer in koji pore fluid	≥500 mg/L (promote); <100 mg/L (de-prioritize koji track)

Notes on Open Questions¶

GLUT9 and urate transport bottleneck: Could engineered koji produce high fructokinase inhibitors to address the fructose-gout link? (Source: gout-deep-dive.md, Section 9)
Delivery route optimization: Is intestinal lumen degradation sufficient, or would systemic absorption of recombinant uricase be superior? (Source: blood-barrier-exploits.md)
Microbiome stability: Will engineered probiotics persist without colonization, or is daily dosing required long-term? (Source: gout-deep-dive.md, Section 8)
Gene therapy as alternative: Should we pursue CRISPR-based uricase gene therapy in parallel? (Source: gout-deep-dive.md, Section 6)

Document maintained as part of the [[open-source-platform]] initiative. All experiments are designed for replication and community contribution.